Amedeo Smart

Free Medical Literature Service

 

Amedeo

Nuclear Medicine
  Free Subscription

Articles published in
J Nucl Med
    August 2026
  1. ZHOU J, Liu Y, Zhou M, Hai W, et al
    [(68)Ga]Ga-NODAGA-SNA006 PET/CT Reveals CD8(+) T-Cell Dynamics in Lung Cancer Progression and Anti-PD-1 Response.
    J Nucl Med. 2026 Aug 27:jnumed.125.271377. doi: 10.2967/jnumed.125.271377.
    >> Share

  2. SCHOLTISSEK H, Reitsam NG, Markl B, Patt M, et al
    Correlation of [(68)Ga]Ga-RAYZ-8009 PET/CT Uptake with Immunohistochemical Glypican-3 Expression in Hepatocellular Carcinoma: A Proof-of-Target Study.
    J Nucl Med. 2026 Aug 27:jnumed.126.272757. doi: 10.2967/jnumed.126.272757.
    >> Share

  3. SP S, Shanbhag ER, Jayachandra PH, Joshi V, et al
    Comparative Evaluation of [(68)Ga]Ga-FAPI-04 PET Versus Conventional Imaging for Peritoneal Carcinomatosis Detection in Ovarian Carcinoma: A Multimodal Imaging Study.
    J Nucl Med. 2026 Aug 27:jnumed.125.271126. doi: 10.2967/jnumed.125.271126.
    >> Share

  4. CHAN DL, Mokhtar S, Bernard EJ, Diakos C, et al
    Dual-Threshold Contouring for [(68)Ga]Ga-DOTATATE PET/CT and Correlation with Overall Survival in Patients with Neuroendocrine Neoplasms.
    J Nucl Med. 2026 Aug 27:jnumed.125.271954. doi: 10.2967/jnumed.125.271954.
    >> Share

  5. JAFARVAND M, Farolfi A, Mei R, Djaileb L, et al
    PSMA PET Imaging for Prostate Cancer Recurrence After Minimally Invasive Focal Therapy: A Single-Center Retrospective Study.
    J Nucl Med. 2026 Aug 20:jnumed.125.271556. doi: 10.2967/jnumed.125.271556.
    >> Share

  6. SUSANNE S, Thomas K, Bucerius J
    Reply LTE, Mathematical Discrepancies in the Per-Lesion Analysis of [(68)Ga]Ga-FAPI-46 and [(18)F]FDG PET/CT in Hepatic Lesions.
    J Nucl Med. 2026 Aug 20:jnumed.126.273476. doi: 10.2967/jnumed.126.273476.
    >> Share

  7. CERCI JJ, Fanti S, Herrmann K, Rodrigues DF, et al
    The Global Theranostics Access Gap: Real-World Disparities in PSMA PET/CT and (177)Lu-PSMA Therapy Between Centers in Brazil and Europe.
    J Nucl Med. 2026 Aug 20:jnumed.126.273029. doi: 10.2967/jnumed.126.273029.
    >> Share

  8. HUANG KW
    Mathematical Discrepancies in the Per-Lesion Analysis of [(68)Ga]Ga-FAPI-46 and [(18)F]FDG PET/CT in Hepatic Lesions.
    J Nucl Med. 2026 Aug 20:jnumed.126.272907. doi: 10.2967/jnumed.126.272907.
    >> Share

  9. SPEKTOR AM, Fried M, Zapata Bonilla SA, Othman A, et al
    (68)Ga-FAPI PET/CT for Differentiation of Malignant Peripheral Nerve Sheath Tumors, Neurofibromas, and Schwannomas.
    J Nucl Med. 2026 Aug 20:jnumed.126.272348. doi: 10.2967/jnumed.126.272348.
    >> Share

  10. PARK HL, Kersting D, Bergstrom CP, Khaki AR, et al
    Association of Early Same-Day Posttherapy Whole-Body SPECT/CT Using Visual RECIP 1.0 with Overall Survival During [(177)Lu]Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2026 Aug 13:jnumed.126.272651. doi: 10.2967/jnumed.126.272651.
    >> Share

  11. DEWARAJA YK, Dickson J, Tran-Gia J
    High Quantitative Accuracy Is Possible with (177)Lu SPECT.
    J Nucl Med. 2026 Aug 13:jnumed.126.272205. doi: 10.2967/jnumed.126.272205.
    >> Share

  12. HESTERMAN JY, Hobbs RF, Kiess AP, Jardine V, et al
    Normal-Organ Absorbed Dose and Response Assessment in alpha-Particle Radiopharmaceutical Therapy.
    J Nucl Med. 2026 Aug 13:jnumed.126.272179. doi: 10.2967/jnumed.126.272179.
    >> Share

  13. KRASULOVA K, Neuzilova B, Dvorakova Bendova K, Hajduova K, et al
    Targeted PET Imaging of Pseudomonas aeruginosa Using a [(68)Ga]Ga-Pyoverdines Cocktail.
    J Nucl Med. 2026 Aug 13:jnumed.125.271909. doi: 10.2967/jnumed.125.271909.
    >> Share

  14. MATHOUX G, Boccalini C, Peretti DE, Scheffler M, et al
    Clinical and Biologic Characterization of a 3-Level Centiloid-Based Classification of Amyloid PET.
    J Nucl Med. 2026 Aug 13:jnumed.126.272655. doi: 10.2967/jnumed.126.272655.
    >> Share

  15. BEKKHOUCHA A, Zaragori T, Olivier P, Claudin M, et al
    Prognostic Value of [(18)F]FDG PET Combined with [(68)Ga]Ga-PSMA PET as Pretreatment Imaging in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with [(177)Lu]Lu-PSMA-617.
    J Nucl Med. 2026 Aug 13:jnumed.126.273113. doi: 10.2967/jnumed.126.273113.
    >> Share

  16. ZHOU L, Keil S, Wang XH, Hojjati SH, et al
    Contribution of Myelin Content to the PET-Measured Amyloid Burden.
    J Nucl Med. 2026 Aug 13:jnumed.126.272591. doi: 10.2967/jnumed.126.272591.
    >> Share

  17. SALERNO B, Akerele M, Thorek DLJ
    Reply LTE, High Quantitative Accuracy is Possible with 177Lu SPECT....
    J Nucl Med. 2026 Aug 13:jnumed.126.272772. doi: 10.2967/jnumed.126.272772.
    >> Share

  18. GAO S, Zhang Z, Shi C, Cheng C, et al
    (68)Ga-HER2 PET/CT for Predicting Pathologic Response to Neoadjuvant Therapy at Early Treatment and Preoperative Stages in HER2-Positive Breast Cancer: A Prospective Study.
    J Nucl Med. 2026 Aug 6:jnumed.125.271529. doi: 10.2967/jnumed.125.271529.
    >> Share

  19. KARAGIANNI S, Moscoso A, Raghavan S, van Essen M, et al
    Concordance Between [(18)F]Flortaucipir PET Visual Reads and CenTauR-Based Quantification.
    J Nucl Med. 2026 Aug 6:jnumed.126.272722. doi: 10.2967/jnumed.126.272722.
    >> Share

  20. SCHWENGBER WK, Sanders J, Pinteric A, Armitage L, et al
    Hematologic Consequences of Radiopharmaceutical Therapy: From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms.
    J Nucl Med. 2026 Aug 6:jnumed.126.272210. doi: 10.2967/jnumed.126.272210.
    >> Share


  21. A PET Revolution: Transforming Imaging with Total-Body PET.
    J Nucl Med. 2026;67:4A.
    >> Share

    July 2026
  22. TAYLOR C, Jupp B, Vivash L
    Neuroinflammatory PET in Epilepsy: Prospects for Epileptogenic Zone Localization and Presurgical Planning.
    J Nucl Med. 2026 Jul 30:jnumed.126.272805. doi: 10.2967/jnumed.126.272805.
    >> Share

  23. GELARDI F, Pini C, Sollini M, Chiti A, et al
    PET Never Lies: Healthy Organ Uptake Beyond Tumor Expression in Theranostic Applications.
    J Nucl Med. 2026 Jul 23:jnumed.126.272839. doi: 10.2967/jnumed.126.272839.
    >> Share

  24. PARIHAR AS, Dehdashti F, Pant N, Ravindra SG, et al
    Evaluating Interim Progression: First Posttherapy (177)Lu-PSMA SPECT/CT Relative to Baseline PSMA PET/CT.
    J Nucl Med. 2026 Jul 23:jnumed.126.272545. doi: 10.2967/jnumed.126.272545.
    >> Share

  25. BOURSIER C, Heyer S, Zouaoui A, Roth N, et al
    Evaluation of 9-Minute Dual-Energy Peak Time-Reduced 360 degrees CZT Total-Body [(177)Lu]Lu-PSMA SPECT/CT Imaging with Comparisons to [(68)Ga]Ga-PSMA PET.
    J Nucl Med. 2026 Jul 23:jnumed.126.272647. doi: 10.2967/jnumed.126.272647.
    >> Share

  26. KARIMZADEH A, Futterer C, Hansen K, Coban O, et al
    Outcome Prediction After [(177)Lu]Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: External Validation of a [(68)Ga]Ga-PSMA-11 PET-Based Model with [(18)F]F-Flotufolastat.
    J Nucl Med. 2026 Jul 23:jnumed.125.270944. doi: 10.2967/jnumed.125.270944.
    >> Share

  27. ZHU W, Huo L
    Reply: PET Never Lies: Healthy Organ Uptake Beyond Tumor Expression in Theranostic Applications.
    J Nucl Med. 2026 Jul 23:jnumed.126.273362. doi: 10.2967/jnumed.126.273362.
    >> Share

  28. JOUGLA A, Nunes P, Giraudet AL, Olivier A, et al
    Prognostic Value of a Composite Score Incorporating Baseline [(18)F]FDG PET/CT and [(68)Ga]Ga-PSMA-11 PET/CT When Screening for [(177)Lu]Lu-PSMA Treatment Eligibility (PROFILE Study).
    J Nucl Med. 2026 Jul 16:jnumed.126.272368. doi: 10.2967/jnumed.126.272368.
    >> Share

  29. HEKIMSOY T, Sauter AP, Tauber R, Horn T, et al
    Toward a Biopsy-Free Diagnosis of Prostate Cancer: Potential of Combined (18)F-Flotufolastat PSMA PET and mpMRI.
    J Nucl Med. 2026 Jul 2:jnumed.125.271916. doi: 10.2967/jnumed.125.271916.
    >> Share

  30. FAROLFI A, Sgro CMP, Brusa I, Dall'Olio D, et al
    PSMA PET/CT-Targeted Biopsy in Men with Negative or Equivocal Multiparametric MRI and Exploratory Dynamic Total-Body PET: The FUPERMAN Study.
    J Nucl Med. 2026 Jul 2:jnumed.126.272108. doi: 10.2967/jnumed.126.272108.
    >> Share

  31. DUAN S, Tan B, Mao Y, Zhang Y, et al
    ICOS-Targeted Peptide Imaging Informs Therapeutic Response of STING Agonist in Lung Adenocarcinoma.
    J Nucl Med. 2026;67:1062-1069.
    >> Share

  32. SONG H, Xiang Z, Wang Y, Zhao J, et al
    First Total-Body Kinetics Study of (18)F-Flurpiridaz in Healthy Volunteers at Rest and Feasibility of Simplified Quantitative Strategies.
    J Nucl Med. 2026;67:1148-1155.
    >> Share

    June 2026
  33. KUPER AT, Shiyam Sundar LK, Djaileb L, Roschlak J, et al
    SSTR-Targeted Radiotheranostics in Breast Cancer: A Comparison of [(68)Ga]Ga-DOTATOC and [(68)Ga]Ga-SSO120 with [(18)F]FDG PET.
    J Nucl Med. 2026 Jun 25:jnumed.126.272521. doi: 10.2967/jnumed.126.272521.
    >> Share

  34. KASHYAP R, Buteau JP, Papa N, Ayati N, et al
    Prognostic Value of Restaging [(18)F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [(177)Lu]Lu-PSMA-617 Therapy.
    J Nucl Med. 2026 Jun 25:jnumed.126.272531. doi: 10.2967/jnumed.126.272531.
    >> Share

  35. LINDSEY MJ, Hernandez R
    Radiation-Induced Senescence in Radiopharmaceutical Therapy: Mechanisms and Therapeutic Implications.
    J Nucl Med. 2026 Jun 25:jnumed.126.272389. doi: 10.2967/jnumed.126.272389.
    >> Share

  36. CHOI H, Bae S, Na KJ
    End-to-End PET/CT Interpretation and Quantification with an LLM-Orchestrated AI Agent: A Real-World Pilot Study.
    J Nucl Med. 2026 Jun 18:jnumed.126.272362. doi: 10.2967/jnumed.126.272362.
    >> Share

  37. KREBS S, Salem AE, Nguyen NC, Sheth RA, et al
    Renal Medullary Carcinoma: Utility of [(18)F]FDG PET/CT in Evaluating Extent of Disease and Impact on Treatment Management.
    J Nucl Med. 2026 Jun 18:jnumed.126.272258. doi: 10.2967/jnumed.126.272258.
    >> Share

  38. BARBER AR, Edwards RS, Dos Santos SN, Emanuelli A, et al
    Imaging xCT with Immuno-PET in Therapy-Resistant Non-Small Cell Lung Cancer.
    J Nucl Med. 2026 Jun 18:jnumed.126.272920. doi: 10.2967/jnumed.126.272920.
    >> Share

  39. SHANBHAG A, Miller RJH, Kavanagh P, Ramirez G, et al
    Revisiting Perfusion in the Forgotten Right Ventricle: Artificial Intelligence-Enhanced Quantification on PET/CT.
    J Nucl Med. 2026 Jun 18:jnumed.125.271894. doi: 10.2967/jnumed.125.271894.
    >> Share

  40. KUMAR R, Ram A, Kumar S, Singh H, et al
    PCa Detection in PI-RADS 4 and 5 Lesions: Comparison of [(68)Ga]Ga-PSMA-11 PET/CT-Guided Robot-Assisted Biopsy Versus mpMRI Cognitive-Fusion TRUS-Guided Prostate Biopsy.
    J Nucl Med. 2026 Jun 18:jnumed.126.272036. doi: 10.2967/jnumed.126.272036.
    >> Share

  41. TIE X, Lee C, Perlman SB, Gowdy C, et al
    Evaluation of Baseline and Interim-Therapy PET Features for Prognostication in High-Risk Pediatric Hodgkin Lymphoma: A Retrospective Analysis of the AHOD1331 Trial.
    J Nucl Med. 2026 Jun 18:jnumed.125.270791. doi: 10.2967/jnumed.125.270791.
    >> Share

  42. KUTEN J, Beattie BJ, Chahwan S, Schoder H, et al
    Functional Renal Assessment via Dynamic LAFOV (18)F-FDG PET/CT in a Patient with Recurrent Extranodal Marginal-Zone Lymphoma.
    J Nucl Med. 2026 Jun 18:jnumed.126.272086. doi: 10.2967/jnumed.126.272086.
    >> Share

  43. JALLINOJA VIJ, Mun JS, Campanella A, Sasson A, et al
    Nonsteroidal (18)F-Labeled PET Tracer for Imaging Androgen Receptors.
    J Nucl Med. 2026 Jun 11:jnumed.125.271531. doi: 10.2967/jnumed.125.271531.
    >> Share

  44. STROSBERG JR, Al-Toubah T, Haider M, El-Haddad G, et al
    Somatostatin Receptor Expression on [(68)Ga]Ga-DOTATATE PET Among Patients with Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas: A Prospective Study.
    J Nucl Med. 2026 Jun 11:jnumed.125.271460. doi: 10.2967/jnumed.125.271460.
    >> Share

  45. TANG H, Song S, Liu F, Xu J, et al
    Total-Body Dynamic PET/CT Imaging of Proton-Induced Activity and Biologic Washout After Proton Therapy.
    J Nucl Med. 2026 Jun 11:jnumed.126.272338. doi: 10.2967/jnumed.126.272338.
    >> Share

  46. LUISI C, De Palma L, Campi C, Boniver C, et al
    [(18)F]FDG PET/MRI in Pediatric Focal Epilepsies.
    J Nucl Med. 2026 Jun 11:jnumed.125.271155. doi: 10.2967/jnumed.125.271155.
    >> Share

  47. PAULE A, Masson S, Rose Dite Modestine J, Kara N, et al
    Role of (18)F-PSMA PET/MRI in Prostate Cancer Recurrence After Prostatectomy.
    J Nucl Med. 2026 Jun 4:jnumed.126.272126. doi: 10.2967/jnumed.126.272126.
    >> Share

  48. MAZZIOTTA J, Czernin J
    From Architecture to Brain Imaging to Leader of a Major Academic Health System: John Mazziotta Talks with Johannes Czernin About an Evolving Career and Its Origins in Nuclear Medicine.
    J Nucl Med. 2026 Jun 4:jnumed.126.273012. doi: 10.2967/jnumed.126.273012.
    >> Share

  49. JIA KY, Kuten J, Jia HY, Bent EH, et al
    Diagnostic Value of Routine Delayed Pelvic Imaging for Patients with Biochemical Recurrence of Prostate Cancer Undergoing (68)Ga-PSMA PET/CT.
    J Nucl Med. 2026 Jun 4:jnumed.126.272009. doi: 10.2967/jnumed.126.272009.
    >> Share

  50. SCHINDLER P, Brandt J, Bobe S, Krahling T, et al
    Initial Results of FAPI PET/MRI to Assess the Extent of Endometriosis.
    J Nucl Med. 2026 Jun 4:jnumed.125.271376. doi: 10.2967/jnumed.125.271376.
    >> Share

  51. KANG HG, Tashima H, Wakizaka H, Minamihisamatsu T, et al
    Sub-0.5-mm Resolution PET Versus Autoradiography: Comparison of mGluR1 Concentrations in Mouse Brain.
    J Nucl Med. 2026 Jun 4:jnumed.125.271600. doi: 10.2967/jnumed.125.271600.
    >> Share

  52. BAUM RP, Zhao T, Jakobsson V, Greifenstein L, et al
    Fibroblast Activation Protein-Targeted Radiopharmaceutical Therapy Using (177)Lu-, (90)Y-, and (225)Ac-Labeled 3BP-3940: First Experience in 21 Different Advanced Malignancies.
    J Nucl Med. 2026;67:910-920.
    >> Share

  53. URBAIN JC
    Nuclear Medicine in an Era of Exponential Growth.
    J Nucl Med. 2026;67:11A-12A.
    >> Share

  54. BRENDEL M, Barthel H, Hoglinger GU
    Biologic Definition of Parkinson Disease: A Pivotal Role for Molecular Imaging.
    J Nucl Med. 2026;67:833-840.
    >> Share

  55. GIARRATANA AO, Jonaitis E, Przybelski RJ, Cody K, et al
    Longitudinal Evaluation of (18)F-MK-6240 Along the Alzheimer Disease Continuum.
    J Nucl Med. 2026;67:981-987.
    >> Share

  56. HUBALEWSKA-DYDEJCZYK A, Decristoforo C, Mikolajczak R, Kolenc P, et al
    Improving the Somatostatin Receptor Status Assessment for Personalized and Precise Management of Neuroendocrine Neoplasms with the Use of a (99m)Tc-Radiolabeled Somatostatin Receptor Antagonist: The Final Results of the ERA PerMed TECANT Clinical Tria
    J Nucl Med. 2026;67:895-902.
    >> Share

  57. VOLTIN CA, Flossdorf S, Kurch L, Winkelmann M, et al
    Risk Assessment in Large B-Cell Lymphoma Using Metabolic Tumor Volume: Real-World Data from a Multicenter Cohort of Patients Undergoing CAR T-Cell Therapy.
    J Nucl Med. 2026;67:871-877.
    >> Share

    May 2026
  58. OSBORNE D, Cutler CS, Chaple IF, Ribeiro Pereira PM, et al
    Industry-Academic Collaboration in Nuclear Medicine: Proceedings from the 2024 CMIIT Industry Partners Circle.
    J Nucl Med. 2026 May 28:jnumed.126.272619. doi: 10.2967/jnumed.126.272619.
    >> Share

  59. PENNINCKX S, Delbart W, Mileva M, Kassas M, et al
    Toward Personalized Radiopharmaceutical Therapy: Radiobiologic Insights Compared with External-Beam Radiotherapy.
    J Nucl Med. 2026 May 28:jnumed.125.271564. doi: 10.2967/jnumed.125.271564.
    >> Share

  60. KO GB, Kim KY, Kang SK, Lee J, et al
    First-in-Human Imaging Results of PHAROS: A Versatile High-Resolution TOF/DOI PET Scanner for Brain, Breast, and Extremity Imaging.
    J Nucl Med. 2026 May 28:jnumed.125.271172. doi: 10.2967/jnumed.125.271172.
    >> Share

  61. KOO H, Plyku D, Marzella L
    Utility of Preclinical Dosimetry for First-in-Human Studies with PET Drugs Labeled with Common Radionuclides: A Systematic Review of Radiation Dose Estimates.
    J Nucl Med. 2026 May 28:jnumed.125.270487. doi: 10.2967/jnumed.125.270487.
    >> Share

  62. MULUGETA PG, O'Brien SR, Mankoff DA, Sartor O, et al
    A Call for High-Level Evidence Before Routine Implementation of Posttreatment SPECT.
    J Nucl Med. 2026 May 21:jnumed.125.271508. doi: 10.2967/jnumed.125.271508.
    >> Share

  63. WANG Y, Wood JL, Thurecht KJ, Yeoh SY, et al
    Assessing Value for Money in Theranostic Nuclear Medicine: A Systematic Review.
    J Nucl Med. 2026 May 21:jnumed.125.271469. doi: 10.2967/jnumed.125.271469.
    >> Share

  64. ARCAY OZTURK A, Liberale G, Deleu AL, Poenaru R, et al
    Preoperative Assessment of Peritoneal Carcinomatosis with [(68)Ga]Ga-FAPI-46 PET/CT: Agreement with Surgicopathologic PCI and Comparison with MRI and [(18)F]FDG PET/CT.
    J Nucl Med. 2026 May 21:jnumed.126.272183. doi: 10.2967/jnumed.126.272183.
    >> Share

  65. SOMMA C, Zimmermann R, Gericke G, Herrmann K, et al
    Targeted Radiopharmaceutical Therapy: Advances, Investment Dynamics, and Future Directions-Part 1.
    J Nucl Med. 2026 May 21:jnumed.125.270855. doi: 10.2967/jnumed.125.270855.
    >> Share

  66. LUCKERATH K, Minguez Gabina P, Eberlein U, Kurth J, et al
    Radiopharmaceutical Therapy Meets Radiobiology: Implications for Trial Design and DNA Repair Inhibitor Combinations.
    J Nucl Med. 2026 May 21:jnumed.125.271527. doi: 10.2967/jnumed.125.271527.
    >> Share

  67. SOMMA C, Zimmermann R, Gericke G, Herrmann K, et al
    Targeted Radiopharmaceutical Therapy: Advances, Investment Dynamics, and Future Directions-Part 2.
    J Nucl Med. 2026 May 21:jnumed.125.270945. doi: 10.2967/jnumed.125.270945.
    >> Share

  68. URIBE C, Iravani A, Savir-Baruch B, Jacene H, et al
    Reply: A Call for High-Level Evidence Before Routine Implementation of Posttreatment SPECT.
    J Nucl Med. 2026 May 21:jnumed.126.272083. doi: 10.2967/jnumed.126.272083.
    >> Share

  69. JIA W, Yan T, An S, Zhang Y, et al
    Immuno-PET/CT Imaging of Trop2 Expression with [(18)F]AlF-RESCA-RT4 Enhances Diagnosis of Breast Cancers and the Metastases.
    J Nucl Med. 2026 May 14:jnumed.125.271093. doi: 10.2967/jnumed.125.271093.
    >> Share

  70. DUIJX LEHW, Lenaerts M, Smidt ML, Vaz SC, et al
    Diagnostic Performance of FAPI PET in Patients with Breast Cancer: A Systematic Review.
    J Nucl Med. 2026 May 14:jnumed.126.272191. doi: 10.2967/jnumed.126.272191.
    >> Share

  71. ULANER GA, Lam R
    Widespread Prostate Cancer Osseous Metastases: Negative on (18)F-Piflufolastat PET but Positive on (18)F-Fluciclovine PET.
    J Nucl Med. 2026 May 6:jnumed.125.272001. doi: 10.2967/jnumed.125.272001.
    >> Share

  72. FOSTER CC, Ganguly T, Hausner SH, Kim E, et al
    [(68)Ga]Ga-DOTA-5G PET/CT Detects Brain and Bone Metastases in a Patient with Metastatic Pancreatic Cancer.
    J Nucl Med. 2026 May 6:jnumed.126.272419. doi: 10.2967/jnumed.126.272419.
    >> Share

  73. WERNER JM, Tomasich E, Mair MJ, Hainfellner JA, et al
    Lack of LAT1 and CD98hc Expression on Tumor Cells of Diffuse Glioma: Revisiting the Molecular Basis for Amino Acid PET Imaging and Theranostics.
    J Nucl Med. 2026 May 6:jnumed.125.271348. doi: 10.2967/jnumed.125.271348.
    >> Share

  74. HOFMAN MS, Corlett A, Pain C, Jackson P, et al
    First Images on a Next-Generation Extended-Field-of-View Digital Bismuth Germanium Oxide Total-Body PET/CT.
    J Nucl Med. 2026 May 6:jnumed.125.271995. doi: 10.2967/jnumed.125.271995.
    >> Share

  75. TAN M, Li L, Zhu Y, Ding H, et al
    First-in-Human [(68)Ga]Ga-DOTA-Folate PET/CT in a Patient with Ovarian Cancer.
    J Nucl Med. 2026 May 6:jnumed.125.271820. doi: 10.2967/jnumed.125.271820.
    >> Share

  76. GOULD KL, Johnson NP
    Multiorgan Perfusion by PET: Potential Multiple Pathophysiology Interacting with the Heart to Guide Systemic and Cardiac Management.
    J Nucl Med. 2026 May 6:jnumed.126.272071. doi: 10.2967/jnumed.126.272071.
    >> Share

  77. KLAUSER PC, Dehlavi G, De Franco M, Loor A, et al
    Efficacy of CLDN18.2-Targeted Radiotheranostics in Patient-Derived Models of Gastric Cancer.
    J Nucl Med. 2026;67:765-772.
    >> Share

  78. NOVRUZOV E, Mamlins E, Widjaja L, Siegmund SC, et al
    Reliability and Practicability of FAP-RADS Version 1.0 for Structured Reporting of FAPI Imaging in Pulmonary and Urothelial Carcinoma.
    J Nucl Med. 2026;67:687-692.
    >> Share

  79. MACSUKA MJ, Driscoll B, Yeung IWT, Publicover J, et al
    Cumulative Absorbed Dose and Successive Cyclic Reduction in Absorbed Dose Predict Response to (177)Lu-DOTATATE in Neuroendocrine Tumors.
    J Nucl Med. 2026;67:751-757.
    >> Share

    April 2026
  80. CHAUHAN A, Hendifar AE, El-Haddad G, Soares HP, et al
    The Equivalents Are Coming! Developing a Shared Nomenclature for Radiopharmaceutical Therapy of Neuroendocrine Tumors, Prostate Cancer, and Beyond.
    J Nucl Med. 2026 Apr 30:jnumed.126.272026. doi: 10.2967/jnumed.126.272026.
    >> Share

  81. LIU H, Qu W, Liang D, Yu X, et al
    Performance Evaluation of SmartBrain: A Wearable PET System for Human Brain Imaging.
    J Nucl Med. 2026 Apr 30:jnumed.125.271350. doi: 10.2967/jnumed.125.271350.
    >> Share

  82. BROSCH-LENZ J, Buther F, Oehler S, Ciamarone A, et al
    Dynamics, Pharmacokinetics, and Dosimetry of First-in-Human [(68)Ga]Ga-OncoACP3-DOTA PET in Patients with Prostate Cancer.
    J Nucl Med. 2026 Apr 30:jnumed.125.271933. doi: 10.2967/jnumed.125.271933.
    >> Share

  83. COCHET A, Besson V, Bertaut A, Fouquier A, et al
    (18)F-FDG and (18)F-Fluorocholine PET as Prognostic Biomarkers in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Prospective Multicenter Study.
    J Nucl Med. 2026 Apr 30:jnumed.125.271382. doi: 10.2967/jnumed.125.271382.
    >> Share

  84. KIRCHHOFF S, Erber B, Rauscher I, Sasse D, et al
    Prognostic Value of [(18)F]Flotufolastat PET Using Visual RECIP in Docetaxel-Treated Metastatic Prostate Cancer.
    J Nucl Med. 2026 Apr 22:jnumed.125.271488. doi: 10.2967/jnumed.125.271488.
    >> Share

  85. MISHRA A, Lisok A, Mease RC, Novakova Z, et al
    PET Imaging of Accessible Prostate-Specific Membrane Antigen Reveals Dose-Dependent and Tumor Burden-Driven Variability.
    J Nucl Med. 2026 Apr 22:jnumed.125.271053. doi: 10.2967/jnumed.125.271053.
    >> Share

  86. BRUSA I, Santoro M, Dall'Olio D, Fuso GA, et al
    Dynamic Total-Body PET Imaging Unfolds [(11)C]Choline Kinetics and Dosimetry in Primary Hyperparathyroidism.
    J Nucl Med. 2026 Apr 16:jnumed.125.270518. doi: 10.2967/jnumed.125.270518.
    >> Share

  87. UNTERRAINER LM, Ndlovu H, Hope TA, Unterrainer M, et al
    Prognostic Value of PSMA PET-Derived Tumor Burden Stratification in Metastatic Hormone-Sensitive Prostate Cancer.
    J Nucl Med. 2026 Apr 16:jnumed.125.271598. doi: 10.2967/jnumed.125.271598.
    >> Share

  88. STANZEL S, Nazerani-Zemann T, Weitzer F, Plhak E, et al
    Prospective Head-to-Head Comparison of Fibroblast Imaging with [(68)Ga]Ga-FAPI-46 PET/CT and [(18)F]FDG PET/CT in Unclear Hepatic Lesions.
    J Nucl Med. 2026 Apr 16:jnumed.125.271597. doi: 10.2967/jnumed.125.271597.
    >> Share

  89. METSER U, Bauman G, Rashid M, Mirshahvalad SA, et al
    Utility of PSMA PET/CT After an Initial Negative Scan: Results from a Prospective Multicenter PSMA PET Registry.
    J Nucl Med. 2026 Apr 16:jnumed.126.272204. doi: 10.2967/jnumed.126.272204.
    >> Share

  90. NAMBIAR DM, Esparza TJ, Lee W, Chung JY, et al
    A Novel CD147-Targeting Nanobody for Immuno-PET Imaging of Liver Cancer.
    J Nucl Med. 2026 Apr 9:jnumed.125.271565. doi: 10.2967/jnumed.125.271565.
    >> Share

  91. MORADPOUR M, Moradi Tochayi A, Houshmand S, Nwihim S, et al
    Patterns of Progression After Peptide Receptor Radiopharmaceutical Therapy.
    J Nucl Med. 2026 Apr 9:jnumed.125.270483. doi: 10.2967/jnumed.125.270483.
    >> Share

  92. AURIAC J, Lemoudda G, Hovhannisyan-Baghdasarian N, Pires M, et al
    Brain Metabolic Activity Measured by [(18)F]FDG PET/CT Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer.
    J Nucl Med. 2026 Apr 9:jnumed.125.271400. doi: 10.2967/jnumed.125.271400.
    >> Share

  93. LI R, Cao R, Zhang G, Ding L, et al
    Development of Dar3A Chelator and Construction of FAP-Targeted PET Probe as Proof of Concept and for First-in-Human Evaluation.
    J Nucl Med. 2026 Apr 9:jnumed.125.271421. doi: 10.2967/jnumed.125.271421.
    >> Share

  94. KIESS AP, Sunderland JJ, Scott PJH, Hope TA, et al
    Response to the FDA Dosage Optimization Draft Guidance for Radiopharmaceutical Therapies.
    J Nucl Med. 2026 Apr 9:jnumed.126.272138. doi: 10.2967/jnumed.126.272138.
    >> Share

  95. CAOBELLI F
    Whole-Body PET and the Brain-Heart Axis: Toward Sex- and Gender-Sensitive Neurocardiovascular Imaging.
    J Nucl Med. 2026 Apr 2:jnumed.126.272293. doi: 10.2967/jnumed.126.272293.
    >> Share

  96. PAKULA V, Dorneich JS, Frontzkowski L, Bartos LM, et al
    Detection of Focal Lesions in Epilepsy with [(18)F]UCB-H Synaptic Vesicle Protein 2A PET Imaging.
    J Nucl Med. 2026 Apr 2:jnumed.125.271505. doi: 10.2967/jnumed.125.271505.
    >> Share

  97. ELLS Z, Meyer C, Kimura K, Wilhalme H, et al
    Dosimetry Analysis of (177)Lu-PSMA-I&T in Patients with Low-Volume Oligometastatic Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the LUNAR Trial.
    J Nucl Med. 2026 Apr 2:jnumed.125.271467. doi: 10.2967/jnumed.125.271467.
    >> Share


  98. Should Nuclear Medicine Be an Independent Department?
    J Nucl Med. 2026;67:4A.
    >> Share

  99. ZANDERIGO F, Laurell GL, Doubrovin M, Molotkov A, et al
    Imaging Microtubule Dynamics In Vivo in Human Brain: Optimal Quantification Based on a Test-Retest Study.
    J Nucl Med. 2026;67:644-650.
    >> Share

  100. GRAVES SA, Bushnell DL, Schultz MK, Jain S, et al
    A Phase 0 Imaging Trial of [(203)Pb]Pb-VMT-alpha-NET to Enable Dosimetry and Treatment Planning for Refractory or Relapsed Metastatic Neuroendocrine Tumors with [(212)Pb]Pb-VMT-alpha-NET.
    J Nucl Med. 2026;67:576-583.
    >> Share

  101. ENKE JS, Baessler J, Chand G, Glantschnig L, et al
    Mass Dose Effects in FAP-Directed Imaging: Influence of Administered Dose of [(68)Ga]Ga-LNTH-1363S on Image Quality.
    J Nucl Med. 2026;67:590-593.
    >> Share

  102. GREISER J, Drescher R, Sonawane M, Kuehnel C, et al
    From Ostrich to Mouse to Human: Translation of the Functional Liver PET Tracer [(68)Ga]Ga-TEoS-DAZA.
    J Nucl Med. 2026;67:615-620.
    >> Share

    March 2026
  103. KIMURA K, Livhits MJ, Laklouk IA, Gupta PK, et al
    [(68)Ga]Ga-FAPI-46 PET/CT in Adrenocortical Neoplasm, Oncocytic Type.
    J Nucl Med. 2026 Mar 26:jnumed.125.270788. doi: 10.2967/jnumed.125.270788.
    >> Share

  104. WIDJAJA L, Hornfeck J, Siegmund SC, Gildehaus FJ, et al
    Prognostic Value of Early Follow-Up PSMA PET/CT After 2 Cycles of [(177)Lu]Lu-PSMA RPT in Patients with mCRPC: Comparison with PSA Dynamics.
    J Nucl Med. 2026 Mar 26:jnumed.125.271859. doi: 10.2967/jnumed.125.271859.
    >> Share

  105. GEENS W, Buyck F, Raes L, Schwarze JK, et al
    Prognostic Value of O-(2-(18)F-Fluoroethyl)-l-Tyrosine PET for Patients with Recurrent Glioblastoma.
    J Nucl Med. 2026 Mar 26:jnumed.125.270727. doi: 10.2967/jnumed.125.270727.
    >> Share

  106. NEISHABOURI A, Ghim M, Varli O, Ahmad AA, et al
    Molecular Imaging of Collagen Turnover in Myocardial Infarction.
    J Nucl Med. 2026 Mar 26:jnumed.125.271721. doi: 10.2967/jnumed.125.271721.
    >> Share

  107. JADVAR H
    Update to the Appropriate Use Criteria for (18)F-FDG PET/CT for Initial Staging of Malignant Disease.
    J Nucl Med. 2026 Mar 19:jnumed.126.272400. doi: 10.2967/jnumed.126.272400.
    >> Share

  108. LOLATTE K, Hess A, Willmann M, Strunk M, et al
    Deciphering Leukocyte Subpopulation Contributions to Ventricle Remodeling and Neuroinflammation After Myocardial Infarction Using Total-Body Molecular Imaging.
    J Nucl Med. 2026 Mar 19:jnumed.125.271451. doi: 10.2967/jnumed.125.271451.
    >> Share

  109. LI EJ, Kraya A, Costa-Pinheiro P, Scheuermann J, et al
    Metabolic Imaging and Molecular Signatures Reveal Metabolic Phenotypes in Recurrent Glioblastoma.
    J Nucl Med. 2026 Mar 19:jnumed.125.271476. doi: 10.2967/jnumed.125.271476.
    >> Share

  110. KASSAS M, Jaafari A, Shagera QA, Devriendt L, et al
    SPECT Versus PET for [(177)Lu]Lu-PSMA Response Assessment Using Quantitative RECIP 1.0.
    J Nucl Med. 2026 Mar 12:jnumed.125.271755. doi: 10.2967/jnumed.125.271755.
    >> Share

  111. ZHENG M, Ma H, Xu T, Mu H, et al
    Single-Domain Antibody Probe with Low Renal Uptake for Claudin 18.2-Targeted PET Imaging of Gastric Cancer: Preclinical and Pilot Clinical Evaluations.
    J Nucl Med. 2026 Mar 12:jnumed.125.271704. doi: 10.2967/jnumed.125.271704.
    >> Share

  112. GHODSI A, Demirci RA, Gulati R, Nelson PS, et al
    Prognostic Value of Cycle 1 SPECT SUV(mean) in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with (177)Lu-PSMA-617.
    J Nucl Med. 2026 Mar 12:jnumed.125.271593. doi: 10.2967/jnumed.125.271593.
    >> Share

  113. LI A, Sultan D, Heo GS, Detering L, et al
    Assessment of CCR2 PET as a Biomarker for Head and Neck Squamous Cell Carcinoma.
    J Nucl Med. 2026 Mar 12:jnumed.125.271601. doi: 10.2967/jnumed.125.271601.
    >> Share

  114. HOBART J, Da Pieve C, Raes F, Borys D, et al
    PD-L1 Immuno-PET Reveals Systemic Effects of Localized Oncolytic Virotherapy in a Mouse Model of Head and Neck Cancer.
    J Nucl Med. 2026 Mar 12:jnumed.125.270922. doi: 10.2967/jnumed.125.270922.
    >> Share

  115. GLANTSCHNIG L, Enke JS, Schuller BW, Fenn EJ, et al
    Initial Clinical Experience with [(177)Lu]Lu-RTX-2358 Radiopharmaceutical Therapy Targeting Fibroblast Activation Protein: Biodistribution, Pharmacokinetics, and Dosimetry.
    J Nucl Med. 2026 Mar 5:jnumed.125.271031. doi: 10.2967/jnumed.125.271031.
    >> Share

  116. SADIK M, Larsson M, Enqvist O, Edenbrandt L, et al
    Validation of an AI Method for Automated Lymphoma Metabolic Tumor Volume Segmentation Using a Public Benchmark PET/CT Dataset.
    J Nucl Med. 2026 Mar 5:jnumed.125.271605. doi: 10.2967/jnumed.125.271605.
    >> Share

  117. ALBANO D, Lanfranchi F, Bauckneht M, Massollo M, et al
    Diagnostic Yield of [(18)F]FDG PET/CT in FUO: An Italian Multicenter Study of 929 Patients.
    J Nucl Med. 2026 Mar 5:jnumed.125.271525. doi: 10.2967/jnumed.125.271525.
    >> Share

  118. POELARENDS RJ, van Dalen JA, Slart RHJA, Vendel BN, et al
    Toward Reliable Lesion Labeling Standards for AI in Nuclear Medicine.
    J Nucl Med. 2026 Mar 5:jnumed.125.271329. doi: 10.2967/jnumed.125.271329.
    >> Share

  119. O'SHEA A, Lewis AJM, Caravan P, Izquierdo-Garcia D, et al
    First-in-Human Study of the Carbohydrate Nanoparticle (64)Cu-Macrin.
    J Nucl Med. 2026;67:449-455.
    >> Share

  120. FRICKE JG, Westerbergh F, McDougall L, Favaretto C, et al
    Targeted beta(-)-Particle Plus Conversion and Auger-Electron Therapy with (161)Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study.
    J Nucl Med. 2026;67:416-422.
    >> Share

    February 2026
  121. BIO IDRISSOU M, Aguiar Ferreira C, Comas Rojas H, Lambert Lepesevich LH, et al
    Preclinical Evaluation of [(177)Lu]Lu-ART-101 for Radiopharmaceutical Therapy of Advanced Prostate Cancer.
    J Nucl Med. 2026 Feb 26:jnumed.125.271543. doi: 10.2967/jnumed.125.271543.
    >> Share

  122. KIANI I, Siri MA, Babaei M, Aliasghari MM, et al
    Quantitative PSMA PET Biomarkers for Predicting Response to (177)Lu-PSMA Therapy in Prostate Cancer: A Systematic Review and Meta-analysis.
    J Nucl Med. 2026 Feb 26:jnumed.125.270872. doi: 10.2967/jnumed.125.270872.
    >> Share

  123. LIU Q, Shi T, Gravel P, Sharma A, et al
    Parametric Cardiac Imaging with (18)F-Flutemetamol PET to Evaluate the Impact of Tafamidis in Patients with Transthyretin Cardiac Amyloidosis.
    J Nucl Med. 2026 Feb 26:jnumed.125.270003. doi: 10.2967/jnumed.125.270003.
    >> Share

  124. KARPIJOKI H, Tuisku J, Palonen S, Han C, et al
    Organ-Specific Perfusion Response to Adenosine as Measured Using Total-Body PET.
    J Nucl Med. 2026 Feb 26:jnumed.125.271613. doi: 10.2967/jnumed.125.271613.
    >> Share

  125. BELLINGE JW, Al-Ogali Z, Hofman MS, Bacchi S, et al
    Clinical Correlation No Longer Required: An LLM Practical Use Scenario in PET Reporting.
    J Nucl Med. 2026 Feb 26:jnumed.126.272216. doi: 10.2967/jnumed.126.272216.
    >> Share

  126. CHAUSSE G, Hou X, Uribe C, Harsini S, et al
    First-in-Human Evaluation of [(68)Ga]Ga-HTK03149, a PSMA-Targeted Tracer for PET Imaging in Prostate Cancer.
    J Nucl Med. 2026 Feb 26:jnumed.123.266357. doi: 10.2967/jnumed.123.266357.
    >> Share

  127. ALWAN M, Sayed A, El Yaman A, Shaikh A, et al
    Prevalence, Predictors, and Outcomes of Impaired Myocardial Flow Reserve Among Symptomatic Patients with a Coronary Artery Calcium Score of 0.
    J Nucl Med. 2026 Feb 26:jnumed.125.271141. doi: 10.2967/jnumed.125.271141.
    >> Share

  128. LANZAFAME H, Mavroeidi IA, Pabst KM, Fragoso Costa P, et al
    (90)Y-FAPI-46 Radiopharmaceutical Therapy in Sarcoma and Other Solid Tumors: An Updated Cohort Analysis.
    J Nucl Med. 2026 Feb 19:jnumed.125.271135. doi: 10.2967/jnumed.125.271135.
    >> Share

  129. KOO H, Mattay V, Hofling AA, Wang SJ, et al
    Advancing Theranostics in Alzheimer Disease: FDA Approval of Amyloid-beta PET Drugs for Selection of Patients for Amyloid-beta-Directed Therapies and Other Labeling Updates.
    J Nucl Med. 2026 Feb 19:jnumed.125.271312. doi: 10.2967/jnumed.125.271312.
    >> Share

  130. HERNANDEZ-MARTIN N, Balayeva T, Naganawa M, Asch RH, et al
    Noninvasive Quantification of [(18)F]SynVesT-2 PET in Healthy Human Brains Using Simplified Reference Tissue Models.
    J Nucl Med. 2026 Feb 12:jnumed.125.271207. doi: 10.2967/jnumed.125.271207.
    >> Share

  131. MOGENSEN AW, Torp-Pedersen C, Norgaard M, Petersen LJ, et al
    Biochemical Recurrence-Free Survival After Radical Prostatectomy in Patients with High-Risk Prostate Cancer: A Nationwide Study of PSMA PET/CT Versus Conventional Imaging.
    J Nucl Med. 2026 Feb 12:jnumed.125.271423. doi: 10.2967/jnumed.125.271423.
    >> Share

  132. KIMURA K, Murthy V, Voter AF, Solnes LB, et al
    PSMA PET/CT-Derived Indicators and Outcomes After [(177)Lu]Lu-PSMA-617: A Multicenter Retrospective Analysis from the U.S. Expanded-Access Program.
    J Nucl Med. 2026 Feb 12:jnumed.125.270789. doi: 10.2967/jnumed.125.270789.
    >> Share

  133. DAWSON DA, Provost K, Soucy JP, Maliha PG, et al
    Isolated Occipital Lobe Hypometabolism on [(18)F]FDG PET.
    J Nucl Med. 2026 Feb 12:jnumed.125.271677. doi: 10.2967/jnumed.125.271677.
    >> Share

  134. COLD S, Sadasivam P, Wessel MM, Ischyropoulou M, et al
    In Vivo Studies of [(161)Tb]Tb-Trastuzumab Radiopharmaceutical Therapy in Human Epidermal Growth Factor Receptor 2-Expressing Breast Tumors Show High Tumor Uptake and Tumor Growth Suppression.
    J Nucl Med. 2026 Feb 12:jnumed.125.269741. doi: 10.2967/jnumed.125.269741.
    >> Share

  135. PRIOR JO, Abdel-Wahab M, Frangos S, Hricak H, et al
    World Health Assembly Resolution WHA78.13 "Strengthening Medical Imaging Capacity": Impact on Nuclear Medicine Globally.
    J Nucl Med. 2026 Feb 12:jnumed.125.271611. doi: 10.2967/jnumed.125.271611.
    >> Share

  136. SCHRAUWEN C, Halloin N, Van Eetveldt A, Laermans Z, et al
    SV2A PET Imaging Detects Severity-Dependent Synaptic Changes After Experimental Traumatic Spinal Cord Injury.
    J Nucl Med. 2026 Feb 5:jnumed.125.271236. doi: 10.2967/jnumed.125.271236.
    >> Share

  137. MACCIONI L, Knyzeliene A, Alcaide-Corral CJ, Reid VJM, et al
    Network-Based Analysis for the Quantification of Brain and Body Immune Axes with Total-Body PET Imaging.
    J Nucl Med. 2026 Feb 5:jnumed.125.271514. doi: 10.2967/jnumed.125.271514.
    >> Share

  138. LI Z, Providencia L, Mohr P, Mostafapour S, et al
    Validation of a Deep-Learning Coregistration Framework for Long-Axial-Field-of-View PET/CT Using Low-Radiation-Exposure Protocols Across Various Tracers.
    J Nucl Med. 2026 Feb 5:jnumed.125.270420. doi: 10.2967/jnumed.125.270420.
    >> Share

  139. HOENIG MC, Dzialas V, Doering E, Bischof GN, et al
    Modifiable Factors Associated with the Longitudinal Increase and Spatial Extent of Tau Pathology in Alzheimer Disease.
    J Nucl Med. 2026;67:291-296.
    >> Share

  140. ROHRICH M, Glatting FM, Geisinger M, Spektor AM, et al
    Digital Biopsy and Network Analysis of Dynamic [(68)Ga]Ga-FAPI-46 Data in Patients with Malignant and Benign Pancreatic Lesions.
    J Nucl Med. 2026;67:304-312.
    >> Share

  141. MORTENSEN ACL, Mohajershojai T, Gustafsson A, Berglund H, et al
    Preclinical Validation of [(177)Lu]Lu-AKIR001, a CD44v6-Targeted Radiotherapeutic Entering First-in-Human Trials.
    J Nucl Med. 2026;67:269-275.
    >> Share

  142. FRAGOSO-NEGRIN JA, Vergara-Gil A, Rahman Hakim A, Hardiansyah D, et al
    OpenDose3D: A Free, Open-Source Clinical Dosimetry Software for Patient-Specific Dosimetry.
    J Nucl Med. 2026;67:276-282.
    >> Share

    January 2026
  143. LI Y, Yang J, Chen B, Xiao L, et al
    Head-to-Head Comparison of mpMRI, PSMA, GRPR PET/CT, and PET/CT Plus MRI for Local Staging of Primary Prostate Cancer and Their Prognostic Value.
    J Nucl Med. 2026 Jan 29:jnumed.125.271410. doi: 10.2967/jnumed.125.271410.
    >> Share

  144. WIDJAJA L, Siegmund SC, Gildehaus FJ, Delker A, et al
    PET-Based Outcome Prediction in Patients with Prostate Cancer Scheduled for [(225)Ac]Ac-PSMA Radiopharmaceutical Therapy.
    J Nucl Med. 2026 Jan 29:jnumed.125.270677. doi: 10.2967/jnumed.125.270677.
    >> Share

  145. GREISER J, Drescher R, Sonawane M, Kuehnel C, et al
    From Ostrich to Mouse to Human: Translation of the Functional Liver PET Tracer [(68)Ga]Ga-TEoS-DAZA.
    J Nucl Med. 2026 Jan 29:jnumed.125.271020. doi: 10.2967/jnumed.125.271020.
    >> Share

  146. CERCI JJ, Fanti S, Lobato EE, Kumar R, et al
    (68)Ga-PSMA-11 PET/CT for Initial Staging of Unfavorable Intermediate-Risk and High-Risk Prostate Cancer Predicts Overall Survival: An IAEA Multicenter Study.
    J Nucl Med. 2026 Jan 29:jnumed.125.271173. doi: 10.2967/jnumed.125.271173.
    >> Share

  147. NIJVELDT JJ, Af Buren S, Tran TA, Jussing E, et al
    Feasibility of [(89)Zr]Zr-Atezolizumab Immuno-PET for PD-L1 Quantification in the Clinical Work-up of Metastatic Triple-Negative Breast Cancer.
    J Nucl Med. 2026 Jan 29:jnumed.125.271459. doi: 10.2967/jnumed.125.271459.
    >> Share

  148. NG E, Jong I, Lau KK, Akram M, et al
    Identification of Aldosterone-Producing Adrenal Adenomas Using [(68)Ga]Ga-Pentixafor PET/CT in an Australian Cohort.
    J Nucl Med. 2026 Jan 29:jnumed.125.271006. doi: 10.2967/jnumed.125.271006.
    >> Share

  149. SATOH R, Ali F, Dickson DW, Lowe VJ, et al
    Subtracting First Principal Component May Improve 4R Tau Detectability on [(18)F]Flortaucipir Tau PET.
    J Nucl Med. 2026 Jan 22:jnumed.125.271019. doi: 10.2967/jnumed.125.271019.
    >> Share

  150. NGAM PI, Anzai Y, Cliatt Brown CJ, Frost NA, et al
    Copathologies of Limbic-Predominant Age-Related TDP-43 Encephalopathy and Alzheimer Disease: [(18)F]FDG PET Statistical Mapping and Quantitative MRI Volumetry.
    J Nucl Med. 2026 Jan 22:jnumed.125.270614. doi: 10.2967/jnumed.125.270614.
    >> Share

  151. CAN C, Komek H, Guzel Y, Akdeniz N, et al
    Head-to-Head Comparison of [(68)Ga]Ga-DOTATATE PET/CT and [(68)Ga]Ga-NODAGA-LM3 PET/CT.
    J Nucl Med. 2026 Jan 16:jnumed.125.271074. doi: 10.2967/jnumed.125.271074.
    >> Share

  152. MIRSHAHVALAD SA, Hodgson D, Kuruvilla J, Veit-Haibach P, et al
    Prognostic Value of Interim [(18)F]FDG PET in Large B-Cell Lymphoma: A Systematic Review and Meta-analysis with a Particular Focus on Interim Deauville Score 5 Disease.
    J Nucl Med. 2026 Jan 16:jnumed.125.271089. doi: 10.2967/jnumed.125.271089.
    >> Share

  153. AKCA U, Song PN, Devalankar D, Yasui N, et al
    Preclinical Comparison of (18)F-Labeled Amino Acids Targeting Different Transporter Systems for PET Imaging of Triple-Negative Breast Cancer.
    J Nucl Med. 2026 Jan 8:jnumed.125.270225. doi: 10.2967/jnumed.125.270225.
    >> Share

  154. ABDEL-WAHAB M, Giammarile F
    Nuclear Medicine and External Beam Radiation Therapy in Prostate Cancer: A Synergistic Approach.
    J Nucl Med. 2026 Jan 8:jnumed.125.271268. doi: 10.2967/jnumed.125.271268.
    >> Share

  155. CHRISTENSEN TN, Langer SW, Dejanovic D, Gillings N, et al
    Malignancy Detection Rates of [(68)Ga]Ga-SSO120 PET/CT in Patients with Small Cell Lung Cancer and Large Cell Neuroendocrine Lung Cancer.
    J Nucl Med. 2026 Jan 8:jnumed.125.270233. doi: 10.2967/jnumed.125.270233.
    >> Share

  156. KESSLER L, Schwaning F, Metzenmacher M, Pabst KM, et al
    Prognostic Value of Fibroblast Activation Protein-Directed PET Imaging in Pleural Mesothelioma.
    J Nucl Med. 2026 Jan 8:jnumed.125.270906. doi: 10.2967/jnumed.125.270906.
    >> Share

  157. WERNER JM, Lohmann P, Kabbasch C, Wollring MM, et al
    Assessment of Response to Regorafenib in Patients with Glioma Relapse Using (18)F-FET PET and MRI.
    J Nucl Med. 2026 Jan 8:jnumed.125.270946. doi: 10.2967/jnumed.125.270946.
    >> Share

  158. SHANG C, Nagao R, Riku Y, Ichihara T, et al
    Serotonin Transporter Distribution in the Brainstem of Multiple-System Atrophy-Parkinsonian Type: Insights from Pathology and (123)I-FP-CIT SPECT Findings.
    J Nucl Med. 2026 Jan 8:jnumed.124.268669. doi: 10.2967/jnumed.124.268669.
    >> Share


  159. SPARC: Overarching Framework for PSMA PET Reporting.
    J Nucl Med. 2026;67:4A.
    >> Share

  160. COOK BE, McLaren DG, Sullivan JM, El Fakhri G, et al
    Central Nervous System Biodistribution and Pharmacokinetics of Radiolabeled Tofersen in Rodents, Nonhuman Primates, and Humans.
    J Nucl Med. 2026;67:139-144.
    >> Share

    December 2025
  161. DEXL J, Gatidis S, Fruh M, Jeblick K, et al
    AutoPET Challenge on Fully Automated Lesion Segmentation in Oncologic PET/CT Imaging, Part 2: Domain Generalization.
    J Nucl Med. 2025 Dec 30:jnumed.125.270260. doi: 10.2967/jnumed.125.270260.
    >> Share

  162. ZHENG X, Zhang Y, Fang J, Li L, et al
    CD70-Targeted Immuno-PET/CT for Detecting Heterogeneous CD70 Expression in Lymphomas: A Pilot Clinical Study.
    J Nucl Med. 2025 Dec 30:jnumed.125.271097. doi: 10.2967/jnumed.125.271097.
    >> Share

  163. LAZZERONI M, Ureba A, Schafer H, Nicolay NH, et al
    Biologically Individualized Radiotherapy Based on PET: A Novel Approach to Treatment Optimization of Head and Neck Cancer.
    J Nucl Med. 2025 Dec 30:jnumed.125.270403. doi: 10.2967/jnumed.125.270403.
    >> Share

  164. MOAR EF, Keilholz M, Sheikh GT, Werner RA, et al
    PSMA PET-Positive Local Recurrences in the Prostate Bed Region and Their Coverage Based on Clinical Target Volume Delineation Guidelines from ESTRO-ACROP, PERYTON, FROGG, GFRU, and RTOG.
    J Nucl Med. 2025 Dec 30:jnumed.125.271324. doi: 10.2967/jnumed.125.271324.
    >> Share

  165. ZHANG B, Long Y, Zhang Y, He Q, et al
    Ascorbic Acid Analog 6-Deoxy-6-(18)F-Fluoro-l-Ascorbic Acid PET Imaging of 23 Various Cancer Types.
    J Nucl Med. 2025 Dec 30:jnumed.125.270983. doi: 10.2967/jnumed.125.270983.
    >> Share

  166. SALERNO I, Dunn N, White H, Miyazaki W, et al
    Quantitative Comparison of SPECT and PET Performance for Clinical Theranostic Applications.
    J Nucl Med. 2025 Dec 30:jnumed.125.270987. doi: 10.2967/jnumed.125.270987.
    >> Share

  167. CATALANO OA, Bhan I, Asmundo L, Bradley WR, et al
    Diagnostic Performance of PSMA PET/MRI in Characterizing LI-RADS 3 Observations in Patients with Cirrhosis.
    J Nucl Med. 2025 Dec 30:jnumed.125.271228. doi: 10.2967/jnumed.125.271228.
    >> Share

  168. VAN BINSBERGEN WH, de Jongh J, Yaqub M, van der Pas S, et al
    Macrophage-Targeted [(11)C]DPA-713 PET/CT Imaging for Early Therapeutic Evaluation of Anti-Tumor Necrosis Factor Treatment in Rheumatoid Arthritis.
    J Nucl Med. 2025 Dec 30:jnumed.125.270289. doi: 10.2967/jnumed.125.270289.
    >> Share

  169. MORRIS MJ, Hope TA, Sartor O
    Concepts in Phase 1 Radiopharmaceutical Therapy Trial Designs: Lessons from the SNMMI Dose Optimization in Radiopharmaceutical Therapy Development Workshop.
    J Nucl Med. 2025 Dec 30:jnumed.125.270792. doi: 10.2967/jnumed.125.270792.
    >> Share

  170. SHEEHAN-KLENK J, Makala H, Chung JY, Lee W, et al
    Tetraspanin-8 as a Tumor-Selective Immuno-PET Target in Hepatocellular Carcinoma.
    J Nucl Med. 2025 Dec 30:jnumed.125.270594. doi: 10.2967/jnumed.125.270594.
    >> Share

  171. RONG Z, Liu H, Teng X, Chen L, et al
    Construction and Evaluation of Guanylyl Cyclase C-Specific Antibody for Noninvasive Diagnosis and Targeted Therapy of Colorectal Cancer.
    J Nucl Med. 2025 Dec 30:jnumed.125.270400. doi: 10.2967/jnumed.125.270400.
    >> Share

  172. ZHANG M, Qian J, Jia Y, Yu S, et al
    Translocator Protein 18 kDa-Targeted Total-Body PET Imaging Reveals Immune-Specific Vascular Inflammation in Large-Vessel Vasculitis: A Prospective Head-to-Head Comparison with (18)F-FDG.
    J Nucl Med. 2025 Dec 18:jnumed.125.270910. doi: 10.2967/jnumed.125.270910.
    >> Share

  173. MARSH IR, Quon H, Santhanam P, Wang H, et al
    Combination Radiopharmaceutical Therapy and Radiotherapy for Thyroid Cancer: Dosimetry-Driven Precision Medicine.
    J Nucl Med. 2025 Dec 18:jnumed.120.253443. doi: 10.2967/jnumed.120.253443.
    >> Share

  174. YEH R
    Reply: The Role of HER2 PET in Treatment of Breast Cancer.
    J Nucl Med. 2025 Dec 11:jnumed.125.271241. doi: 10.2967/jnumed.125.271241.
    >> Share

  175. MA C, Cao M, Li L, Wu Q, et al
    CD70-Targeted [(18)F]RCCB6 Immuno-PET/CT for Diagnosing Clear Cell Renal Cell Carcinoma Metastases: A Prospective Study.
    J Nucl Med. 2025 Dec 11:jnumed.125.270958. doi: 10.2967/jnumed.125.270958.
    >> Share

  176. VAN DEN BROEK SL, Bratteby K, Aguilar X, Tran TA, et al
    Radionuclide Selection Influences Imaging Outcomes in Immuno-PET with a Brain-Penetrating Anti-Amyloid-beta Antibody.
    J Nucl Med. 2025 Dec 11:jnumed.125.271194. doi: 10.2967/jnumed.125.271194.
    >> Share

  177. BRINK A, Kleynhans J, Grigoryan A, Omar W, et al
    The Current Status of Nuclear Medicine in Africa.
    J Nucl Med. 2025 Dec 11:jnumed.125.271248. doi: 10.2967/jnumed.125.271248.
    >> Share

  178. SONG J, Ye J
    Critical Evaluation of HER2 PET Imaging in Metastatic Breast Cancer: Addressing Key Challenges and Future Directions.
    J Nucl Med. 2025 Dec 11:jnumed.125.271101. doi: 10.2967/jnumed.125.271101.
    >> Share

  179. URSO L, Boschi A, Schillaci O, Filippi L, et al
    Illuminating Multiple Sclerosis: Next-Generation PET Tracers for Molecular Insights.
    J Nucl Med. 2025 Dec 11:jnumed.125.271204. doi: 10.2967/jnumed.125.271204.
    >> Share

  180. HEO GS, Nai YH, Otaegui JR, Yang S, et al
    Preclinical Evaluation of (64)Cu-LNTH-1363S to Detect Cardiac FAP-Positive Fibroblasts Using PET Imaging.
    J Nucl Med. 2025 Dec 11:jnumed.125.270555. doi: 10.2967/jnumed.125.270555.
    >> Share

  181. BADING JR, Mortimer JE
    The Role of HER2 PET in Treatment of Breast Cancer.
    J Nucl Med. 2025 Dec 11:jnumed.125.271364. doi: 10.2967/jnumed.125.271364.
    >> Share

  182. AUER B, De Moraes A, Pabon AJR, Clerc OF, et al
    Dynamic Acquisition of [(99m)Tc]Tc-Pyrophosphate SPECT/CT Images in Transthyretin Cardiac Amyloidosis: A Pilot Study.
    J Nucl Med. 2025 Dec 11:jnumed.125.270405. doi: 10.2967/jnumed.125.270405.
    >> Share

  183. SPECHT JM, van Geel JJL, Song S, Liu C, et al
    The Role of Estrogen Receptor-Targeted PET with 16alpha-(18)F-Fluoro-17beta-Estradiol in Predicting Response to Endocrine Therapies in Metastatic Breast Cancer: A Metaanalysis.
    J Nucl Med. 2025 Dec 4:jnumed.125.270763. doi: 10.2967/jnumed.125.270763.
    >> Share

  184. CHEN Y, Mintzer RA, Cho S, Pocci D, et al
    Development of a Prototype AWSM-PET Device for Augmented Whole-Body PET Imaging and Initial Human Study.
    J Nucl Med. 2025 Dec 4:jnumed.125.270117. doi: 10.2967/jnumed.125.270117.
    >> Share

  185. MAURER A, Muehlematter UJ, Sivakumar T, Mortezavi A, et al
    High-Intensity Focused Ultrasound in Prostate Cancer: Can PSMA PET Improve Focal Therapy Outcomes?
    J Nucl Med. 2025 Dec 4:jnumed.125.271318. doi: 10.2967/jnumed.125.271318.
    >> Share

  186. HU Q, Zhang S, Yang K, Yin Y, et al
    (68)Ga-FAPI-04 PET for Detecting Occult Peritoneal Metastasis in Locally Advanced Gastric Cancer: Diagnostic Performance and Cost Analyses in a Single-Center, Prospective Cohort Study.
    J Nucl Med. 2025 Dec 4:jnumed.125.270633. doi: 10.2967/jnumed.125.270633.
    >> Share

  187. TREVES ST, Fahey FH, Valencia VF, Burchell N, et al
    Summary of the 2024 Update of the North American Guidelines for Pediatric Administered Radiopharmaceutical Activities.
    J Nucl Med. 2025 Dec 4:jnumed.125.270478. doi: 10.2967/jnumed.125.270478.
    >> Share

  188. MURTHY V, Kimura K, Theus L, Nguyen A, et al
    Linking Baseline PSMA PET-Derived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [(177)Lu]Lu-PSMA-617: A Single-Center Retrospective Study.
    J Nucl Med. 2025 Dec 4:jnumed.125.270916. doi: 10.2967/jnumed.125.270916.
    >> Share


  189. PET-Guided Radiotherapy: Reflections?
    J Nucl Med. 2025;66:4A.
    >> Share

  190. URBAIN JL
    A New Era of Precision Medicine: The SNMMI Is Leading Progress in Nuclear Medicine and Radiopharmaceutical Therapy.
    J Nucl Med. 2025;66:7A-8A.
    >> Share

  191. CZERNIN J
    A New Department for a New Era of Nuclear Medicine and Theranostics.
    J Nucl Med. 2025;66:1847.
    >> Share

  192. DECK A, Lane S, Liles A, Viola NT, et al
    Nuclear Imaging Strategies to Evaluate Cytokine Production in Autoimmune, Inflammatory, and Neoplastic Diseases: A Review of Current Preclinical Research.
    J Nucl Med. 2025;66:2002-2013.
    >> Share

  193. ZHANG J, Soleimani-Meigooni DN, Koeppe R, Ackley S, et al
    Exploring Centiloid Robustness: Impact of Sample Size and Image Resolution on Centiloid Conversion Accuracy.
    J Nucl Med. 2025;66:1976-1984.
    >> Share

  194. ROWE SP, Shuch BM, Ball MW, Bex A, et al
    SNMMI/EANM/ACNM Procedure Standard/Procedure Guideline on the Use of Molecular Imaging for Renal Mass Characterization.
    J Nucl Med. 2025;66:1863-1870.
    >> Share

  195. VOLPI T, Gallezot JD, Henry S, Dias M, et al
    Carotid Artery Image-Derived Blood Time-Activity Curves on the NeuroEXPLORER: Initial Multitracer Validation Against Arterial Sampling.
    J Nucl Med. 2025;66:1993-2001.
    >> Share

  196. MILLER SR, Chung DH, Gonzalez RT, Jackson WC, et al
    Impact of PSMA PET Staging on Initial Treatment in Newly Diagnosed Prostate Cancer.
    J Nucl Med. 2025;66:1891-1897.
    >> Share

    November 2025
  197. GABLER N, Kirchhoff S, Sauter A, Heck M, et al
    [(18)F]Flotufolastat PET/MRI in Patients with Suspected Prostate Cancer: Correlation with Histopathologic Biopsy Results.
    J Nucl Med. 2025 Nov 25:jnumed.125.270435. doi: 10.2967/jnumed.125.270435.
    >> Share

  198. RAHMIM A, Bradshaw TJ, Davidzon G, Dutta J, et al
    Nuclear Medicine AI in Action: The Bethesda Report (AI Summit 2024).
    J Nucl Med. 2025 Nov 25:jnumed.125.269540. doi: 10.2967/jnumed.125.269540.
    >> Share

  199. HESSE L, Gillett D, MacFarlane J, Pirlich M, et al
    Comparative PET Imaging for Radiosurgical Target Delineation in Residual Acromegaly.
    J Nucl Med. 2025 Nov 25:jnumed.125.270365. doi: 10.2967/jnumed.125.270365.
    >> Share

  200. BUCH-OLSEN KM, Vilstrup MH, Hansen S, Poulsen MH, et al
    Primary Staging of Intermediate- and High-Risk Prostate Cancer Using [(18)F]PSMA-1007 PET/CT and [(18)F]NaF PET/CT: A Head-to-Head Comparison of Diagnostic Accuracy, Staging, and Patient Management.
    J Nucl Med. 2025 Nov 25:jnumed.125.270710. doi: 10.2967/jnumed.125.270710.
    >> Share

  201. SCOTT PJH, VanBrocklin HF, Cumming RC, Dick DW, et al
    FDA Investigator Training for PET Drug Manufacturing Inspections.
    J Nucl Med. 2025 Nov 25:jnumed.125.271221. doi: 10.2967/jnumed.125.271221.
    >> Share

  202. CHIOTIS K, Wang Y, La Joie R, Rabinovici GD, et al
    The Role of Amyloid-beta and Tau PET in the New Era of Alzheimer Disease Therapies.
    J Nucl Med. 2025 Nov 25:jnumed.124.268339. doi: 10.2967/jnumed.124.268339.
    >> Share

  203. HARTENBACH M, Rasul S, Grubmuller B, Kramer G, et al
    PSMA-Directed PET/MRI Enables Noninvasive Diagnosis and Prognosis in Patients with Increased PSA Levels: Results from the Prospective Randomized RAPID Trial.
    J Nucl Med. 2025 Nov 20:jnumed.125.270404. doi: 10.2967/jnumed.125.270404.
    >> Share

  204. RAHEEM SJ, Bashyal S, Haj-Mirzaian A, Khazaei Monfared Y, et al
    Claudin 18.2 as a Biomarker for Imaging and Radiopharmaceutical Therapy in Gastric and Pancreatic Tumors.
    J Nucl Med. 2025 Nov 20:jnumed.125.270568. doi: 10.2967/jnumed.125.270568.
    >> Share

  205. BARTEL T, Pabst KM, Barg C, Berliner CA, et al
    [(68)Ga]Ga-FAPI-46 PET/CT of Patients with Gastrointestinal Stromal Tumors in Comparison to 2-[(18)F]FDG PET/CT and Contrast-Enhanced CT: Results from a Prospective Observational Study.
    J Nucl Med. 2025 Nov 20:jnumed.125.270850. doi: 10.2967/jnumed.125.270850.
    >> Share

  206. KESNER AL, Batista N, Zanzonico P, Cutler CS, et al
    A Cures Act-Forged Pathway to Patient-Tailored Radiopharmaceutical Therapy and Call for Regulatory Transparency.
    J Nucl Med. 2025 Nov 20:jnumed.125.270348. doi: 10.2967/jnumed.125.270348.
    >> Share

  207. WANG G, Lai Y, Chen D, Jin W, et al
    First-in-Human PET Imaging of Prostate Cancer Using [(68)Ga]Ga-AZ-093 and Its Nitroimidazole-Conjugated Derivative [(68)Ga]Ga-AZ-NI-093.
    J Nucl Med. 2025 Nov 20:jnumed.125.270703. doi: 10.2967/jnumed.125.270703.
    >> Share

  208. GHEZZO S, Mapelli P, Cogrossi LL, Samanes Gajate AM, et al
    Diagnostic Accuracy of Fully Hybrid PET/MRI with [(68)Ga]Ga-PSMA-11 and [(68)Ga]Ga-RM2 in Detecting Primary Prostate Cancer: A Phase 2 Trial with Histology as Gold Standard.
    J Nucl Med. 2025 Nov 20:jnumed.125.269782. doi: 10.2967/jnumed.125.269782.
    >> Share

  209. HOEKSTRA RJ, Peeters L, Beulens A, Roef MJ, et al
    Prospective Histopathologic Comparison Between [(18)F]PSMA-1007 PET/CT and [(18)F]Fluciclovine PET/CT of Intraprostatic Tumor Detection: The TRACER Study.
    J Nucl Med. 2025 Nov 13:jnumed.125.270650. doi: 10.2967/jnumed.125.270650.
    >> Share

  210. ZAJICEK F, Elvas F, Miranda A, Akkermans J, et al
    In Vivo PET Imaging of [(18)F]CHDI-385, a Radioligand for Mutant Huntingtin Aggregates in a Mouse Model of Huntington Disease.
    J Nucl Med. 2025 Nov 13:jnumed.125.270660. doi: 10.2967/jnumed.125.270660.
    >> Share

  211. NIMMAGADDA S
    SIRPalpha Immuno-PET Provides a Pan-Myeloid View of Immune Activity During COVID-19.
    J Nucl Med. 2025 Nov 13:jnumed.125.270781. doi: 10.2967/jnumed.125.270781.
    >> Share

  212. HOLZGREVE A, Mona CE, Kimura K, Li X, et al
    Liquid Biopsy of Circulating Tumor Cells and DNA in the Context of PSMA Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Nov 13:jnumed.125.270651. doi: 10.2967/jnumed.125.270651.
    >> Share

  213. CERCI JJ, Fanti S, Lobato EE, Kumar R, et al
    (68)Ga-PSMA-11 in Staging of Unfavorable Intermediate- and High-Risk Prostate Cancer Reduces Indication for Noncurative Prostatectomy: A Prospective, Multicenter, International IAEA Study.
    J Nucl Med. 2025 Nov 13:jnumed.125.270537. doi: 10.2967/jnumed.125.270537.
    >> Share

  214. XIA M, Bayerlein R, Chemli Y, Liu X, et al
    On Hallucinations in Artificial Intelligence-Generated Content for Nuclear Medicine Imaging (the DREAM Report).
    J Nucl Med. 2025 Nov 6:jnumed.125.270653. doi: 10.2967/jnumed.125.270653.
    >> Share

  215. MICHALSKI K, Reiter FP, Kosmala A, Hartrampf PE, et al
    Diagnostic Performance of [(18)F]PSMA-1007 PET/CT on Proven PSMA-Positive Hepatocellular Carcinoma: A Prospective Clinical Study.
    J Nucl Med. 2025 Nov 6:jnumed.125.270755. doi: 10.2967/jnumed.125.270755.
    >> Share

  216. KRAUSEWITZ P, Essler M, Gaertner FC, Attenberger U, et al
    Impact of Initial Prostate-Specific Membrane Antigen PET/CT Staging and Prostate-Specific Membrane Antigen-Targeted Biopsy on Treatment Decisions in Prostate Cancer: Results from the Phase 2 DEPROMP Trial.
    J Nucl Med. 2025 Nov 6:jnumed.125.271344. doi: 10.2967/jnumed.125.271344.
    >> Share

  217. ORTNER G, Hoderlein X, Barbato F, Beyersdorff D, et al
    The Pelvic Rosetta Classification Project: An Interdisciplinary Proposal for a Lymph Node Map of the Pelvis in Prostate Cancer.
    J Nucl Med. 2025 Nov 6:jnumed.125.270667. doi: 10.2967/jnumed.125.270667.
    >> Share

  218. VIERING O, Brosch-Lenz J, Bundschuh RA, Scholtissek H, et al
    Biodistribution and Radiation Dosimetry of [(68)Ga]Ga-RAYZ-8009, a Glypican 3-Targeting Compound for Imaging of Hepatocellular Carcinoma.
    J Nucl Med. 2025;66:1737-1742.
    >> Share

  219. JACKSON P, Buteau JP, McIntosh L, Sun Y, et al
    Deep Learning for Automated Measures of SUV and Molecular Tumor Volume in [(68)Ga]PSMA-11 or [(18)F]DCFPyL, [(18)F]FDG, and [(177)Lu]Lu-PSMA-617 Imaging with Global Threshold Regional Consensus Network.
    J Nucl Med. 2025;66:1811-1817.
    >> Share

  220. MARQUIS H, Gustafsson J, Schmidtlein CR, de Nijs R, et al
    MIRD Pamphlet No. 33: MIRDpvc-A Software Tool for Recovery Coefficient-Based Partial-Volume Correction.
    J Nucl Med. 2025;66:1803-1810.
    >> Share

    October 2025
  221. ANDERSSON M, Goudin N, Pontoglio M, Reynaert N, et al
    A Computational Multinephron Model for Small-Scale Preclinical Renal Dosimetry in Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Oct 30:jnumed.125.270151. doi: 10.2967/jnumed.125.270151.
    >> Share

  222. MOHR P, Li Z, van Sluis J, Lub-de Hooge MN, et al
    Delayed [(89)Zr]Zr-N-Succinyldesferal-Trastuzumab Imaging Enabled by Long-Axial-Field-of-View PET/CT.
    J Nucl Med. 2025 Oct 30:jnumed.125.270547. doi: 10.2967/jnumed.125.270547.
    >> Share

  223. JUENGLING F, Riauka T, Shiyam Sundar LK
    Safeguarding Global AI Progress: The Role of Scientific Societies in Ensuring Equitable Data Access in Nuclear Medicine.
    J Nucl Med. 2025 Oct 30:jnumed.125.270717. doi: 10.2967/jnumed.125.270717.
    >> Share

  224. DJAILEB L, Farolfi A, Rauscher I, Haghighatian M, et al
    Clinical Impact of Changes in Tumor Uptake and Volume on PSMA PET/CT During [(177)Lu]Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2025 Oct 30:jnumed.125.270239. doi: 10.2967/jnumed.125.270239.
    >> Share

  225. AKCA U, Zhang Y, Yasui N, Hensley C, et al
    PET Imaging of System A Amino Acid Transport Detects Early Response to Immune Checkpoint Inhibitor Therapy in a Syngeneic Mouse Model.
    J Nucl Med. 2025 Oct 23:jnumed.125.270466. doi: 10.2967/jnumed.125.270466.
    >> Share

  226. JACENE HA, Urbain JL, Lewis JS, Nadel H, et al
    Radiopharmaceutical Therapy: Rapid Growth, Rising Challenges, and the Critical Need for Expertise.
    J Nucl Med. 2025 Oct 23:jnumed.125.271028. doi: 10.2967/jnumed.125.271028.
    >> Share

  227. GEBRUERS J, Terwinghe C, Graven LH, Everaert H, et al
    Extravasation of Therapeutic Radiopharmaceuticals: A Systematic Review and Management Proposal.
    J Nucl Med. 2025 Oct 23:jnumed.125.270215. doi: 10.2967/jnumed.125.270215.
    >> Share

  228. RAHBAR K, Giesel FL, Herrmann K, Yun M, et al
    Efficacy of [(18)F]PSMA-1007 PET/CT in Primary Staging of Prostate Carcinoma: A Systematic Review and Metaanalysis.
    J Nucl Med. 2025 Oct 23:jnumed.125.269818. doi: 10.2967/jnumed.125.269818.
    >> Share

  229. EDER AC, Omrane MA, El Fakiri M, Wielenberg CF, et al
    First-in-Human PET Imaging of MT1-MMP in a Patient with Breast and Muscle-Invasive Urothelial Bladder Cancer Using the Bicyclic Radiotracer [(68)Ga]Ga-BCY25286.
    J Nucl Med. 2025 Oct 16:jnumed.125.269882. doi: 10.2967/jnumed.125.269882.
    >> Share

  230. MSHERGHI A, Wong F, Xu G, Mawlawi O, et al
    (18)F-FDG PET Reveals Voxel-Based Decreases in Brain Glucose Uptake After Chemotherapy in Leukemia Patients: A Retrospective Matched-Control Study.
    J Nucl Med. 2025 Oct 16:jnumed.125.270661. doi: 10.2967/jnumed.125.270661.
    >> Share

  231. KOEHLER D, Shenas F, Sauer M, Apostolova I, et al
    PSMA PET Evaluation with a Deep Learning Platform Compared with a Standard Image Viewer and Histopathology.
    J Nucl Med. 2025 Oct 16:jnumed.125.270242. doi: 10.2967/jnumed.125.270242.
    >> Share

  232. TOLBOOM N, Albert NL, Braat AJAT, Snijders TJ, et al
    From Compassionate Use Toward High-Level Evidence for Radiopharmaceutical Therapy in Recurrent Meningioma: The LUMEN-1 and MOMENTUM-1 Trials.
    J Nucl Med. 2025 Oct 16:jnumed.125.270820. doi: 10.2967/jnumed.125.270820.
    >> Share

  233. MILLER SR, Chung DH, Gonzalez RT, Jackson WC, et al
    Impact of PSMA PET Staging on Initial Treatment in Newly Diagnosed Prostate Cancer.
    J Nucl Med. 2025 Oct 16:jnumed.125.270825. doi: 10.2967/jnumed.125.270825.
    >> Share

  234. HOLZGREVE A, Unterrainer LM, Flores K, Lam EC, et al
    FAP Expression in Renal Tumors Assessed by [(68)Ga]Ga-FAPI-46 PET Imaging and FAP Immunohistochemistry: A Case Series of Six Patients from the Prospective Exploratory Trial NCT04147494.
    J Nucl Med. 2025 Oct 16:jnumed.125.270346. doi: 10.2967/jnumed.125.270346.
    >> Share

  235. MCGAHAN W, Chadwick A, Lindsay K, Gulhane B, et al
    (68)Ga-FAPI PET/CT Prevents Futile Surgery and Demonstrates Tumor Biology in Patients with Pancreatic Ductal Adenocarcinoma.
    J Nucl Med. 2025 Oct 9:jnumed.125.270510. doi: 10.2967/jnumed.125.270510.
    >> Share

  236. MADSEN C, Zacho HD, Fuglo D, Nielsen K, et al
    (18)F-PSMA PET/CT Versus (18)F-NaF PET/CT for Staging and Treating Newly Diagnosed High-Risk Prostate Cancer: A Prospective Single-Center Study.
    J Nucl Med. 2025 Oct 9:jnumed.125.270822. doi: 10.2967/jnumed.125.270822.
    >> Share

  237. CHEN DC, Buteau JP, Papa N, Akhurst T, et al
    Prognostic Value of Initial Imaging and PSA Change with [(177)Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis.
    J Nucl Med. 2025 Oct 9:jnumed.125.270804. doi: 10.2967/jnumed.125.270804.
    >> Share

  238. GOLDSTEIN DS, Holmes C, Ding YS
    Multitracer PET to Assess Cardiac Sympathetic Innervation and Vesicular Storage in Lewy Body Diseases.
    J Nucl Med. 2025 Oct 3:jnumed.125.269840. doi: 10.2967/jnumed.125.269840.
    >> Share

  239. MOSTAFAPOUR S, van Sluis J, van Snick JH, Noordzij W, et al
    Influence of Ultra-Low-Dose CT on PET Image Quantification and Visual Assessment.
    J Nucl Med. 2025 Oct 3:jnumed.124.269188. doi: 10.2967/jnumed.124.269188.
    >> Share

  240. SARTOR O, Emmett L, Herrmann K
    Resisting RECIST: PSMA PET and Regulatory Change in Prostate Cancer.
    J Nucl Med. 2025 Oct 3:jnumed.125.271144. doi: 10.2967/jnumed.125.271144.
    >> Share

  241. HOYVIK AJK, Stenberg VY, Liukaityte R, Repetto-Llamazares A, et al
    Optimizing [(212)Pb]Pb-AB001 Radiopharmaceutical Therapy Schedules in PSMA-Positive Subcutaneous Prostate Cancer Xenografts.
    J Nucl Med. 2025 Oct 3:jnumed.125.270444. doi: 10.2967/jnumed.125.270444.
    >> Share

  242. KUCUK NO, Coskun N, Araz M, Alan Selcuk N, et al
    Initial Multicenter Experience with [(161)Tb]Tb-PSMA in [(177)Lu]Lu-PSMA-Refractory Metastatic Castration-Resistant Prostate Cancer: Preliminary Results.
    J Nucl Med. 2025 Oct 3:jnumed.125.270952. doi: 10.2967/jnumed.125.270952.
    >> Share

  243. KUJAWSKI M, Aniogo E, Wong P, Hui S, et al
    Combination Image-Guided and Antibody-Targeted alpha-Therapy Before Targeted Immunotherapy for Treatment of Solid Tumors.
    J Nucl Med. 2025;66:1605-1611.
    >> Share

    September 2025
  244. CIUCIULKAITE I, Zuccotti GA, Jallo C, Hautzel H, et al
    Thyroid Hormone Withdrawal Yields Higher (131)I Absorbed Dose to Metastases Than rhTSH Stimulation in Differentiated Thyroid Cancer: Evidence from a Large (124)I PET/CT Dosimetry Cohort.
    J Nucl Med. 2025 Sep 25:jnumed.125.270391. doi: 10.2967/jnumed.125.270391.
    >> Share

  245. LAZAR A, Matassa G, Hammami DW, Chiti A, et al
    Diagnostic Reliability and Clinical Impact of [(11)C]Choline PET/CT for Detecting Hyperfunctioning Parathyroid Glands.
    J Nucl Med. 2025 Sep 25:jnumed.125.270664. doi: 10.2967/jnumed.125.270664.
    >> Share

  246. DOYON V, Sarrhini O, Loignon-Houle F, Toussaint M, et al
    PET Imaging of the Human Brain with Microvolumetric Spatial Resolution.
    J Nucl Med. 2025 Sep 25:jnumed.124.268809. doi: 10.2967/jnumed.124.268809.
    >> Share

  247. MURTHY V, Kimura K, Theus L, Nguyen A, et al
    Prognostic Value of AI-Assisted Lesion Tracking on End-of-Treatment PSMA PET in mCRPC Patients Treated with (177)Lu-PSMA: A Retrospective, Single-Center Study.
    J Nucl Med. 2025 Sep 25:jnumed.125.269971. doi: 10.2967/jnumed.125.269971.
    >> Share

  248. VEIT-HAIBACH P
    Reply: Making Green Nuclear Medicine and Radiotheranostics Real in a Developing Country.
    J Nucl Med. 2025 Sep 18:jnumed.125.270767. doi: 10.2967/jnumed.125.270767.
    >> Share

  249. DUAN X, Sarkar S, Lyo V, Romeo S, et al
    Quantification of (18)F-FDG Delivery Rate for Liver Inflammation Using Shortened Dynamic PET Imaging Protocols.
    J Nucl Med. 2025 Sep 18:jnumed.124.269434. doi: 10.2967/jnumed.124.269434.
    >> Share

  250. MALDONADO SP, Pedraza CM, Forero PA, Yepes MM, et al
    Making Green Nuclear Medicine and Radiotheranostics Real in a Developing Country.
    J Nucl Med. 2025 Sep 18:jnumed.125.270499. doi: 10.2967/jnumed.125.270499.
    >> Share

  251. SHIYAM SUNDAR LK, Gutschmayer S, Pires M, Ferrara D, et al
    Fully Automated Image-Based Multiplexing of Serial PET/CT Imaging for Facilitating Comprehensive Disease Phenotyping.
    J Nucl Med. 2025 Sep 18:jnumed.125.269688. doi: 10.2967/jnumed.125.269688.
    >> Share

  252. WEIBERG D, Wilhelm LM, Felgenhauer T, Ross T, et al
    (68)Ga-FAPI-46 PET/CT in Primary Sclerosing Cholangitis and Suspected Cholangiocarcinoma.
    J Nucl Med. 2025 Sep 18:jnumed.125.270434. doi: 10.2967/jnumed.125.270434.
    >> Share

  253. DIEKMANN J, Konig T, Hess A, Zwadlo C, et al
    CXCR4 PET/CT Predicts Left Ventricular Recovery 8 Months After Acute Myocardial Infarction.
    J Nucl Med. 2025 Sep 18:jnumed.125.270807. doi: 10.2967/jnumed.125.270807.
    >> Share

  254. PACKARD RRS, Maddahi J, Pelletier-Galarneau M, Al-Mallah MH, et al
    SNMMI/EANM/ASNC/ACNM Procedure Standard/Practice Guideline for (18)F-Flurpiridaz PET Myocardial Perfusion Imaging and Blood Flow Quantitation.
    J Nucl Med. 2025 Sep 18:jnumed.125.270873. doi: 10.2967/jnumed.125.270873.
    >> Share

  255. HOSSEINI A, Haj-Yehia E, Korste S, Kuzay Y, et al
    How Rapidly Does the FAPI PET Signal Reverse Following Therapy? Assessing the FAPI PET Signal in Hypertensive Cardiac Injury and Fibrosis in Mice.
    J Nucl Med. 2025 Sep 11:jnumed.124.268860. doi: 10.2967/jnumed.124.268860.
    >> Share

  256. KUNSCH J, Zaragori T, Olivier P, Claudin M, et al
    Prognostic Value of Comprehensive Analysis of Metastatic Prostate Tumor Changes from First to Last [(177)Lu]Lu-PSMA Therapy Injections Through Serial High-Speed Whole-Body 360 degrees Cadmium-Zinc-Telluride SPECT.
    J Nucl Med. 2025 Sep 11:jnumed.125.270358. doi: 10.2967/jnumed.125.270358.
    >> Share

  257. BEINTNER-SKAWRAN S, Gafita A, Lorenzini T, Tauber R, et al
    [(68)Ga]Ga-PSMA-11 PET Tumor Volume Predicts Overall Survival of Patients with Metastatic Prostate Cancer Undergoing Taxane-Based Chemotherapy.
    J Nucl Med. 2025 Sep 11:jnumed.125.269584. doi: 10.2967/jnumed.125.269584.
    >> Share

  258. VERA P, Calais J
    From Nuclear Medicine Specialist to Cancer Center Director: Jeremie Calais Talks with Pierre Vera about Leading Through Change in Nuclear Medicine.
    J Nucl Med. 2025 Sep 11:jnumed.125.270978. doi: 10.2967/jnumed.125.270978.
    >> Share

  259. ZHOU IY, Zhang C, Sojoodi M, Rotile NJ, et al
    (18)F-FPP-RGD(2) PET Imaging for Interrogating Target Engagement and Antifibrotic Activity of an Integrin Antagonist in a Mouse Model of Metabolic Dysfunction-Associated Steatohepatitis.
    J Nucl Med. 2025 Sep 11:jnumed.125.270047. doi: 10.2967/jnumed.125.270047.
    >> Share

  260. URIBE C, Iravani A, Savir-Baruch B, Jacene H, et al
    Summary: SNMMI/ACNM Procedure Standard for Posttreatment Imaging of (177)Lu-Based Radiopharmaceuticals.
    J Nucl Med. 2025 Sep 11:jnumed.125.270979. doi: 10.2967/jnumed.125.270979.
    >> Share

  261. EBNER R, Braach J, Rubenthaler J, Cyran CC, et al
    Retrospective Evaluation of the Correlation Between Somatostatin Receptor PET/CT and Histopathology in Patients with Suspected Intracranial Meningiomas.
    J Nucl Med. 2025 Sep 11:jnumed.125.270115. doi: 10.2967/jnumed.125.270115.
    >> Share

  262. YOO HB, Kang SK, Shin SA, Kim D, et al
    Artificial Intelligence-Powered Quantification of Flortaucipir PET for Detecting Tau Pathology.
    J Nucl Med. 2025 Sep 11:jnumed.125.269636. doi: 10.2967/jnumed.125.269636.
    >> Share

  263. VISSER D, Golla SSV, Palard-Novello X, Verfaillie SCJ, et al
    Varying Levels of Inflammatory Activity in Brain and Body of Patients with Persistent Fatigue and Difficulty Concentrating After COVID-19: A TSPO PET Study.
    J Nucl Med. 2025 Sep 11:jnumed.124.269297. doi: 10.2967/jnumed.124.269297.
    >> Share

  264. SMITH R, Garibotto V, Hagerstrom D, Jogi J, et al
    Evaluation of a Sensitive Visual Read Algorithm for Assessing 3R/4R Tau PET Images.
    J Nucl Med. 2025 Sep 4:jnumed.125.269685. doi: 10.2967/jnumed.125.269685.
    >> Share

  265. GRAVEL P, Gu J, Wang C, Volpi T, et al
    Toward Imaging of the GABA Transporter Type 1 In Vivo: Quantitative Evaluation of 4 Novel PET Radiotracers in Nonhuman Primates.
    J Nucl Med. 2025 Sep 4:jnumed.125.270332. doi: 10.2967/jnumed.125.270332.
    >> Share

  266. PANDIT-TASKAR N, Basu E, Pirasteh A, Behr G, et al
    Lesion Analysis of (18)F-Metafluorobenzylguanidine PET Imaging in Neuroblastoma.
    J Nucl Med. 2025 Sep 4:jnumed.125.269833. doi: 10.2967/jnumed.125.269833.
    >> Share

  267. HUANG B, Dai B, Lapi SE, Liles G, et al
    High-Resolution Positronium Lifetime Tomography at Clinical Activity Levels on the PennPET Explorer.
    J Nucl Med. 2025;66:1464-1470.
    >> Share

  268. CHEN L, Rizzo G, Bulawa C, Van Dijk KRA, et al
    Evaluation of Mitochondrial Complex 1 Density with [(18)F]BCPP-EF in a Murine Model and Individuals with Friedreich Ataxia.
    J Nucl Med. 2025;66:1434-1439.
    >> Share

  269. LANZAFAME H, Heilig CE, Wardelmann E, Desaulniers M, et al
    (90)Y-FAPI-46 Theranostics Leads to Near-Complete Metabolic Response in 3 Patients with Solitary Fibrous Tumors.
    J Nucl Med. 2025;66:1378-1384.
    >> Share

  270. HOOIVELD-NOEKEN JS, de Ruijter LK, van de Donk PP, Smit LM, et al
    Heterogeneity of CD8 T-Cell Changes in Advanced Melanomas After Initiation of Immunotherapy.
    J Nucl Med. 2025;66:1345-1351.
    >> Share

  271. VAN BINSBERGEN WH, Zwezerijnen GJC, Windhorst AD, Schober P, et al
    SUVs Versus Dynamic Pharmacokinetic [(18)F]Fluoro-Polyethylene Glycol-Folate Uptake Parameters in Joints of Rheumatoid Arthritis Patients at Baseline and at 4 Weeks of Antitumor Necrosis Factor Therapy.
    J Nucl Med. 2025;66:1458-1463.
    >> Share

    August 2025
  272. ALTUNAY B, Schafer L, Morgenroth A, Pena Q, et al
    Combining PSMA-Targeted Radiopharmaceutical Therapy with Immunotherapy.
    J Nucl Med. 2025 Aug 28:jnumed.125.270317. doi: 10.2967/jnumed.125.270317.
    >> Share

  273. STAMMES MA, Koopman G, Wagner TR, Traenkle B, et al
    Noninvasive Monitoring of Inflammatory Processes by Myeloid Cell-Directed PET Tracers in an Experimental Severe Acute Respiratory Syndrome Coronavirus 2 Infection Model.
    J Nucl Med. 2025 Aug 28:jnumed.125.269721. doi: 10.2967/jnumed.125.269721.
    >> Share

  274. ROYA M, Tsoumpas C, van Snick JH, Dao V, et al
    Impact of Ultrahigh Sensitivity and Continuous Bed Motion on Performance Characteristics of Biograph Vision Quadra PET/CT.
    J Nucl Med. 2025 Aug 28:jnumed.125.270078. doi: 10.2967/jnumed.125.270078.
    >> Share

  275. LI X, Zhao Y, Hsu JC, Sarduy EA, et al
    [(44)Sc]Sc-CHX-A''-DTPA-RCCB6: A PET Tracer for Imaging CD70 Expression Across Latency Types of Burkitt Lymphoma.
    J Nucl Med. 2025 Aug 28:jnumed.125.269991. doi: 10.2967/jnumed.125.269991.
    >> Share

  276. UPRIMNY C, von Guggenberg E, Sviridenko A, Bayerschmidt S, et al
    Diagnostic Performance of the (68)Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors.
    J Nucl Med. 2025 Aug 28:jnumed.125.269863. doi: 10.2967/jnumed.125.269863.
    >> Share

  277. WANG S, Lu Y, Xue Y, Han H, et al
    Serial [(18)F]AlF-NOTA-FAPI PET/CT and CT Angiography in Type B Aortic Dissection Before and After Thoracic Endovascular Aortic Repair.
    J Nucl Med. 2025 Aug 21:jnumed.125.270511. doi: 10.2967/jnumed.125.270511.
    >> Share

  278. FLAUS A, Levigoureux E, Haesebaert J, Briet C, et al
    Prospective Multicenter Evaluation of [(11)C]Methionine PET/MRI Sensitivity Compared with MRI for Localizing Small Pituitary Neuroendocrine Tumor or Pituitary Adenoma in Cushing Disease.
    J Nucl Med. 2025 Aug 21:jnumed.124.269392. doi: 10.2967/jnumed.124.269392.
    >> Share

  279. RYU J, Han S, Yoo TR, Lee SB, et al
    Diagnostic Performance of (18)F-Fluoroestradiol PET/CT for Axillary Lymph Node Metastasis in Invasive Lobular Carcinoma: A Prospective Feasibility Study.
    J Nucl Med. 2025 Aug 14:jnumed.125.269573. doi: 10.2967/jnumed.125.269573.
    >> Share

  280. SCHILLER F, Brumberg J, Frings L, Deschamps J, et al
    Clinical Validation of Deep Learning for Image Restoration of Ultra-Low-Count [(18)F]FDG PET for Dementia Diagnostics.
    J Nucl Med. 2025 Aug 14:jnumed.124.269234. doi: 10.2967/jnumed.124.269234.
    >> Share

  281. MINGELS C, Chung KJ, Nalbant H, Abdelhafez YG, et al
    Lymphoma Therapy Response Assessment with Low-Dose [(18)F]FDG Total-Body PET/CT.
    J Nucl Med. 2025 Aug 14:jnumed.124.268841. doi: 10.2967/jnumed.124.268841.
    >> Share

  282. JACOBSON O, Zhang HH, Olkowski CP, Ghaemi B, et al
    Monitoring T-Cell Activation in the Tumor Microenvironment by PET Imaging of the Chemokine CXCL9.
    J Nucl Med. 2025 Aug 14:jnumed.125.269795. doi: 10.2967/jnumed.125.269795.
    >> Share

  283. PACKARD RRS, Buckley C, Cooke CD, Moody JB, et al
    Comparison, Agreement, and Significance Cutoffs of (18)F-Flurpiridaz PET Myocardial Blood Flow Quantitation Methods and Software Packages.
    J Nucl Med. 2025 Aug 7:jnumed.124.269398. doi: 10.2967/jnumed.124.269398.
    >> Share

  284. GRKOVSKI M, Krebs SS, O'Donoghue JA, Kuten J, et al
    Lesion Absorbed Dose-Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [(177)Lu]Lu-PSMA-617 Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Aug 7:jnumed.125.270170. doi: 10.2967/jnumed.125.270170.
    >> Share

  285. RIKKEN RM, van de Giessen E, Brumberg J, Aarnio R, et al
    Imaging Proinflammatory Microglia in Parkinson Disease Using [(11)C]SMW139 PET: A Multicenter Study.
    J Nucl Med. 2025 Aug 7:jnumed.125.269671. doi: 10.2967/jnumed.125.269671.
    >> Share

  286. HUANG W, Li L, Chao F, Yang Q, et al
    [(64)Cu]Cu-NOTA-EV-F(ab')(2) Enables Same-Day Immuno-PET Imaging of Nectin-4 in Triple-Negative Breast and Urothelial Bladder Cancers.
    J Nucl Med. 2025 Aug 7:jnumed.125.270132. doi: 10.2967/jnumed.125.270132.
    >> Share

  287. ENKE JS, Schuller BW, Glantschnig L, Kircher M, et al
    Biodistribution and Radiation Dosimetry for [(68)Ga]Ga-LNTH-1363S, a Probe Targeting Fibroblast Activation Protein alpha.
    J Nucl Med. 2025;66:1284-1290.
    >> Share

  288. CARSON R
    2024 SNMMI Highlights Lecture: Neurosciences.
    J Nucl Med. 2025;66:1176-1183.
    >> Share

  289. BOELLAARD R, Rahmim A, Eertink JJ, Duehrsen U, et al
    Summary Report of the SNMMI AI Task Force Radiomics Challenge 2024.
    J Nucl Med. 2025;66:1169-1175.
    >> Share

    July 2025
  290. MAKALA H, Sheehan-Klenk J, Lee W, Chung JY, et al
    CD24 as a Novel Radiopharmaceutical Target for Hepatocellular Carcinoma.
    J Nucl Med. 2025 Jul 31:jnumed.125.270167. doi: 10.2967/jnumed.125.270167.
    >> Share

  291. DENIS CS, Cousin F, De Laere B, Vanwelkenhuyzen J, et al
    Assessing Interlesional Tumor Response and Patient Outcomes with Sequential PSMA PET/CT in Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2025 Jul 31:jnumed.125.269729. doi: 10.2967/jnumed.125.269729.
    >> Share

  292. KALITA M, Kuo RC, Reyes ST, Colburg DRC, et al
    Advancing In Vivo Detection of T-Cell Function: Development and Preclinical Evaluation of (89)Zr-Ivuxolimab, a Human OX40 PET Tracer.
    J Nucl Med. 2025 Jul 24:jnumed.125.269799. doi: 10.2967/jnumed.125.269799.
    >> Share

  293. BUNNING S, Christodoulou D, Cohen JE, Cutler CS, et al
    Proceedings: PET Drugs-A 2023 Workshop on Product Quality, Regulatory Submissions, Facility Inspections, and Benefit-Risk Considerations.
    J Nucl Med. 2025 Jul 24:jnumed.125.270011. doi: 10.2967/jnumed.125.270011.
    >> Share

  294. CHEN B, Zheng C, Balayeva T, Toyonaga T, et al
    [(18)F]SynVesT-1 PET Detects SV2A Changes in the Spinal Cord and Brain of Rats with Spinal Cord Injury.
    J Nucl Med. 2025 Jul 17:jnumed.124.269291. doi: 10.2967/jnumed.124.269291.
    >> Share

  295. DERLIN T, Hanke JS, Werner RA, Ziegler SI, et al
    Characterization of Left Ventricular Assist Device-Specific Infection by Whole-Body Parametric PET Imaging.
    J Nucl Med. 2025 Jul 17:jnumed.125.270252. doi: 10.2967/jnumed.125.270252.
    >> Share

  296. CHEN Y, Zhang X, Wang X, Liu Y, et al
    Interspecies Variability in Biodistribution and PET Imaging Performance of [(18)F]Di-PyL: A Dimeric, PSMA-Targeted PET Agent for Prostate Cancer.
    J Nucl Med. 2025 Jul 17:jnumed.125.270069. doi: 10.2967/jnumed.125.270069.
    >> Share

  297. BRADSHAW TJ, Brosch-Lenz J, Uribe C, Karakatsanis N, et al
    Recommendations for Standardizing Nuclear Medicine Terminology and Data in the Era of Theranostics and Artificial Intelligence.
    J Nucl Med. 2025 Jul 10:jnumed.124.269424. doi: 10.2967/jnumed.124.269424.
    >> Share

  298. DAKANALI M, Zigler SS, Schwarz SW, Nickels ML, et al
    Reply to "Foregoing Nonclinical Dosimetry Studies to Support First-in-Human Studies of Certain PET Radiopharmaceuticals".
    J Nucl Med. 2025 Jul 10:jnumed.125.270467. doi: 10.2967/jnumed.125.270467.
    >> Share

  299. PLYKU D, Koo H, Park L, Hofling A, et al
    Foregoing Nonclinical Dosimetry Studies to Support First-in-Human Studies of Certain PET Radiopharmaceuticals.
    J Nucl Med. 2025 Jul 10:jnumed.125.270320. doi: 10.2967/jnumed.125.270320.
    >> Share

  300. SCHAEFER R, Kunze LH, Haertel M, Zhu Y, et al
    Image-Derived Blood Normalization of Antibody-Based TREM2 PET in Mouse Models of Amyloidosis and Myocardial Infarction.
    J Nucl Med. 2025 Jul 10:jnumed.125.269472. doi: 10.2967/jnumed.125.269472.
    >> Share

  301. KURCH L, Landman-Parker J, Georgi TW, Attarbaschi A, et al
    Quantitative Deauville Scoring to Uncover Prognostic Information from (18)F-FDG PET-Based Response Assessment: Data from the EuroNet-PHL-C1 Trial.
    J Nucl Med. 2025 Jul 10:jnumed.125.269603. doi: 10.2967/jnumed.125.269603.
    >> Share

  302. KOHAN A, Metser U, Luke W, Rashid M, et al
    A Prospective Provincial Registry of (18)F-PSMA PET/CT for Recurrent Prostate Cancer: Results for 4,135 Men.
    J Nucl Med. 2025 Jul 3:jnumed.125.269653. doi: 10.2967/jnumed.125.269653.
    >> Share

  303. BANG YH, Kim JH, Kim YH, Kim HR, et al
    Distinct Prognostic Roles of (18)F-FDG PET Metabolic Response Assessed After Induction Chemotherapy or Chemoradiotherapy in Localized Esophageal Squamous Cell Carcinoma.
    J Nucl Med. 2025 Jul 3:jnumed.125.269775. doi: 10.2967/jnumed.125.269775.
    >> Share

  304. SUNDERLAND JJ, Boellaard R, Dickson JC, Graves SA, et al
    Standardization of PET/CT Performance Requirements for Whole-Body Quantitative Imaging: An International Proposal.
    J Nucl Med. 2025 Jul 3:jnumed.124.269349. doi: 10.2967/jnumed.124.269349.
    >> Share

  305. KASHYAP R, Buteau JP, Bressel M, Eifer M, et al
    Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [(177)Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials.
    J Nucl Med. 2025 Jul 3:jnumed.125.269640. doi: 10.2967/jnumed.125.269640.
    >> Share

  306. TAIEB D, Prior JO, Dierckx RAJO
    Embracing Flow: Exploring Panta Rhei in the Context of Nuclear Medicine.
    J Nucl Med. 2025 Jul 3:jnumed.125.270179. doi: 10.2967/jnumed.125.270179.
    >> Share

  307. CHAN DL, Hayes A, Karfis I, Conner A, et al
    [(18)F]FDG Metabolic Tumor Volume as a Prognostic Marker in Neuroendocrine Neoplasm: A Multicenter Study.
    J Nucl Med. 2025;66:1012-1017.
    >> Share

  308. STOKKEL MPM, Gotthardt M, Herrmann K, Gnanasegaran G, et al
    Theranostics in Perspective: White Paper.
    J Nucl Med. 2025;66:1007-1011.
    >> Share

    June 2025
  309. AHLSTROM A, Lindstrom E, Maaniittyy T, Iida H, et al
    Automated Total-Body Perfusion Imaging with (15)O-Water PET Using Basis Functions and Organ-Specific Model Selection.
    J Nucl Med. 2025 Jun 26:jnumed.124.269409. doi: 10.2967/jnumed.124.269409.
    >> Share

  310. SAYED A, Al Rifai M, Al-Mallah M
    Differential Association of PET-Derived Rest and Stress Myocardial Blood Flow with Cardiovascular Outcomes.
    J Nucl Med. 2025 Jun 18:jnumed.125.269457. doi: 10.2967/jnumed.125.269457.
    >> Share

  311. XIA Y, Dhaynaut M, Chemli Y, Lois C, et al
    Quantitative Measurement of Tau Burden in a Dual-Time-Window Dynamic PET Imaging Protocol with [(18)F]M6240.
    J Nucl Med. 2025 Jun 18:jnumed.125.270165. doi: 10.2967/jnumed.125.270165.
    >> Share

  312. JADVAR H, Atkins MB, Bartel T, de Geus-Oei LF, et al
    Summary: Appropriate Use Criteria for (18)F-FDG PET/CT for Initial Staging of Malignant Disease.
    J Nucl Med. 2025 Jun 18:jnumed.125.270429. doi: 10.2967/jnumed.125.270429.
    >> Share

  313. MOGENSEN AW, Torp-Pedersen C, Norgaard M, Petersen LJ, et al
    The Use of PSMA PET/CT Improves Overall Survival in Men with Biochemically Recurrent Prostate Cancer Treated with Salvage Radiotherapy: Real-World Data from an Entire Country.
    J Nucl Med. 2025 Jun 12:jnumed.125.269996. doi: 10.2967/jnumed.125.269996.
    >> Share

  314. BOBBA KN, Wadhwa A, Bidkar AP, Raveendran A, et al
    Evaluation of (134)Ce/(134)La-PSMA-617 for PET Imaging and Auger Electron Therapy of Prostate Cancer.
    J Nucl Med. 2025 Jun 12:jnumed.125.269751. doi: 10.2967/jnumed.125.269751.
    >> Share

  315. YUE J, Zhang Y, Miu Y, Zhao Y, et al
    Radiopharmaceutical Therapy: Balancing Absorbed Dose and Antitumor Immunity.
    J Nucl Med. 2025 Jun 12:jnumed.125.269868. doi: 10.2967/jnumed.125.269868.
    >> Share

  316. KWON D, Li EJ, Dulal C, Daube-Witherspoon M, et al
    Dual-Tracer Imaging on a Long-Axial-Field-of-View PET: A Proof-of-Principle Study with [(18)F]FGln and [(18)F]FDG.
    J Nucl Med. 2025 Jun 12:jnumed.124.268831. doi: 10.2967/jnumed.124.268831.
    >> Share

  317. DRZEZGA A, Barthel H
    Imaging and Fluid Biomarkers of Alzheimer Disease: Complementation Rather Than Competition.
    J Nucl Med. 2025;66.
    >> Share

  318. FANTI S, Robles Barba JJ, Behr S, Maurer T, et al
    Imaging Efficacy of [(18)F]CTT1057 PET/CT in Patients with Biochemically Recurrent Prostate Cancer: Results from GuidePath-A Phase 3, Prospective Multicenter Study.
    J Nucl Med. 2025 Jun 5:jnumed.124.269266. doi: 10.2967/jnumed.124.269266.
    >> Share

  319. IAGARU A, Suarez JF, Behr S, Aggarwal R, et al
    Imaging Efficacy of [(18)F]CTT1057 PET for the Detection of PSMA-Positive Tumors Using Histopathology as Standard of Truth: Results from the GuideView Phase 2/3 Prospective Multicenter Study.
    J Nucl Med. 2025 Jun 5:jnumed.124.269007. doi: 10.2967/jnumed.124.269007.
    >> Share

  320. GAFITA A, Schroeder JA, Ceci F, Oldan JD, et al
    Treatment Response Evaluation in Prostate Cancer Using PSMA PET/CT.
    J Nucl Med. 2025 Jun 5:jnumed.124.268071. doi: 10.2967/jnumed.124.268071.
    >> Share

  321. MANSUR A, McConathy JE, Stringer-Reasor E, Rocque G, et al
    Quantitative [(89)Zr]Zr-Trastuzumab PET and Diffusion- Weighted MRI for Characterization of Metastatic HER2-Positive Breast Cancer with PET/MRI.
    J Nucl Med. 2025 Jun 5:jnumed.124.268931. doi: 10.2967/jnumed.124.268931.
    >> Share

  322. COOLS R, Vermeulen K, Vonck E, Baekelandt V, et al
    In Vivo Visualization and Quantification of Brain Heat Shock Protein 90 with [(11)C]HSP990 in Healthy Aging and Neurodegeneration.
    J Nucl Med. 2025;66:940-947.
    >> Share

  323. KAYAL G, Roseland ME, Wang C, Fitzpatrick K, et al
    Multicycle Dosimetric Behavior and Dose-Effect Relationships in [(177)Lu]Lu-DOTATATE Peptide Receptor Radionuclide Therapy.
    J Nucl Med. 2025;66:900-908.
    >> Share

    May 2025
  324. PALARD-NOVELLO X, Visser D, Yaqub M, van de Giessen E, et al
    Whole-Body [(18)F]DPA-714 Kinetic Assessment Using PET/CT Scanner with Long Axial Field of View.
    J Nucl Med. 2025 May 29:jnumed.124.268979. doi: 10.2967/jnumed.124.268979.
    >> Share

  325. LYNCH SE, Crawford C, Hunt AL, Sligh LL, et al
    Granzyme B PET Imaging Predicts Response to Immunotherapy in a Diet-Induced Obesity Model of Breast Cancer.
    J Nucl Med. 2025 May 29:jnumed.124.268938. doi: 10.2967/jnumed.124.268938.
    >> Share

  326. LILBURN DML, Garthwaite HS, Ganeshan B, Win T, et al
    [(18)F]FDG PET/CT Predicts Patient Survival in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease.
    J Nucl Med. 2025 May 29:jnumed.125.269497. doi: 10.2967/jnumed.125.269497.
    >> Share

  327. AKHAVANALLAF A, Lu Z, Peterson AB, Blakkisrud J, et al
    Can (177)Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data.
    J Nucl Med. 2025 May 22:jnumed.124.269098. doi: 10.2967/jnumed.124.269098.
    >> Share

  328. TRAUTWEIN NF, Mattern S, Hinterleitner M, Reischl G, et al
    Histologic Ex Vivo Validation of the [(18)F]SITATE Somatostatin Receptor PET Tracer.
    J Nucl Med. 2025 May 22:jnumed.125.269619. doi: 10.2967/jnumed.125.269619.
    >> Share

  329. RAMOS CD
    Redefining Nuclear Medicine: "Biodistribution" Should Be the Core Concept.
    J Nucl Med. 2025 May 22:jnumed.125.270245. doi: 10.2967/jnumed.125.270245.
    >> Share

  330. MOSTAFAPOUR S, van Sluis J, Lammertsma AA, Tsoumpas C, et al
    Reply to "(176)Lu Radiation in Long-Axial-Field-of-View PET Scanners: A Nonissue for Patient Safety".
    J Nucl Med. 2025 May 15:jnumed.125.270027. doi: 10.2967/jnumed.125.270027.
    >> Share

  331. ZHANG W, Yao W, Shen G
    [(68)Ga]Ga-FAPI PET/CT Monitors Response to Receptor Activator of Nuclear Factor-kappaB Ligand Inhibitor in a Giant Cell Tumor of Bone: Correlation with Histopathology.
    J Nucl Med. 2025 May 15:jnumed.124.269432. doi: 10.2967/jnumed.124.269432.
    >> Share

  332. CARTER LM, Milman R, Ocampo Ramos JC, Kesner AL, et al
    (176)Lu Radiation in Long-Axial-Field-of-View PET Scanners: A Nonissue for Patient Safety.
    J Nucl Med. 2025 May 15:jnumed.125.269846. doi: 10.2967/jnumed.125.269846.
    >> Share

  333. BAILEY DL, Meikle SR, Calamante F, Angelis G, et al
    The Australian National Total-Body PET Facility-A Shared Resource and Risk Model for Implementing Total-Body PET.
    J Nucl Med. 2025 May 15:jnumed.125.269859. doi: 10.2967/jnumed.125.269859.
    >> Share

  334. ZHAO Q, Liow JS, Jee JE, Montero Santamaria J, et al
    [(11)C]ZTP-1: An Effective Short-Lived Radioligand for PET of Rat and Monkey Brain Phosphodiesterase Type 4 Subtype B.
    J Nucl Med. 2025 May 8:jnumed.124.269159. doi: 10.2967/jnumed.124.269159.
    >> Share

  335. YEH R, Pareja F, Shobeiri P, Ross D, et al
    Detection of HER2-Low Lesions Using HER2-Targeted PET Imaging in Patients with Metastatic Breast Cancer: A Paired HER2 PET and Tumor Biopsy Analysis.
    J Nucl Med. 2025 May 8:jnumed.124.269227. doi: 10.2967/jnumed.124.269227.
    >> Share

  336. DUBROFF JG, Hsieh CJ, Wiers CE, Lee H, et al
    [(11)C]Carfentanil PET Whole-Body Imaging of mu-Opioid Receptors: A First in-Human Study.
    J Nucl Med. 2025 May 8:jnumed.124.269413. doi: 10.2967/jnumed.124.269413.
    >> Share

  337. ICHIJO S, Arisawa T, Hatano M, Nakajima W, et al
    First-in-Human Study of (18)F-Labeled PET Tracer for Glutamate AMPA Receptor [(18)F]K-40: A Derivative of [(11)C]K-2.
    J Nucl Med. 2025 May 8:jnumed.124.269405. doi: 10.2967/jnumed.124.269405.
    >> Share

  338. ZARAGORI T, Chevalier E, Citerne Q, Roch V, et al
    Assessment of [(177)Lu]Lu-DOTATATE Dosimetry from High-Speed Whole-Body Recordings Provided by a 360 degrees Cadmium-Zinc-Telluride Camera Compared with Results from a Conventional Anger-Camera Protocol.
    J Nucl Med. 2025;66:771-777.
    >> Share

  339. PICHLER V, Schwingenschlogl-Maisetschlager V, Duman I, Monforte X, et al
    Bioanalytic Hybrid System Merging 3-Dimensional Cell Culture and Chromatographic Precision for Unprecedented Preclinical Insights in Molecular Imaging.
    J Nucl Med. 2025;66:813-816.
    >> Share

  340. TOURNIER N, Langer O
    Imaging the Activity of Efflux Transporters at the Blood-Brain Barrier in Neurologic Diseases: Radiotracer Selection Criteria.
    J Nucl Med. 2025;66:676-680.
    >> Share

    April 2025
  341. CHUNG KJ, Chaudhari AJ, Nardo L, Jones T, et al
    Quantitative Total-Body Imaging of Blood Flow with High-Temporal-Resolution Early Dynamic (18)F-FDG PET Kinetic Modeling.
    J Nucl Med. 2025 Apr 30:jnumed.124.268706. doi: 10.2967/jnumed.124.268706.
    >> Share

  342. FROEHNER M, Zophel K
    (177)Lu-PSMA Radiopharmaceutical Therapy or Cabazitaxel?
    J Nucl Med. 2025 Apr 30:jnumed.125.269875. doi: 10.2967/jnumed.125.269875.
    >> Share

  343. FELBER V, Holzleitner N, Joksch M, Suhrbier T, et al
    First-in-Human Serum Stability Studies of [(177)Lu]Lu-AMTG: A Step Toward Improved GRPR-Targeted Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Apr 30:jnumed.124.269132. doi: 10.2967/jnumed.124.269132.
    >> Share

  344. WENZEL M, Groener D, Chun FKH, Mandel P, et al
    Reply to "(177)Lu-PSMA Radiopharmaceutical Therapy or Cabazitaxel?".
    J Nucl Med. 2025 Apr 30:jnumed.125.270028. doi: 10.2967/jnumed.125.270028.
    >> Share

  345. TRIVIERI MG, Devesa A, Robson PM, Bose S, et al
    Prevalence of Persistent Cardiovascular and Pulmonary Abnormalities on PET/MRI and DECT Imaging in Long COVID Patients.
    J Nucl Med. 2025 Apr 30:jnumed.124.268980. doi: 10.2967/jnumed.124.268980.
    >> Share

  346. PARIHAR AS, Pant N, Heidari P, Fong L, et al
    Approaches to Imaging Immune Activation Using PET.
    J Nucl Med. 2025 Apr 30:jnumed.124.268289. doi: 10.2967/jnumed.124.268289.
    >> Share

  347. SHI B, Zhang Y, Wu S, Xu D, et al
    CD70-Targeted [(18)F]RCCB6 Immuno-PET/CT Imaging in Patients with Nasopharyngeal Carcinoma: A Proof-of-Concept Study.
    J Nucl Med. 2025 Apr 30:jnumed.125.269585. doi: 10.2967/jnumed.125.269585.
    >> Share

  348. FRANCA VELO A, Giantini Larsen A, Humm JL, Zanzonico P, et al
    Determination of the Intralesional Distribution of Theranostic (124)I-Omburtamab Convection-Enhanced Delivery in Treatment of Diffuse Intrinsic Pontine Glioma.
    J Nucl Med. 2025 Apr 30:jnumed.124.267995. doi: 10.2967/jnumed.124.267995.
    >> Share

  349. DERLIN T, Kleine-Dopke D, Neubert L, Ross TL, et al
    Initial Experience with Dual-Time-Point [(18)F]Flurpiridaz PET/CT for Localization of Parathyroid Adenomas in Primary Hyperparathyroidism.
    J Nucl Med. 2025 Apr 24:jnumed.124.269387. doi: 10.2967/jnumed.124.269387.
    >> Share

  350. ZIMMERMANN R, Beyer T
    Stakeholders of Theranostics: Thomas Beyer Talks with Richard Zimmermann About the Golden Age of Nuclear Medicine.
    J Nucl Med. 2025 Apr 24:jnumed.125.270085. doi: 10.2967/jnumed.125.270085.
    >> Share

  351. UNTERRAINER LM, De Leiris N, Unterrainer M, Delker A, et al
    Evidence-Based Clinical Protocols to Monitor Efficacy of [(177)Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data.
    J Nucl Med. 2025 Apr 24:jnumed.124.269431. doi: 10.2967/jnumed.124.269431.
    >> Share

  352. SMITH CLC, Zwezerijnen GJC, den Hollander ME, Zijlstra JM, et al
    Feasibility of Ultra-Low-Activity (18)F-FDG PET/CT Imaging Using a Long-Axial-Field-of-View PET/CT System.
    J Nucl Med. 2025 Apr 24:jnumed.124.269272. doi: 10.2967/jnumed.124.269272.
    >> Share

  353. THACKERAY JT
    2024 SNMMI Highlights Lecture: Cardiovascular Sciences.
    J Nucl Med. 2025 Apr 24:jnumed.125.269988. doi: 10.2967/jnumed.125.269988.
    >> Share

  354. DAKANALI M, Zigler SS, Schwarz SW, Nickels ML, et al
    FDA Reconsiders Rules Around Radiation Dosimetry for First-in-Human Studies of Investigational PET Radiopharmaceuticals.
    J Nucl Med. 2025 Apr 17:jnumed.125.269885. doi: 10.2967/jnumed.125.269885.
    >> Share

  355. SCHINDLER TH, Bateman TM, Berman DS, Chareonthaitawee P, et al
    FDA Approval of (18)F-Flurpiridaz Is for PET: Stepping into a New Area of Myocardial Perfusion Imaging?
    J Nucl Med. 2025 Apr 17:jnumed.124.269154. doi: 10.2967/jnumed.124.269154.
    >> Share

  356. ALBERTS I, More S, Knapp K, Mei R, et al
    Is Long-Axial-Field-of-View PET/CT Cost-Effective? An International Health-Economic Analysis.
    J Nucl Med. 2025 Apr 17:jnumed.124.269203. doi: 10.2967/jnumed.124.269203.
    >> Share

  357. BRUMBERG J, Schroter N, Blazhenets G, Omrane MA, et al
    [(18)F]Florzolotau PET for the Differential Diagnosis of Parkinsonism in Patients with Suspected 4-Repeat Tauopathies.
    J Nucl Med. 2025 Apr 17:jnumed.124.268956. doi: 10.2967/jnumed.124.268956.
    >> Share

  358. FAROLFI A, Casadei B, Malizia C, Ussia R, et al
    Semiquantitative PET Parameters Refine Prognosis in CAR T-Treated Lymphoma After 1 and 3 Months: A Prospective Single-Center Study.
    J Nucl Med. 2025 Apr 17:jnumed.125.269670. doi: 10.2967/jnumed.125.269670.
    >> Share

  359. HACHEY JS, Viray TD, Matasci M, Ravazza D, et al
    Targeting Extra Domain A of Fibronectin to Improve Noninvasive Detection of Triple-Negative Breast Cancer.
    J Nucl Med. 2025 Apr 17:jnumed.124.268859. doi: 10.2967/jnumed.124.268859.
    >> Share

  360. DE OLIVEIRA TAVEIRA M, Razmaria AA, Schoder H, Yeh R, et al
    Prostate Cancer Recurrence Due to Isolated Testicular Metastases Detected by PSMA PET/CT.
    J Nucl Med. 2025 Apr 10:jnumed.124.269361. doi: 10.2967/jnumed.124.269361.
    >> Share

  361. SARI H, Teimoorisichani M, Viscione M, Mingels C, et al
    Feasibility of an Ultra-Low-Dose PET Scan Protocol with CT-Based and LSO-TX-Based Attenuation Correction Using a Long-Axial-Field-of-View PET/CT Scanner.
    J Nucl Med. 2025 Apr 10:jnumed.124.268380. doi: 10.2967/jnumed.124.268380.
    >> Share

  362. ZHANG Y, Yue J, Yang X, Fei G, et al
    [(68)Ga]Ga-RAYZ-8009: A Peptide PET Tracer for Targeting HCC in Humans.
    J Nucl Med. 2025 Apr 10:jnumed.124.269294. doi: 10.2967/jnumed.124.269294.
    >> Share

  363. HICKS RJ
    Diagnostic Radiopharmaceutical Trial Design: Is It Time to Change Nomenclature?
    J Nucl Med. 2025 Apr 3:jnumed.125.269496. doi: 10.2967/jnumed.125.269496.
    >> Share

  364. BARRY N, Kendrick J, Rowshanfarzad P, Hassan GM, et al
    An External, Independent Validation of an O-(2-[(18)F]Fluoroethyl)-l-Tyrosine PET Automatic Segmentation Network on a Single-Center, Prospective Dataset of Patients with Glioblastoma.
    J Nucl Med. 2025 Apr 3:jnumed.124.268925. doi: 10.2967/jnumed.124.268925.
    >> Share

  365. LEE Y, Nguyen TD, Du Y, Coughlin JM, et al
    Validating the Utility of Supervised Clustering Algorithm for Precise [(11)C]DPA-713 PET Brain Image Quantification.
    J Nucl Med. 2025 Apr 3:jnumed.124.268519. doi: 10.2967/jnumed.124.268519.
    >> Share

  366. SCHOLTISSEK H, Reitsam NG, Dierks A, Kroncke T, et al
    Noninvasive Characterization of Hepatic Lesions by Means of Glypican-3-Directed PET/CT.
    J Nucl Med. 2025 Apr 3:jnumed.124.269290. doi: 10.2967/jnumed.124.269290.
    >> Share

  367. GIORGIO J, Soleimani-Meigooni DN, Janabi M, Baker SL, et al
    Imaging Synaptic Density in Aging and Alzheimer Disease with [(18)F]SynVesT-1.
    J Nucl Med. 2025;66:620-625.
    >> Share

  368. LI X, Zhang Y, Mixdorf JC, Wu Q, et al
    Development and Preclinical Evaluation of [(64)Cu]Cu-NOTA-ABDB6: A CD70 and Albumin Dual-Binding Tracer with Improved Pharmacokinetics.
    J Nucl Med. 2025;66:552-558.
    >> Share

  369. LI S, Abdelhafez YG, Nardo L, Cherry SR, et al
    Total-Body Parametric Imaging Using Relative Patlak Plot.
    J Nucl Med. 2025;66:654-661.
    >> Share

  370. MILLER RJH, Kavanagh P, Lemley M, Liang JX, et al
    Artificial Intelligence-Enhanced Perfusion Scoring Improves the Diagnostic Accuracy of Myocardial Perfusion Imaging.
    J Nucl Med. 2025;66:648-653.
    >> Share

  371. UDOVICICH C, Bressel M, Manji J, Ali M, et al
    PSMA-Guided Metastasis-Directed Therapy for Oligometastatic Renal Cell Carcinoma: The Proof-of-Concept PEDESTAL Study.
    J Nucl Med. 2025;66:531-536.
    >> Share

    March 2025
  372. AL-IBRAHEEM A, Scott AM, Abdlkadir AS, Vrachimis A, et al
    Consensus Nomenclature for Radionuclide Therapy: Initial Recommendations from Nuclear Medicine Global Initiative.
    J Nucl Med. 2025 Mar 27:jnumed.124.269215. doi: 10.2967/jnumed.124.269215.
    >> Share

  373. MECKEL M, Ehrenberg S, Schmidt T, Ritt P, et al
    Reduced Renal Uptake of Various Radiopharmaceuticals with Sodium Paraaminohippurate Coadministration in a Rat Model.
    J Nucl Med. 2025 Mar 27:jnumed.124.268411. doi: 10.2967/jnumed.124.268411.
    >> Share

  374. SABAHI Z, Nguyen A, Wong K, Li S, et al
    Diagnostic Potential of (68)Ga-NeoB PET/CT with Estrogen Receptor- and Progesterone Receptor-Positive Breast Cancer Undergoing Staging or Restaging for Metastatic Disease.
    J Nucl Med. 2025 Mar 27:jnumed.124.268896. doi: 10.2967/jnumed.124.268896.
    >> Share

  375. CHEN DC, Buteau JP, Emmett L, Alipour R, et al
    Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate- to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on [(68)Ga]Ga-PSMA-11 PET/CT in the proPSMA Study.
    J Nucl Med. 2025 Mar 27:jnumed.124.268901. doi: 10.2967/jnumed.124.268901.
    >> Share

  376. HERR FL, Dascalescu C, Fabritius MP, Sheikh GT, et al
    PET- and CT-Based Imaging Criteria for Response Assessment of Gastroenteropancreatic Neuroendocrine Tumors Under Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Mar 27:jnumed.124.268621. doi: 10.2967/jnumed.124.268621.
    >> Share

  377. HINDIE E, Patel RB
    Synergy Between Radiopharmaceutical Therapy and Immune Response: Deciphering the Underpinning Mechanisms for Future Actions.
    J Nucl Med. 2025 Mar 27:jnumed.125.269644. doi: 10.2967/jnumed.125.269644.
    >> Share

  378. SUN H, Cheng D, Du X, Sun C, et al
    A Rare Influenza B Virus-Associated Cerebellitis Detected by (18)F-FDG PET/CT Imaging.
    J Nucl Med. 2025 Mar 27:jnumed.125.269548. doi: 10.2967/jnumed.125.269548.
    >> Share

  379. TANG W, Qi L, Chen M, Zhang Y, et al
    Additive Value of [(68)Ga]Ga-RM26 PET/CT to [(68)Ga]Ga-PSMA-617 PET/CT in Detecting Pelvic Lymph Node Metastasis in Prostate Cancer: A Prospective, Single-Center, Phase II Study.
    J Nucl Med. 2025 Mar 20:jnumed.124.269189. doi: 10.2967/jnumed.124.269189.
    >> Share

  380. BOELLAARD R, Zwezerijnen GJC, Buvat I, Champion L, et al
    Measuring Total Metabolic Tumor Volume from (18)F-FDG PET: A Reality Check.
    J Nucl Med. 2025 Mar 13:jnumed.124.269271. doi: 10.2967/jnumed.124.269271.
    >> Share

  381. HAUSMANN P, Zschaeck S, Furth C, Nikulin P, et al
    Tumor Asphericity in FDG PET Is an Independent Prognostic Parameter Improving Risk Stratification in Patients with Head and Neck Squamous Cell Carcinoma.
    J Nucl Med. 2025 Mar 13:jnumed.124.268972. doi: 10.2967/jnumed.124.268972.
    >> Share

  382. CONSTANTINO CS, Oliveira FPM, Machado M, Vinga S, et al
    The Use of Maximum-Intensity Projections and Deep Learning Adds Value to the Fully Automatic Segmentation of Lesions Avid for [(18)F]FDG and [(68)Ga]Ga-PSMA in PET/CT.
    J Nucl Med. 2025 Mar 13:jnumed.124.269067. doi: 10.2967/jnumed.124.269067.
    >> Share

  383. REED MB, Murgas M, Lanzenberger R, Hahn A, et al
    The Value of Functional PET in Quantifying Neurotransmitter Dynamics.
    J Nucl Med. 2025 Mar 13:jnumed.124.269238. doi: 10.2967/jnumed.124.269238.
    >> Share

  384. TUNALI I, Wang J, Arora AK, Kim MJ, et al
    Development and Validation of a (18)F-Flortaucipir PET Visual Stratification Method.
    J Nucl Med. 2025 Mar 13:jnumed.124.268700. doi: 10.2967/jnumed.124.268700.
    >> Share

  385. MORRIS ED, Emvalomenos GM, Hoye J, Meikle SR, et al
    Reply to "The Value of Functional PET in Quantifying Neurotransmitter Dynamics".
    J Nucl Med. 2025 Mar 13:jnumed.125.269473. doi: 10.2967/jnumed.125.269473.
    >> Share

  386. PARIHAR AS, Vaz S, Sutcliffe S, Pant N, et al
    (18)F-Fluoroestradiol PET/CT for Predicting Benefit from Endocrine Therapy in Patients with Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Metaanalysis.
    J Nucl Med. 2025 Mar 13:jnumed.124.269163. doi: 10.2967/jnumed.124.269163.
    >> Share

  387. MORAITIS A, Prochnow A, Poeppel TD, Schmitz J, et al
    Tumor Dose-Response Relationship of [(131)I]MIBG Therapy in Patients with Neural Crest Tumors by Means of [(124)I]MIBG PET.
    J Nucl Med. 2025 Mar 13:jnumed.124.269377. doi: 10.2967/jnumed.124.269377.
    >> Share

  388. BERNER K, Hernes E, Kvassheim M, Revheim ME, et al
    First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen-Targeted (212)Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2025 Mar 13:jnumed.124.269299. doi: 10.2967/jnumed.124.269299.
    >> Share

  389. LIU S, Pan Q, Zhang H, Peng L, et al
    Differences in Fibroinflammatory Activity Shown on (68)Ga-FAPI-04 and (18)F-FDG PET/CT in the Two Subtypes of IgG4-Related Disease.
    J Nucl Med. 2025 Mar 6:jnumed.124.268943. doi: 10.2967/jnumed.124.268943.
    >> Share

  390. JUWEID ME, Al-Leimon O, Al-Qasem SF, Aljarah I, et al
    Self-Citation Among Highly Cited Nuclear Medicine and Medical Imaging Researchers.
    J Nucl Med. 2025 Mar 6:jnumed.124.269357. doi: 10.2967/jnumed.124.269357.
    >> Share

  391. METSER U, Lukovic J, Mesci A, MacCrostie P, et al
    [(18)F]-FDG PET/CT in the Initial Staging of Squamous Cell Cancer of the Anal Canal: Results of a Prospective Multicenter Registry.
    J Nucl Med. 2025 Mar 6:jnumed.124.269289. doi: 10.2967/jnumed.124.269289.
    >> Share

  392. FOXTON C, Waldron B, Veggerby Gronlund R, Simon JJ, et al
    Preclinical Evaluation of (177)Lu-rhPSMA-10.1, a Radiopharmaceutical for Prostate Cancer: Biodistribution and Therapeutic Efficacy.
    J Nucl Med. 2025 Mar 6:jnumed.124.268508. doi: 10.2967/jnumed.124.268508.
    >> Share

  393. KNUUTI J, Kobylecka M, Krajewski S, Steczek L, et al
    Biodistribution, Safety Profile, and Radiation Dosimetry of [(18)F]SYN2, a PET Cardiac Perfusion Tracer, in Healthy Subjects.
    J Nucl Med. 2025 Mar 6:jnumed.124.268872. doi: 10.2967/jnumed.124.268872.
    >> Share

  394. IMBER BS, Yu KKH, Abida W, Pike LRG, et al
    Symptomatic Prostate-Specific Membrane Antigen PET-Positive Radionecrosis After Multimodality Brain Metastasis-Directed Treatment Including [(177)Lu]Lu-PSMA-617.
    J Nucl Med. 2025 Mar 6:jnumed.124.269175. doi: 10.2967/jnumed.124.269175.
    >> Share

  395. WANG R, Wang J, Xiang J, Sui H, et al
    Comparison of [(68)Ga]Ga-Fibroblast Activation Protein Inhibitor-04 and [(18)F]FDG PET Imaging for Solitary Fibrous Tumor and Preliminary Application of FAP-Targeted Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Mar 6:jnumed.124.268258. doi: 10.2967/jnumed.124.268258.
    >> Share

  396. KURKOWSKA S, Brosch-Lenz J, Dewaraja YK, Frey E, et al
    An International Study of Factors Affecting Variability of Dosimetry Calculations, Part 4: Impact of Fitting Functions in Estimated Absorbed Doses.
    J Nucl Med. 2025;66:441-448.
    >> Share

  397. BODEI L, Cremonesi M, Ferrari M, Mittra ES, et al
    Dosimetry of [(177)Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial.
    J Nucl Med. 2025;66:449-456.
    >> Share

  398. FU JF, Juttukonda MR, Garimella A, Salvatore AN, et al
    [(18)F]MK-6240 Radioligand Delivery Indices as Surrogates of Cerebral Perfusion: Bias and Correlation Against [(15)O]Water.
    J Nucl Med. 2025;66:410-417.
    >> Share

  399. AHMAD AA, Ghim M, Kukreja G, Neishabouri A, et al
    Collagen Hybridizing Peptide-Based Radiotracers for Molecular Imaging of Collagen Turnover in Pulmonary Fibrosis.
    J Nucl Med. 2025;66:425-433.
    >> Share

  400. GILLETT D, Senanayake R, MacFarlane J, Bashari W, et al
    A Phase I/IIa Clinical Trial to Evaluate Safety and Adrenal Uptake of Para-Chloro-2-[(18)F]Fluoroethyletomidate in Healthy Volunteers and Patients with Primary Aldosteronism.
    J Nucl Med. 2025;66:434-440.
    >> Share

  401. MARQUIS H, Schmidtlein CR, de Nijs R, Minguez Gabina P, et al
    MIRD Pamphlet No. 32: A MIRD Recovery Coefficient Model for Resolution Characterization and Shape-Specific Partial-Volume Correction.
    J Nucl Med. 2025;66:457-465.
    >> Share

    February 2025
  402. MURTHY V, Ludwig V, Gafita A, Hope TA, et al
    The Role of PSMA PET Parameters as Biomarkers for Response to PSMA-Targeted Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Feb 27:jnumed.124.268818. doi: 10.2967/jnumed.124.268818.
    >> Share

  403. MENCH A, Winters C, Mittra E, Szidonya L, et al
    Navigating Radiation Safety After Radiopharmaceutical Therapies: Proposed Workflow and Essential Guidelines for Nonspecialists.
    J Nucl Med. 2025 Feb 27:jnumed.124.268522. doi: 10.2967/jnumed.124.268522.
    >> Share

  404. WANG J, Lan X, Shi H, Li S, et al
    A Brief Report on the Results of the 2024 National Survey of Nuclear Medicine Conducted by the Chinese Society of Nuclear Medicine.
    J Nucl Med. 2025 Feb 27:jnumed.124.269044. doi: 10.2967/jnumed.124.269044.
    >> Share

  405. CONSTANZO J, Parach A, David T, Karam J, et al
    MHC-I-Driven Antitumor Immunity Counterbalances Low Absorbed Doses of Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Feb 27:jnumed.124.268857. doi: 10.2967/jnumed.124.268857.
    >> Share

  406. TURCO F, Gillessen S, Herrmann K, Paone G, et al
    Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Feb 27:jnumed.124.267730. doi: 10.2967/jnumed.124.267730.
    >> Share

  407. VERA P, Giraud P, Hapdey S, Gouel P, et al
    Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of Radiochemotherapy in Patients with Inoperable Stage III Nonsmall Cell Lung Cancer.
    J Nucl Med. 2025 Feb 27:jnumed.124.268499. doi: 10.2967/jnumed.124.268499.
    >> Share

  408. GAJECKI L, Lebedeva IV, Liao YR, Ambriz D, et al
    IL13Ralpha2-Targeting Antibodies for Immuno-PET in Solid Malignancies.
    J Nucl Med. 2025 Feb 20:jnumed.124.268762. doi: 10.2967/jnumed.124.268762.
    >> Share

  409. CHEVALEYRE C, Zimmermann L, Specklin S, Kereselidze D, et al
    PET Imaging of PD-L1 Occupancy for Preclinical Assessment of the Efficacy of Combined Anti-PD-L1 Immunotherapy and Targeted Therapy.
    J Nucl Med. 2025 Feb 20:jnumed.124.268586. doi: 10.2967/jnumed.124.268586.
    >> Share

  410. VIERING O, Holzleitner N, Claus R, Amerein A, et al
    CCK(2) Receptor Ligand [(68)Ga]Ga-DOTA-CCK-66 PET/CT Outperforms [(68)Ga]Ga-DOTATOC PET/CT in a Patient with Small Cell Lung Cancer.
    J Nucl Med. 2025 Feb 20:jnumed.124.269201. doi: 10.2967/jnumed.124.269201.
    >> Share

  411. VAN RIJSEWIJK ND, Lanz P, Wouthuyzen-Bakker M, Glaudemans AWJM, et al
    Evaluating Bone Healing with [(18)F]NaF PET/CT During Bone Segment Transport in Femoral Fracture Treatment.
    J Nucl Med. 2025 Feb 20:jnumed.124.268913. doi: 10.2967/jnumed.124.268913.
    >> Share

  412. BABEKER H, Njotu FN, Pougoue Ketchemen J, Monzer A, et al
    (225)Ac/(89)Zr-Labeled N4MU01 Radioimmunoconjugates as Theranostics Against Nectin-4-Positive Triple-Negative Breast Cancer.
    J Nucl Med. 2025 Feb 20:jnumed.124.268387. doi: 10.2967/jnumed.124.268387.
    >> Share

  413. SANTORO-FERNANDES V, Schott B, Weisman AJ, Lokre O, et al
    Full-Body Tumor Response Heterogeneity of Metastatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Feb 13:jnumed.124.267809. doi: 10.2967/jnumed.124.267809.
    >> Share

  414. MOSTAFAPOUR S, van Sluis J, Lammertsma AA, Tsoumpas C, et al
    (176)Lu Radiation Dose of Long-Axial Field of View PET Scanners.
    J Nucl Med. 2025 Feb 13:jnumed.124.269187. doi: 10.2967/jnumed.124.269187.
    >> Share

  415. YU S, Yang Z, Ding Z, Jia Y, et al
    (68)Ga-FAPI-04 PET/CT Imaging for Assessing Renal Tubulointerstitial Fibrosis in Lupus Nephritis.
    J Nucl Med. 2025 Feb 13:jnumed.124.268643. doi: 10.2967/jnumed.124.268643.
    >> Share

  416. SUN Y, Hao Z, Gao H, Yang G, et al
    [(99m)Tc]Tc-MY6349 Probe for Trop2-Targeted SPECT Imaging: From Preclinical to Pilot Clinical Study.
    J Nucl Med. 2025 Feb 13:jnumed.124.268564. doi: 10.2967/jnumed.124.268564.
    >> Share

  417. YUSUFALY T, Roncali E, Brosch-Lenz J, Uribe C, et al
    Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Current Tools, Techniques, and Uncharted Territories.
    J Nucl Med. 2025 Feb 13:jnumed.124.267927. doi: 10.2967/jnumed.124.267927.
    >> Share

  418. BABICH J, Kostakoglu L
    New Approaches in Radiopharmaceutical Development: John Babich Talks with Lale Kostakoglu About Current and Coming Trends in Diagnostics and Therapeutics.
    J Nucl Med. 2025 Feb 13:jnumed.125.269492. doi: 10.2967/jnumed.125.269492.
    >> Share

  419. SUN L, Sun Y, Zuo K, Fan L, et al
    Pilot Study of Nectin-4-Targeted PET Imaging Agent (68)Ga-FZ-NR-1 in Triple-Negative Breast Cancer from Bench to First-in-Human.
    J Nucl Med. 2025 Feb 13:jnumed.124.269024. doi: 10.2967/jnumed.124.269024.
    >> Share

  420. CZERNIN J, Bodei L, Modlin I, Calais J, et al
    Reflections on the Demand for PSMA- and SSTR-Targeted Radiopharmaceutical Therapies: Why We Were Wrong (and Why We Will Be Right Eventually).
    J Nucl Med. 2025 Feb 6:jnumed.124.269401. doi: 10.2967/jnumed.124.269401.
    >> Share

  421. LASSEN ML, Kertesz H, Rausch I, Panin V, et al
    Positron Range Correction Helps Enhance the Image Quality of Cardiac (82)Rb PET/CT.
    J Nucl Med. 2025 Feb 6:jnumed.124.267855. doi: 10.2967/jnumed.124.267855.
    >> Share

  422. MORAITIS A, Kahl T, Kandziora J, Jentzen W, et al
    Evaluation of Surgical Margins with Intraoperative PSMA PET/CT and Their Prognostic Value in Radical Prostatectomy.
    J Nucl Med. 2025 Feb 6:jnumed.124.268719. doi: 10.2967/jnumed.124.268719.
    >> Share

  423. DERLIN T, Widjaja L, Harke NN, Czerner C, et al
    (99m)Tc-MIP-1404 SPECT/CT Companion Diagnostic for (177)Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2025 Feb 6:jnumed.124.269319. doi: 10.2967/jnumed.124.269319.
    >> Share

  424. VAN DER GAAG S, Vis AN, Bartelink IH, Koppes JCC, et al
    Exploring the Flare Phenomenon in Patients with Castration-Resistant Prostate Cancer: Enzalutamide-Induced PSMA Upregulation Observed on PSMA PET.
    J Nucl Med. 2025 Feb 6:jnumed.124.268340. doi: 10.2967/jnumed.124.268340.
    >> Share

  425. GHEYSENS O, Pelletier-Galarneau M, Treglia G, Israel O, et al
    Summary: EANM/SNMMI Release Joint Guideline/Procedure Standard for [(18)F]FDG Hybrid PET Use in Infection and Inflammation in Adults, Version 2.0.
    J Nucl Med. 2025 Feb 6:jnumed.125.269538. doi: 10.2967/jnumed.125.269538.
    >> Share

  426. LINDENBERG L, Hope TA, Lin FI, Rowe SP, et al
    Safety, Dosimetry, and Feasibility of [(68)Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate Cancer.
    J Nucl Med. 2025 Feb 6:jnumed.124.268318. doi: 10.2967/jnumed.124.268318.
    >> Share

  427. OGATA A, Ikenuma H, Yasuno F, Nihashi T, et al
    First-in-Human Study of [(11)C]NCGG401 for Imaging Colony-Stimulating Factor 1 Receptors in the Brain.
    J Nucl Med. 2025;66:302-308.
    >> Share

  428. OLAFSON E, Tonietto M, Klein G, Teng E, et al
    In Vivo Head-to-Head Comparison of [(18)F]GTP1 with [(18)F]MK-6240 and [(18)F]PI-2620 in Alzheimer Disease.
    J Nucl Med. 2025;66:277-285.
    >> Share

  429. SONG Y, Lee JH, Kim HK, Lee JH, et al
    Longitudinal Trajectory of Dopamine and Serotonin Transporters in Parkinson Disease.
    J Nucl Med. 2025;66:286-292.
    >> Share

  430. OH M, Brumberg J, Sossi V, Varrone A, et al
    Preserved Serotonin Transporter Availability in Parkinson Disease Measured with Either [(11)C]MADAM or [(11)C]DASB: A Study Including 2 Separate Cohorts of Nondepressed Patients.
    J Nucl Med. 2025;66:309-314.
    >> Share

    January 2025
  431. WANG X, Dong Y, Zhang S
    China's Innovations in Nuclear Medicine: Global Insights into Clinical Advancements and Impact.
    J Nucl Med. 2025 Jan 30:jnumed.124.269185. doi: 10.2967/jnumed.124.269185.
    >> Share

  432. MIEDERER I, Buchholz HG, Rademacher L, Eckart C, et al
    Dopaminergic Mechanisms of Cognitive Flexibility: An [(18)F]Fallypride PET Study.
    J Nucl Med. 2025 Jan 30:jnumed.124.268317. doi: 10.2967/jnumed.124.268317.
    >> Share

  433. ULANER GA, Lewis J, Landgren O
    CD38-Targeted (89)Zr-DFO-Daratumumab PET of Myeloma: Immuno-PET Impacting Clinical Care.
    J Nucl Med. 2025 Jan 30:jnumed.124.269393. doi: 10.2967/jnumed.124.269393.
    >> Share

  434. STRIGARI L, Schwarz J, Bradshaw T, Brosch-Lenz J, et al
    Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Ethical, Regulatory, and Socioeconomic Dimensions of Theranostic Digital Twins.
    J Nucl Med. 2025 Jan 23:jnumed.124.268186. doi: 10.2967/jnumed.124.268186.
    >> Share

  435. VAN GEEL JJL, Moustaquim J, Boers J, Elias SG, et al
    Intrapatient 16alpha-[(18)F]Fluoro-17beta-Estradiol PET Heterogeneity as a Prognostic Factor for Endocrine Therapy Response and Survival in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
    J Nucl Med. 2025 Jan 23:jnumed.124.268984. doi: 10.2967/jnumed.124.268984.
    >> Share

  436. WANG R, Huang M, Wang W, Li M, et al
    Preclinical Evaluation of (68)Ga/(177)Lu-Labeled FAP-Targeted Peptide for Tumor Radiopharmaceutical Imaging and Therapy.
    J Nucl Med. 2025 Jan 23:jnumed.124.268689. doi: 10.2967/jnumed.124.268689.
    >> Share

  437. LAWAL IO, Mushtaq A, Jani AB, Rupji M, et al
    Diuresis During (18)F-Flotufolastat (rhPSMA-7.3) PET/CT Improves Recurrence Detection After Prostatectomy: A Prospective Phase II Trial.
    J Nucl Med. 2025 Jan 23:jnumed.124.268574. doi: 10.2967/jnumed.124.268574.
    >> Share

  438. YAN X, Noergaard M, Morse CL, Liow JS, et al
    PET Quantification in Healthy Humans of Cyclooxygenase-2, a Potential Biomarker of Neuroinflammation.
    J Nucl Med. 2025 Jan 23:jnumed.124.268525. doi: 10.2967/jnumed.124.268525.
    >> Share

  439. VEIT-HAIBACH P, Herrmann K, Zimmermann R, Hustinx R, et al
    Green Nuclear Medicine and Radiotheranostics.
    J Nucl Med. 2025 Jan 23:jnumed.124.268928. doi: 10.2967/jnumed.124.268928.
    >> Share

  440. BAILEY DL, Willowson KP, O'Keefe G, Goodman S, et al
    A Method for Validating PET and SPECT Cameras for Quantitative Clinical Imaging Trials Using Novel Radionuclides.
    J Nucl Med. 2025 Jan 16:jnumed.124.268578. doi: 10.2967/jnumed.124.268578.
    >> Share

  441. ENKE JS, Reitsam NG, Dintner S, Liesche-Starnecker F, et al
    Comprehensive Characterization via Molecular Imaging, Longitudinal Multisite Sampling, and Autoptic Work-up in Advanced Small Cell Lung Cancer Undergoing SSTR-Directed Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Jan 16:jnumed.124.268513. doi: 10.2967/jnumed.124.268513.
    >> Share

  442. BARBRY F, Chevalier B, Beron A, Lion G, et al
    Redifferentiation of a RET-Fusion, Radioiodine-Refractory, Differentiated Thyroid Cancer with Selpercatinib: Flip-Flop Between [(18)F]FDG PET/CT and (131)I Posttreatment Scanning.
    J Nucl Med. 2025 Jan 16:jnumed.124.268539. doi: 10.2967/jnumed.124.268539.
    >> Share

  443. CERIANI L, Milan L, Pirosa MC, Martelli M, et al
    PET-Based Risk Stratification in Primary Mediastinal B-Cell Lymphoma: A Comparative Analysis of Different Segmentation Methods in the IELSG37 Trial Patient Cohort.
    J Nucl Med. 2025 Jan 16:jnumed.124.268874. doi: 10.2967/jnumed.124.268874.
    >> Share

  444. PRASAD N, Harris E, DeFilippis EM, Sayer G, et al
    PET/CT with Myocardial Blood Flow Assessment Is Prognostic of Cardiac Allograft Vasculopathy Progression and Clinical Outcomes.
    J Nucl Med. 2025 Jan 16:jnumed.124.268713. doi: 10.2967/jnumed.124.268713.
    >> Share

  445. GAO M, Daube-Witherspoon ME, Karp JS, Surti S, et al
    Total-Body PET System Designs with Axial and Transverse Gaps: A Study of Lesion Quantification and Detectability.
    J Nucl Med. 2025 Jan 16:jnumed.124.267769. doi: 10.2967/jnumed.124.267769.
    >> Share

  446. LANGEN KJ, Stoffels G, Filss CP, Kocher M, et al
    Borderline Findings in O-(2-[(18)F]-Fluoroethyl)-l-Tyrosine PET of Patients with Suspected Glioma Relapse: Role in Clinical Practice.
    J Nucl Med. 2025 Jan 16:jnumed.124.268768. doi: 10.2967/jnumed.124.268768.
    >> Share

  447. RAMOS-TORRES KM, Conti S, Zhou YP, Tiss A, et al
    Imaging Demyelinated Axons After Spinal Cord Injuries with PET Tracer [(18)F]3F4AP.
    J Nucl Med. 2025 Jan 16:jnumed.124.268242. doi: 10.2967/jnumed.124.268242.
    >> Share

  448. VON GUGGENBERG E, di Santo G, Uprimny C, Bayerschmidt S, et al
    Safety, Biodistribution, and Radiation Dosimetry of the (68)Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors.
    J Nucl Med. 2025 Jan 16:jnumed.124.268877. doi: 10.2967/jnumed.124.268877.
    >> Share

  449. VRAKA C, Homolya M, Ozer O, Spittler A, et al
    RadioFlow Cytometry Reveals That [(18)F]FDG Uptake in K-RAS Lung Cancer Is Driven by Immune Cells: An Analysis on a Single-Cell Level.
    J Nucl Med. 2025 Jan 16:jnumed.124.268799. doi: 10.2967/jnumed.124.268799.
    >> Share

  450. RABINOVICI GD, Knopman DS, Arbizu J, Benzinger TLS, et al
    Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.
    J Nucl Med. 2025 Jan 8:jnumed.124.268756. doi: 10.2967/jnumed.124.268756.
    >> Share

  451. MADSEN C, Fuglo D, Pedersen M, Broholm R, et al
    Prospective Head-to-Head Comparison of (18)F-PSMA PET/CT and (18)F-NaF PET/CT for Assessing Bone Metastases in 160 Patients with Newly Diagnosed High-Risk Prostate Cancer.
    J Nucl Med. 2025 Jan 8:jnumed.124.268275. doi: 10.2967/jnumed.124.268275.
    >> Share

  452. MILLER SR, Gonzalez RT, Jackson WC, Caram MEV, et al
    Rates of PSMA PET Staging and Positivity in Newly Diagnosed Prostate Cancer in a National Health Care System.
    J Nucl Med. 2025;66:75-83.
    >> Share

  453. UNTERRAINER LM, Hope TA, Fendler WP, Grogan T, et al
    Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study.
    J Nucl Med. 2025;66:54-60.
    >> Share

  454. MILLER RJH, Patel KK, Kwiecinski J, Slipczuk L, et al
    Nuclear Cardiology Surrogate Biomarkers in Clinical Trials.
    J Nucl Med. 2025;66:4-11.
    >> Share

  455. HOU P, Chen H, Liang S, Guo W, et al
    Targeting Fibroblast Activation Protein for Molecular Imaging of Fibrotic Remodeling in Pulmonary Arterial Hypertension.
    J Nucl Med. 2025;66:98-103.
    >> Share

  456. BARTEL T
    2024 SNMMI Highlights Lecture: General Clinical Specialties.
    J Nucl Med. 2025;66:158-161.
    >> Share

  457. MICHNO M, Schmitz J, Foerges AL, Beer S, et al
    Effect of Acute Hypoxia Exposure on the Availability of A(1) Adenosine Receptors and Perfusion in the Human Brain.
    J Nucl Med. 2025;66:142-149.
    >> Share

  458. OMIDVARI N, Shanina E, Leung EK, Sun X, et al
    Quantitative Accuracy Assessment of the NeuroEXPLORER for Diverse Imaging Applications: Moving Beyond Standard Evaluations.
    J Nucl Med. 2025;66:150-157.
    >> Share

  459. PARIHAR AS, Mhlanga JC, Royal HD, Siegel BA, et al
    Comparability of Quantifying Relative Lung Ventilation with Inhaled (99m)Tc-Technegas and (133)Xe in Patients Undergoing Evaluation for Lung Transplantation.
    J Nucl Med. 2025;66:104-109.
    >> Share

  460. GHAZANFARI N, Liow JS, Kim MJ, Cureton R, et al
    [(11)C]PS13 Demonstrates Pharmacologically Selective and Substantial Binding to Cyclooxygenase-1 in the Human Brain.
    J Nucl Med. 2025;66:117-122.
    >> Share

  461. SCHWEIGER L, Maurer T, Simon R, Horn T, et al
    Pattern of Failure in Patients with Biochemical Recurrence After PSMA Radioguided Surgery.
    J Nucl Med. 2025;66:67-72.
    >> Share

  462. GOTO T, Kikuchi S, Sakurai Y, Tsuruta Y, et al
    Cardiac Presynaptic Sympathetic Nervous Function Evaluated by Cardiac PET in Patients with Chronotropic Incompetence Without Heart Failure.
    J Nucl Med. 2025 Jan 2:jnumed.124.268638. doi: 10.2967/jnumed.124.268638.
    >> Share

  463. EMMETT L
    SPECT Deserves RESPECT: The Potential of SPECT/CT to Optimize Patient Outcomes with Theranostics Therapy.
    J Nucl Med. 2025 Jan 2:jnumed.124.268325. doi: 10.2967/jnumed.124.268325.
    >> Share

    December 2024
  464. CHENG K, Ge L, Song M, Li W, et al
    Preclinical Evaluation and Pilot Clinical Study of CD137 PET Radiotracer for Noninvasive Monitoring Early Responses of Immunotherapy.
    J Nucl Med. 2024 Dec 12:jnumed.124.268068. doi: 10.2967/jnumed.124.268068.
    >> Share

  465. ROUSSEAU JA, Maier M, Ait-Mohand S, Dumulon-Perreault V, et al
    Antibody-Based PET Imaging of Misfolded Superoxide Dismutase 1 in an Amyotrophic Lateral Sclerosis Mouse Model.
    J Nucl Med. 2024 Dec 12:jnumed.124.268343. doi: 10.2967/jnumed.124.268343.
    >> Share

  466. WEEKS JK, Pantel AR, Gitto SB, Liu F, et al
    [(18)F]Fluorthanatrace PET in Ovarian Cancer: Comparison with [(18)F]FDG PET, Lesion Location, Tumor Grade, and Breast Cancer Gene Mutation Status.
    J Nucl Med. 2024 Dec 5:jnumed.124.267627. doi: 10.2967/jnumed.124.267627.
    >> Share

  467. VAN DER WEIJDEN CWJ, Ahmed AKMA, van der Hoorn A, Zhu J, et al
    Myelin Imaging of the Spinal Cord in Animal Models and Patients with Multiple Sclerosis Using [(11)C]MeDAS PET: A Translational Study.
    J Nucl Med. 2024 Dec 5:jnumed.123.266896. doi: 10.2967/jnumed.123.266896.
    >> Share

  468. CUTLER CS
    A Banner Year for Nuclear Medicine, Molecular Imaging, and Theranostics.
    J Nucl Med. 2024;65:7A-8A.
    >> Share

  469. VERGOTE VKJ, Verhoef G, Janssens A, Woei-A-Jin FJSH, et al
    International Metabolic Prognostic Index Is Superior to Other Metabolic Tumor Volume-Based Prognostication Methods in a Real-Life Cohort of Diffuse Large B-Cell Lymphoma.
    J Nucl Med. 2024;65:1876-1883.
    >> Share

  470. MICHALSKI K, Kosmala A, Hartrampf PE, Heinrich M, et al
    [(18)F]FDG and [(68)Ga]Ga-FAPI-04-Directed Imaging for Outcome Prediction in Patients with High-Grade Neuroendocrine Neoplasms.
    J Nucl Med. 2024;65:1899-1903.
    >> Share

    November 2024
  471. HOPE TA, Calais J, Goenka AH, Haberkorn U, et al
    SNMMI Procedure Standard/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET.
    J Nucl Med. 2024 Nov 21:jnumed.124.269002. doi: 10.2967/jnumed.124.269002.
    >> Share

  472. JACENE H, Czernin J
    Solving Challenging Puzzles: Heather Jacene Talks with Johannes Czernin About Leadership in Clinical Nuclear Medicine and the SNMMI.
    J Nucl Med. 2024 Nov 21:jnumed.124.269029. doi: 10.2967/jnumed.124.269029.
    >> Share

  473. ERMIS E, Bachmann N, Lutz K, Pyka T, et al
    Meningioma Revisited: Should Whole-Body Staging with [(68)Ga]Ga-DOTATOC PET/CT of High-Grade Meningiomas Become Standard Practice?
    J Nucl Med. 2024 Nov 21:jnumed.124.267934. doi: 10.2967/jnumed.124.267934.
    >> Share

  474. DEMIRCI RA, Ghodsi A, Gulati R, Behnia S, et al
    PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received (177)Lu-PSMA-617: Importance of (18)F-FDG-Avid Discordant Findings.
    J Nucl Med. 2024 Nov 14:jnumed.124.268167. doi: 10.2967/jnumed.124.268167.
    >> Share

  475. WENZEL M, Koll F, Hoeh B, Humke C, et al
    Real-World Comparison of Cabazitaxel Versus (177)Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 Nov 14:jnumed.124.268807. doi: 10.2967/jnumed.124.268807.
    >> Share

  476. COLLIJ LE, Bischof GN, Altomare D, Bader I, et al
    Quantification Supports Amyloid PET Visual Assessment of Challenging Cases: Results from the AMYPAD Diagnostic and Patient Management Study.
    J Nucl Med. 2024 Nov 14:jnumed.124.268119. doi: 10.2967/jnumed.124.268119.
    >> Share

  477. LOU K, Wang J, He H, Wang Y, et al
    Value of [(68)Ga]Ga-NYM046 PET/CT, in Comparison with (18)F-FDG PET/CT, for Diagnosis of Clear Cell Renal Cell Carcinoma.
    J Nucl Med. 2024 Nov 14:jnumed.124.267527. doi: 10.2967/jnumed.124.267527.
    >> Share

  478. HUANG W, Cao M, Wu Y, Zhang Y, et al
    Immuno-PET/CT Imaging of Trop2 with [(18)F]AlF-RESCA-T4 Differentiates Lung Cancer from Inflammation.
    J Nucl Med. 2024 Nov 14:jnumed.124.268751. doi: 10.2967/jnumed.124.268751.
    >> Share

  479. DEMIRCI RA, Gulati R, Hawley JE, Yezefski T, et al
    SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving (177)Lu-PSMA-617.
    J Nucl Med. 2024 Nov 7:jnumed.124.267665. doi: 10.2967/jnumed.124.267665.
    >> Share

  480. ZHANG H, Ren C, Liu Y, Yan X, et al
    Performance Characteristics of a New Generation 148-cm Axial Field-of-View uMI Panorama GS PET/CT System with Extended NEMA NU 2-2018 and EARL Standards.
    J Nucl Med. 2024 Nov 7:jnumed.124.267963. doi: 10.2967/jnumed.124.267963.
    >> Share

  481. ZHOU X, Wu Q, Zhai W, Zhang Y, et al
    CD70-Targeted Immuno-PET/CT Imaging of Clear Cell Renal Cell Carcinoma: A Translational Study.
    J Nucl Med. 2024 Nov 7:jnumed.124.268509. doi: 10.2967/jnumed.124.268509.
    >> Share

  482. KONIAR H, Wharton L, Ingham A, Morales Oliver AP, et al
    Preclinical Evaluation of (226)Ac as a Theranostic Agent: Imaging, Dosimetry, and Therapy.
    J Nucl Med. 2024;65:1762-1768.
    >> Share

    October 2024
  483. SONNI I, Weiner AB, Doddipalli S, Deol M, et al
    Clinical, Pathologic, and Imaging Variables Associated with Prostate Cancer Detection by PSMA PET/CT and Multiparametric MRI.
    J Nucl Med. 2024 Oct 30:jnumed.124.268443. doi: 10.2967/jnumed.124.268443.
    >> Share

  484. YOUNG AJ, Pantel AR, Kiani M, Doot RK, et al
    Kinetic Analysis and Metabolism of Poly(Adenosine Diphosphate-Ribose) Polymerase-1-Targeted (18)F-Fluorthanatrace PET in Breast Cancer.
    J Nucl Med. 2024 Oct 30:jnumed.124.268254. doi: 10.2967/jnumed.124.268254.
    >> Share

  485. HUANG RR, Zuo C, Mona CE, Holzgreve A, et al
    FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study.
    J Nucl Med. 2024 Oct 30:jnumed.124.268037. doi: 10.2967/jnumed.124.268037.
    >> Share

  486. SWIHA M, Pathmanandavel S, Papa N, Sabahi Z, et al
    Comparison of Posttherapy 4- and 24-Hour [(177)Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 Oct 30:jnumed.124.267606. doi: 10.2967/jnumed.124.267606.
    >> Share

  487. HELISCH A, Kratochwil C, Kleist C, Kramer S, et al
    Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with (213)Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors.
    J Nucl Med. 2024 Oct 30:jnumed.124.268386. doi: 10.2967/jnumed.124.268386.
    >> Share

  488. WANG R, Kang W, Liu Z, Zheng Y, et al
    Head-to-Head Comparison of [(68)Ga]Ga-NOTA-RM26 and [(18)F]FDG PET/CT in Patients with Gastrointestinal Stromal Tumors: A Prospective Study.
    J Nucl Med. 2024 Oct 24:jnumed.124.267810. doi: 10.2967/jnumed.124.267810.
    >> Share

  489. MORRIS ED, Emvalomenos GM, Hoye J, Meikle SR, et al
    Modeling PET Data Acquired During Nonsteady Conditions: What If Brain Conditions Change During the Scan?
    J Nucl Med. 2024 Oct 24:jnumed.124.267494. doi: 10.2967/jnumed.124.267494.
    >> Share

  490. KATUGAMPOLA S, Wang J, Howell RW
    MIRD Pamphlet No. 31: MIRDcell V4-Artificial Intelligence Tools to Formulate Optimized Radiopharmaceutical Cocktails for Therapy.
    J Nucl Med. 2024 Oct 24:jnumed.123.267238. doi: 10.2967/jnumed.123.267238.
    >> Share

  491. LEVI J, Das M, Vasanawala MS, Behl D, et al
    [(18)F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy.
    J Nucl Med. 2024 Oct 24:jnumed.124.268253. doi: 10.2967/jnumed.124.268253.
    >> Share

  492. AMEREIN A, Maurer C, Kircher M, Gable A, et al
    Intraarterial Administration of Peptide Receptor Radionuclide Therapy in Patients with Advanced Meningioma: Initial Safety and Efficacy.
    J Nucl Med. 2024 Oct 24:jnumed.124.268217. doi: 10.2967/jnumed.124.268217.
    >> Share

  493. BOSS M, Eriksson O, Mikkola K, Eek A, et al
    Improved Localization of Insulinomas Using (68)Ga-NODAGA-Exendin-4 PET/CT.
    J Nucl Med. 2024 Oct 17:jnumed.124.268158. doi: 10.2967/jnumed.124.268158.
    >> Share

  494. ARBIZU J, Morbelli S, Minoshima S, Barthel H, et al
    SNMMI Procedure Standard/EANM Practice Guideline for Brain [(18)F]FDG PET Imaging, Version 2.0.
    J Nucl Med. 2024 Oct 17:jnumed.124.268754. doi: 10.2967/jnumed.124.268754.
    >> Share

  495. JANNUSCH K, Umutlu L, Kirchner J, Bruckmann NM, et al
    Impact of (18)F-FDG PET/MRI on Therapeutic Management of Women with Newly Diagnosed Breast Cancer: Results from a Prospective Double-Center Trial.
    J Nucl Med. 2024 Oct 10:jnumed.124.268065. doi: 10.2967/jnumed.124.268065.
    >> Share

  496. LIU Q, Xu X, Yang Z, Zhang J, et al
    Granzyme B PET/CT Imaging Evaluates Early Response to Immunotherapy in Gastric Cancer.
    J Nucl Med. 2024 Oct 10:jnumed.124.267529. doi: 10.2967/jnumed.124.267529.
    >> Share

  497. GAFITA A, Menard AR, Solnes LB
    Diagnostic Radiopharmaceuticals: A Sustainable Path to the Improvement of Patient Care.
    J Nucl Med. 2024 Oct 10:jnumed.124.268608. doi: 10.2967/jnumed.124.268608.
    >> Share

  498. HOTTA M, Kim GHJ, Rerkpichaisuth V, Teng PY, et al
    Correlation of FAPI PET Uptake with Immunohistochemistry in Explanted Lungs from Patients with Advanced Interstitial Lung Disease.
    J Nucl Med. 2024 Oct 3:jnumed.124.268351. doi: 10.2967/jnumed.124.268351.
    >> Share

  499. PELLETIER-GALARNEAU M, Simard F, Tadros R, Tremblay-Gravel M, et al
    Arrhythmias in Nongranulomatous Myocarditis: Is There a Role for PET?
    J Nucl Med. 2024 Oct 3:jnumed.124.268033. doi: 10.2967/jnumed.124.268033.
    >> Share

  500. PRATT EC, Mezzadra R, Kulick A, Kaminsky S, et al
    uPAR Immuno-PET in Pancreatic Cancer, Aging, and Chemotherapy-Induced Senescence.
    J Nucl Med. 2024 Oct 3:jnumed.124.268278. doi: 10.2967/jnumed.124.268278.
    >> Share

  501. FERRANDEZ MC, Golla SSV, Eertink JJ, Wiegers SE, et al
    Validation of an Artificial Intelligence-Based Prediction Model Using 5 External PET/CT Datasets of Diffuse Large B-Cell Lymphoma.
    J Nucl Med. 2024 Oct 3:jnumed.124.268191. doi: 10.2967/jnumed.124.268191.
    >> Share

  502. CARLSEN EA, Loft M, Johnbeck CB, Knigge U, et al
    Routine Use of [(64)Cu]Cu-DOTATATE PET/CT in a Neuroendocrine Tumor Center: Referral Patterns and Image Results of 2,249 Consecutive Scans.
    J Nucl Med. 2024 Oct 3:jnumed.124.267939. doi: 10.2967/jnumed.124.267939.
    >> Share

  503. CALAIS J, Morris MJ, Kendi AT, Kalebasty AR, et al
    Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy.
    J Nucl Med. 2024 Oct 3:jnumed.124.268363. doi: 10.2967/jnumed.124.268363.
    >> Share

  504. LEE H, Alhamshari AS, Patel V, Bhattaru A, et al
    Cardiac Neuroendocrine Tumor Metastases on (68)Ga-DOTATATE PET/CT: Identification and Prognostic Significance.
    J Nucl Med. 2024 Oct 3:jnumed.124.267948. doi: 10.2967/jnumed.124.267948.
    >> Share

  505. MILLER RJH, Lemley M, Shanbhag A, Ramirez G, et al
    The Updated Registry of Fast Myocardial Perfusion Imaging with Next-Generation SPECT (REFINE SPECT 2.0).
    J Nucl Med. 2024 Oct 3:jnumed.124.268292. doi: 10.2967/jnumed.124.268292.
    >> Share

  506. PISANO G, van Oosterom MN, Berrens AC, Slof LJ, et al
    Freehand SPECT Combined with 3-Dimensional Light Detection and Ranging as Alternative Means of Specimen Scanning During Prostate Cancer Surgery.
    J Nucl Med. 2024 Oct 3:jnumed.124.268256. doi: 10.2967/jnumed.124.268256.
    >> Share

  507. RYU J, Hyung J, Han S, Jeong JH, et al
    Impact of (18)F-FES PET/CT on Clinical Decisions in the Management of Recurrent or Metastatic Breast Cancer.
    J Nucl Med. 2024 Oct 3:jnumed.124.267913. doi: 10.2967/jnumed.124.267913.
    >> Share

  508. ZHANG X, Lin Z, Feng Y, Lin Z, et al
    Predicting Pathologic Complete Response in Locally Advanced Rectal Cancer with [(68)Ga]Ga-FAPI-04 PET, [(18)F]FDG PET, and Contrast-Enhanced MRI: Lesion-to-Lesion Comparison with Pathology.
    J Nucl Med. 2024;65:1548-1556.
    >> Share

  509. VAN SLUIS J, van Snick JH, Glaudemans AWJM, Slart RHJA, et al
    Ultrashort Oncologic Whole-Body [(18)F]FDG Patlak Imaging Using LAFOV PET.
    J Nucl Med. 2024;65:1652-1657.
    >> Share

  510. ENKE JS, Ritzel K, Asbach E, Reitsam NG, et al
    C-X-C Motif Chemokine Receptor 4-Directed Scintigraphy Using [(99m)Tc]Tc-Pentixatec in Primary Aldosteronism: A Proof-of-Concept Study.
    J Nucl Med. 2024;65:1640-1644.
    >> Share

  511. ROOHANI B, Mendez AS, Dangarwala M, Katz S, et al
    Nuclear Imaging of Bispecific Antibodies on the Rise.
    J Nucl Med. 2024;65:1512-1517.
    >> Share

    September 2024
  512. DONG Y, Wang Z, Hu X, Sun Y, et al
    [(18)F]AlF-NOTA-FAPI-04 PET/CT for Predicting Pathologic Response of Resectable Esophageal Squamous Cell Carcinoma to Neoadjuvant Camrelizumab and Chemotherapy: A Phase II Clinical Trial.
    J Nucl Med. 2024 Sep 26:jnumed.124.268557. doi: 10.2967/jnumed.124.268557.
    >> Share

  513. BERNARDINO RM, Lajkosz K, Yin LB, Sayyid RK, et al
    Association of Free-to-Total PSA Ratio and (18)F-DCFPyL Prostate-Specific Membrane Antigen PET/CT Findings in Patients with Biochemical Recurrence After Radical Prostatectomy: A Prospective Single-Center Study.
    J Nucl Med. 2024 Sep 26:jnumed.124.267877. doi: 10.2967/jnumed.124.267877.
    >> Share

  514. POULIOT F, Saad F, Rousseau E, Richard PO, et al
    Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study.
    J Nucl Med. 2024 Sep 26:jnumed.124.268020. doi: 10.2967/jnumed.124.268020.
    >> Share

  515. PALESTRO CJ, Abikhzer G, Bar-Sever Z, Bartel T, et al
    Summary: Appropriate Use Criteria for the Use of Nuclear Medicine in Fever of Unknown Origin.
    J Nucl Med. 2024 Sep 26:jnumed.124.268797. doi: 10.2967/jnumed.124.268797.
    >> Share

  516. BYUN JW, Paeng JC, Kim YJ, Lee SP, et al
    Evaluation of Fibroblast Activation Protein Expression Using (68)Ga-FAPI46 PET in Hypertension-Induced Tissue Changes.
    J Nucl Med. 2024 Sep 26:jnumed.124.267489. doi: 10.2967/jnumed.124.267489.
    >> Share

  517. JADVAR H, Iravani A, Bodei L, Calais J, et al
    Challenges with (177)Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical Practice.
    J Nucl Med. 2024 Sep 19:jnumed.124.268023. doi: 10.2967/jnumed.124.268023.
    >> Share

  518. YOUNG JJ, O'Dell RS, Naganawa M, Toyonaga T, et al
    Validation of a Simplified Tissue-to-Reference Ratio Measurement Using SUVR to Assess Synaptic Density Alterations in Alzheimer Disease with [(11)C]UCB-J PET.
    J Nucl Med. 2024 Sep 19:jnumed.124.267419. doi: 10.2967/jnumed.124.267419.
    >> Share

  519. TUNCER O, Steinberger D, Steiner J, Hinojos M, et al
    Quantitative SPECT/CT Metrics in Early Prediction of [(177)Lu]Lu-DOTATATE Treatment Response in Gastroenteropancreatic Neuroendocrine Tumor Patients.
    J Nucl Med. 2024 Sep 12:jnumed.124.267964. doi: 10.2967/jnumed.124.267964.
    >> Share

  520. POOT AJ, Lapa C, Weber WA, Lam MGEH, et al
    [(68)Ga]Ga-RAYZ-8009: A Glypican-3-Targeted Diagnostic Radiopharmaceutical for Hepatocellular Carcinoma Molecular Imaging-A First-in-Human Case Series.
    J Nucl Med. 2024 Sep 12:jnumed.124.268147. doi: 10.2967/jnumed.124.268147.
    >> Share

  521. METSER U, Nunez JE, Chan D, Kulanthaivelu R, et al
    Dual Somatostatin Receptor/(18)F-FDG PET/CT Imaging in Patients with Well-Differentiated, Grade 2 and 3 Gastroenteropancreatic Neuroendocrine Tumors.
    J Nucl Med. 2024 Sep 12:jnumed.124.267982. doi: 10.2967/jnumed.124.267982.
    >> Share

  522. AL-IBRAHEEM A, Abdlkadir A, Herrmann K, Bomanji J, et al
    Diagnostic Accuracy of [(18)F]FDG PET/MRI in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Metaanalysis.
    J Nucl Med. 2024 Sep 12:jnumed.124.268049. doi: 10.2967/jnumed.124.268049.
    >> Share

  523. ALAKONYA H, Koustoulidou S, Hopkins SL, Veal M, et al
    Molecular Imaging of p53 in Mouse Models of Cancer Using a Radiolabeled Antibody TAT Conjugate with SPECT.
    J Nucl Med. 2024 Sep 12:jnumed.124.267736. doi: 10.2967/jnumed.124.267736.
    >> Share

  524. GALBIATI A, Bocci M, Ravazza D, Mock J, et al
    Preclinical Evaluation of (177)Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors.
    J Nucl Med. 2024 Sep 12:jnumed.124.268200. doi: 10.2967/jnumed.124.268200.
    >> Share

  525. POTY S, Ordas L, Dekempeneer Y, Parach AA, et al
    Optimizing the Therapeutic Index of sdAb-Based Radiopharmaceuticals Using Pretargeting.
    J Nucl Med. 2024 Sep 12:jnumed.124.267624. doi: 10.2967/jnumed.124.267624.
    >> Share

  526. WRAY R, Mauguen A, Michaud L, Leithner D, et al
    Development of (18)F-Fluoromisonidazole Hypoxia PET/CT Diagnostic Interpretation Criteria and Validation of Interreader Reliability, Reproducibility, and Performance.
    J Nucl Med. 2024 Sep 12:jnumed.124.267775. doi: 10.2967/jnumed.124.267775.
    >> Share

  527. SULLIVAN R, Hou J, Yu L, Wilk B, et al
    Design, Synthesis, and Preclinical Evaluation of a High-Affinity (18)F-Labeled Radioligand for Myocardial Growth Hormone Secretagogue Receptor Before and After Myocardial Infarction.
    J Nucl Med. 2024 Sep 12:jnumed.124.267578. doi: 10.2967/jnumed.124.267578.
    >> Share

  528. SIVAKUMARAN T, Cardin A, Callahan J, Wong HL, et al
    Evaluating the Utility of (18)F-FDG PET/CT in Cancer of Unknown Primary.
    J Nucl Med. 2024 Sep 5:jnumed.123.267274. doi: 10.2967/jnumed.123.267274.
    >> Share

  529. EISSES B, van Geel JJL, Brouwers AH, Bensch F, et al
    Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer.
    J Nucl Med. 2024 Sep 5:jnumed.124.267636. doi: 10.2967/jnumed.124.267636.
    >> Share

  530. BAUCKNEHT M, D'Amico F, Albano D, Balma M, et al
    Composite Prediction Score to Interpret Bone Focal Uptake in Hormone-Sensitive Prostate Cancer Patients Imaged with [(18)F]PSMA-1007 PET/CT.
    J Nucl Med. 2024 Sep 5:jnumed.124.267751. doi: 10.2967/jnumed.124.267751.
    >> Share

  531. KULKARNI HR, Maupin KA, Brennan T, Forsberg J, et al
    First-in-Human Total-Body PET/CT Imaging Using (89)Zr-Labeled MUC5AC Antibody in a Patient with Pancreatic Adenocarcinoma.
    J Nucl Med. 2024 Sep 5:jnumed.124.268074. doi: 10.2967/jnumed.124.268074.
    >> Share


  532. Robert Carretta, MD, 1941-2023.
    J Nucl Med. 2024;65:1498.
    >> Share

  533. BEHRENBRUCH C
    FINDing the Future of Radiopharma.
    J Nucl Med. 2024;65:1333-1335.
    >> Share

    August 2024
  534. KIM D, Kang SK, Shin SA, Choi H, et al
    Improving (18)F-FDG PET Quantification Through a Spatial Normalization Method.
    J Nucl Med. 2024 Aug 29:jnumed.123.267360. doi: 10.2967/jnumed.123.267360.
    >> Share

  535. MWANIA MM, Gitau SN, Shah J, Makhdomi K, et al
    Association Between CA 15-3 and (18)F-FDG PET/CT Findings in Recurrent Breast Cancer Patients at a Tertiary Referral Hospital in Kenya.
    J Nucl Med. 2024 Aug 29:jnumed.124.267851. doi: 10.2967/jnumed.124.267851.
    >> Share

  536. THIN P, Hotta M, Gafita A, Grogan T, et al
    Clinical Factors That Influence Repeat (68)Ga-PSMA-11 PET/CT Scan Positivity in Patients with Recurrent Prostate Cancer Under Observation After a Negative (68)Ga-PSMA-11 PET/CT Scan: A Single-Center Retrospective Study.
    J Nucl Med. 2024 Aug 21:jnumed.124.267591. doi: 10.2967/jnumed.124.267591.
    >> Share

  537. HO KV, Tatum DS, Watkinson L, Carmack T, et al
    Single Chelator-Minibody Theranostic Agents for (89)Zr PET Imaging and (177)Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer.
    J Nucl Med. 2024 Aug 14:jnumed.124.267667. doi: 10.2967/jnumed.124.267667.
    >> Share

  538. INCE S, Laforest R, Itani M, Prasad V, et al
    Quantitative Assessments of Tumor Activity in a General Oncologic PET/CT Population: Which Metric Minimizes Tracer Uptake Time Dependence?
    J Nucl Med. 2024 Aug 14:jnumed.123.266469. doi: 10.2967/jnumed.123.266469.
    >> Share

  539. PANDIT-TASKAR N, Zanzonico PB, Grkovski M, Donzelli M, et al
    Theranostic Intratumoral Convection-Enhanced Delivery of (124)I-Omburtamab in Patients with Diffuse Intrinsic Pontine Glioma: Pharmacokinetics and Lesion Dosimetry.
    J Nucl Med. 2024 Aug 14:jnumed.123.266365. doi: 10.2967/jnumed.123.266365.
    >> Share

  540. MAINTA IC, Neroladaki A, Wolf NB, Benamran D, et al
    [(68)Ga]Ga-PSMA-11 PET and Prostate Cancer Bone Metastases: Diagnostic Performance of Available Standardized Criteria.
    J Nucl Med. 2024 Aug 8:jnumed.124.267899. doi: 10.2967/jnumed.124.267899.
    >> Share

  541. YADAV S, Lowery B, Tuchayi AM, Jiang F, et al
    Impact of Posttreatment SPECT/CT on Patient Management During (177)Lu-PSMA-617 Radiopharmaceutical Therapy.
    J Nucl Med. 2024 Aug 8:jnumed.124.267955. doi: 10.2967/jnumed.124.267955.
    >> Share

  542. OSMAN MM, Iravani A, Mitchell C, Hicks RJ, et al
    (18)F-DCFPyL PSMA PET/CT Tracheobronchial Uptake in Patients with Prostate Cancer: Incidence and Etiology.
    J Nucl Med. 2024 Aug 1:jnumed.124.267772. doi: 10.2967/jnumed.124.267772.
    >> Share

  543. LI S, Nguyen A, Counter W, John NC, et al
    Utility of (64)Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on (68)Ga-PSMA-11 PET/CT.
    J Nucl Med. 2024 Aug 1:jnumed.124.267881. doi: 10.2967/jnumed.124.267881.
    >> Share

  544. BOELLAARD R, Buvat I, Nioche C, Ceriani L, et al
    International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline (18)F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation.
    J Nucl Med. 2024 Aug 1:jnumed.124.267789. doi: 10.2967/jnumed.124.267789.
    >> Share

  545. NIKITAS J, Castellanos Rieger A, Farolfi A, Seyedroudbari A, et al
    Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 Aug 1:jnumed.124.267922. doi: 10.2967/jnumed.124.267922.
    >> Share

  546. RIETBERGEN DDD, Buckle T, Slof LJ, van Meerbeek MP, et al
    hHEPATO-Cy5, a Bimodal Tracer for Image-Guided Hepatobiliary Surgery.
    J Nucl Med. 2024;65:1301-1306.
    >> Share

  547. SCHELBERT H, Schoder H, Czernin J
    Illuminating Cardiac Function: Heinz Schelbert Talks with Heiko Schoder and Johannes Czernin About a Pioneering Career in Nuclear Cardiology.
    J Nucl Med. 2024;65:1163-1165.
    >> Share

  548. RESCH S, Ziegler SI, Sheikh G, Unterrainer LM, et al
    Impact of the Reference Multiple-Time-Point Dosimetry Protocol on the Validity of Single-Time-Point Dosimetry for [(177)Lu]Lu-PSMA-I&T Therapy.
    J Nucl Med. 2024;65:1272-1278.
    >> Share

  549. ANGAPPULIGE DH, Barashi NS, Pickersgill N, Weimholt C, et al
    Prostate-Specific Membrane Antigen-Targeted Imaging and Its Correlation with HOXB13 Expression.
    J Nucl Med. 2024;65:1210-1216.
    >> Share

  550. CAPTIER N, Orlhac F, Hovhannisyan-Baghdasarian N, Luporsi M, et al
    RadShap: An Explanation Tool for Highlighting the Contributions of Multiple Regions of Interest to the Prediction of Radiomic Models.
    J Nucl Med. 2024;65:1307-1312.
    >> Share

  551. LUDWIG V, Maliha PG, Shen J, Tonnelet D, et al
    [(68)Ga]Ga-FAPI-46 False-Positive Uptake After Chemotherapy in Nonseminomatous Germ Cell Tumor Metastatic Lesions.
    J Nucl Med. 2024;65:1328-1329.
    >> Share

    July 2024
  552. BUDDENKOTTE T, Buchert R
    Unrealistic Data Augmentation Improves the Robustness of Deep Learning-Based Classification of Dopamine Transporter SPECT Against Variability Between Sites and Between Cameras.
    J Nucl Med. 2024 Jul 25:jnumed.124.267570. doi: 10.2967/jnumed.124.267570.
    >> Share

  553. PICCARDO A, Bottoni G, Puppo C, Massollo M, et al
    Role of (64)CuCl(2) PET/CT in Detecting and Staging Muscle-Invasive Bladder Cancer: Comparison with Contrast-Enhanced CT and (18)F-FDG PET/CT.
    J Nucl Med. 2024 Jul 25:jnumed.124.267474. doi: 10.2967/jnumed.124.267474.
    >> Share

  554. GEBRE RK, Rial AM, Raghavan S, Wiste HJ, et al
    Advancing Tau PET Quantification in Alzheimer Disease with Machine Learning: Introducing THETA, a Novel Tau Summary Measure.
    J Nucl Med. 2024 Jul 25:jnumed.123.267273. doi: 10.2967/jnumed.123.267273.
    >> Share

  555. PIROZZI MA, Gaudieri V, Prinster A, Magliulo M, et al
    StepBrain: A 3-Dimensionally Printed Multicompartmental Anthropomorphic Brain Phantom to Simulate PET Activity Distributions.
    J Nucl Med. 2024 Jul 18:jnumed.123.267277. doi: 10.2967/jnumed.123.267277.
    >> Share

  556. BASACO BERNABEU T, Mansi R, Del Pozzo L, Zanger S, et al
    (61)Cu-PSMA-Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human Imaging.
    J Nucl Med. 2024 Jul 18:jnumed.123.267126. doi: 10.2967/jnumed.123.267126.
    >> Share

  557. KANG F, Xie Z, Ma W, Quan Z, et al
    Validation and Evaluation of a Vendor-Provided Head Motion Correction Algorithm on the uMI Panorama PET/CT System.
    J Nucl Med. 2024 Jul 11:jnumed.124.267446. doi: 10.2967/jnumed.124.267446.
    >> Share

  558. LARIVE T, Boursier C, Claudin M, Varlot J, et al
    Factors Associated with Myocardial Uptake on Oncologic Somatostatin PET Investigations and Differentiation from Myocardial Uptake of Acute Myocarditis.
    J Nucl Med. 2024 Jul 11:jnumed.123.267219. doi: 10.2967/jnumed.123.267219.
    >> Share

  559. CLEMENT C, Leclere JC, Maheo C, Le Pennec R, et al
    Diagnostic Performance of (18)F-FDG PET/CT According to Delay After Treatment to Detect Subclinical Recurrence of Head and Neck Squamous Cell Carcinoma.
    J Nucl Med. 2024 Jul 11:jnumed.124.267391. doi: 10.2967/jnumed.124.267391.
    >> Share

  560. KESSLER L, Schwaning F, Metzenmacher M, Pabst K, et al
    Fibroblast Activation Protein-Directed Imaging Outperforms (18)F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial.
    J Nucl Med. 2024 Jul 3:jnumed.124.267473. doi: 10.2967/jnumed.124.267473.
    >> Share

  561. OSTER C, Kessler L, Blau T, Keyvani K, et al
    The Role of Fibroblast Activation Protein in Glioblastoma and Gliosarcoma: A Comparison of Tissue, (68)Ga-FAPI-46 PET Data, and Survival Data.
    J Nucl Med. 2024 Jul 3:jnumed.123.267151. doi: 10.2967/jnumed.123.267151.
    >> Share

  562. BORGWARDT L, Brok J, Andersen KF, Madsen J, et al
    Performing [(18)F]MFBG Long-Axial-Field-of-View PET/CT Without Sedation or General Anesthesia for Imaging of Children with Neuroblastoma.
    J Nucl Med. 2024 Jul 3:jnumed.123.267256. doi: 10.2967/jnumed.123.267256.
    >> Share

  563. ELLS Z, Grogan TR, Czernin J, Dahlbom M, et al
    Dosimetry of [(177)Lu]Lu-PSMA-Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis.
    J Nucl Med. 2024 Jul 3:jnumed.124.267452. doi: 10.2967/jnumed.124.267452.
    >> Share

  564. LU Z, Polan DF, Wei L, Aryal MP, et al
    PET/CT-Based Absorbed Dose Maps in (90)Y Selective Internal Radiation Therapy Correlate with Spatial Changes in Liver Function Derived from Dynamic MRI.
    J Nucl Med. 2024 Jul 3:jnumed.124.267421. doi: 10.2967/jnumed.124.267421.
    >> Share

  565. WARFVINGE CF, Gustafsson J, Roth D, Tennvall J, et al
    Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [(177)Lu]Lu-DOTATATE.
    J Nucl Med. 2024;65:1070-1075.
    >> Share

    June 2024
  566. COMBET-CURT V, Buchalet C, Malicot KL, Lemanski C, et al
    Prognostic Value of (18)F-FDG PET/CT Assessment After Radiotherapy of Squamous Cell Carcinoma of the Anus in Patients from the National Multicentric Cohort FFCD-ANABASE.
    J Nucl Med. 2024 Jun 27:jnumed.124.267626. doi: 10.2967/jnumed.124.267626.
    >> Share

  567. BAUCKNEHT M, Lanfranchi F, Albano D, Triggiani L, et al
    Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study).
    J Nucl Med. 2024 Jun 27:jnumed.124.267586. doi: 10.2967/jnumed.124.267586.
    >> Share

  568. LAVERDIERE I, Matte G, Darveau M, Beauregard JM, et al
    Nuclear Pharmacy Training in the Era of Theranostics: Toward Meeting the Needs of Nuclear Medicine Patients for Comprehensive Pharmaceutical Care.
    J Nucl Med. 2024 Jun 21:jnumed.124.267603. doi: 10.2967/jnumed.124.267603.
    >> Share

  569. LI H, Badawi RD, Cherry SR, Fontaine K, et al
    Performance Characteristics of the NeuroEXPLORER, a Next-Generation Human Brain PET/CT Imager.
    J Nucl Med. 2024 Jun 13:jnumed.124.267767. doi: 10.2967/jnumed.124.267767.
    >> Share

  570. MONASTERO F, Vetrone L, Cardisciani L, Renzulli M, et al
    [(68)Ga]Ga-PSMA-11 PET/CT-Positive Hepatic Inflammatory Pseudotumor: Possible PSMA-Avid Pitfall in Nuclear Imaging.
    J Nucl Med. 2024 Jun 13:jnumed.124.267518. doi: 10.2967/jnumed.124.267518.
    >> Share

  571. FONSECA CABRERA GO, Ma X, Lin W, Zhang T, et al
    Synthesis of (64)Cu-, (55)Co-, and (68)Ga-Labeled Radiopharmaceuticals Targeting Neurotensin Receptor-1 for Theranostics: Adjusting In Vivo Distribution Using Multiamine Macrocycles.
    J Nucl Med. 2024 Jun 13:jnumed.124.267469. doi: 10.2967/jnumed.124.267469.
    >> Share

  572. MUKKAMALA R, Carlson DJ, Miller NK, Lindeman SD, et al
    Design of a Fibroblast Activation Protein-Targeted Radiopharmaceutical Therapy with High Tumor-to-Healthy-Tissue Ratios.
    J Nucl Med. 2024 Jun 13:jnumed.124.267756. doi: 10.2967/jnumed.124.267756.
    >> Share

  573. KUO PH, Esposito G, Ulaner GA, Yoo D, et al
    Interreader and Intrareader Reproducibility of (18)F-Flotufolastat Image Interpretation in Patients with Newly Diagnosed or Recurrent Prostate Cancer: Data from Two Phase 3 Prospective Multicenter Studies.
    J Nucl Med. 2024 Jun 13:jnumed.123.267306. doi: 10.2967/jnumed.123.267306.
    >> Share

  574. PHAM TT, Chenoweth A, Patel N, Banu A, et al
    In Vivo PET Imaging of (89)Zr-Labeled Natural Killer Cells and the Modulating Effects of a Therapeutic Antibody.
    J Nucl Med. 2024 Jun 6:jnumed.124.267876. doi: 10.2967/jnumed.124.267876.
    >> Share

  575. EVANGELISTA L, Zattoni F, Burei M, Bertin D, et al
    A Prospective Randomized Multicenter Study on the Impact of [(18)F]F-Choline PET/CT Versus Conventional Imaging for Staging Intermediate- to High-Risk Prostate Cancer.
    J Nucl Med. 2024 Jun 6:jnumed.123.267355. doi: 10.2967/jnumed.123.267355.
    >> Share

  576. SHIYAM SUNDAR LK, Beyer T
    Is Automatic Tumor Segmentation on Whole-Body (18)F-FDG PET Images a Clinical Reality?
    J Nucl Med. 2024 Jun 6:jnumed.123.267183. doi: 10.2967/jnumed.123.267183.
    >> Share

  577. NADEL HR
    Innovation and Dedication Spur Excellence in Nuclear Medicine and Molecular Imaging.
    J Nucl Med. 2024;65:11A-12A.
    >> Share

  578. CZERNIN J
    JNM Editors' Choice Awards for 2023.
    J Nucl Med. 2024;65:825.
    >> Share

  579. BEEKMAN F, Czernin J, Mona C
    Inventing His Own Career Path: Freek Beekman Talks with Johannes Czernin and Christine Mona About Success in Academia and Industry.
    J Nucl Med. 2024;65:826-828.
    >> Share

  580. RICH AA, Taunk NK, Mankoff DA, Pantel AR, et al
    [(18)F]Fluoroestradiol Uptake in Irradiated Lung Parenchyma and Draining Nodes.
    J Nucl Med. 2024;65:990-991.
    >> Share

    May 2024
  581. LECY EE, Min HK, Apgar CJ, Maltais DD, et al
    Patterns of Early Neocortical Amyloid-beta Accumulation: A PET Population-Based Study.
    J Nucl Med. 2024 May 23:jnumed.123.267150. doi: 10.2967/jnumed.123.267150.
    >> Share

  582. IMBERTI C, De Gregorio R, Korsen JA, Hoang TT, et al
    CEACAM5-Targeted Immuno-PET in Androgen Receptor-Negative Prostate Cancer.
    J Nucl Med. 2024 May 23:jnumed.123.267107. doi: 10.2967/jnumed.123.267107.
    >> Share

  583. SMEETS EMM, Trajkovic-Arsic M, Geijs D, Karakaya S, et al
    Histology-Based Radiomics for [(18)F]FDG PET Identifies Tissue Heterogeneity in Pancreatic Cancer.
    J Nucl Med. 2024 May 23:jnumed.123.266262. doi: 10.2967/jnumed.123.266262.
    >> Share

  584. WATANABE M, Fendler WP, Grafe H, Hirmas N, et al
    Prognostic Implications of (68)Ga-FAPI-46 PET/CT-Derived Parameters on Overall Survival in Various Types of Solid Tumors.
    J Nucl Med. 2024 May 23:jnumed.123.266981. doi: 10.2967/jnumed.123.266981.
    >> Share

  585. SADAGHIANI MS, Baskaran S, Gorin MA, Rowe SP, et al
    Utility of PSMA PET/CT in Staging and Restaging of Renal Cell Carcinoma: A Systematic Review and Metaanalysis.
    J Nucl Med. 2024 May 23:jnumed.124.267417. doi: 10.2967/jnumed.124.267417.
    >> Share

  586. FLEMING MT, Hermsen R, Purysko AS, Chau A, et al
    True-Positive (18)F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study.
    J Nucl Med. 2024 May 23:jnumed.123.267271. doi: 10.2967/jnumed.123.267271.
    >> Share

  587. HEIDARI P, Haj-Mirzaian A, Prabhu S, Ataeinia B, et al
    Granzyme B PET Imaging for Assessment of Disease Activity in Inflammatory Bowel Disease.
    J Nucl Med. 2024 May 16:jnumed.123.267344. doi: 10.2967/jnumed.123.267344.
    >> Share

  588. YADAV S, Jiang F, Kurkowska S, Saelee R, et al
    Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection.
    J Nucl Med. 2024 May 9:jnumed.123.267208. doi: 10.2967/jnumed.123.267208.
    >> Share

  589. CAOBELLI F, Gozlugol N, Bakula A, Rominger A, et al
    Prognostic Value of [(99m)Tc]Tc-DPD Quantitative SPECT/CT in Patients with Suspected and Confirmed Amyloid Transthyretin-Related Cardiomyopathy and Preserved Left Ventricular Function.
    J Nucl Med. 2024 May 9:jnumed.123.266926. doi: 10.2967/jnumed.123.266926.
    >> Share

  590. LANZAFAME H, Mavroeidi IA, Pabst KM, Desaulniers M, et al
    (68)Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy.
    J Nucl Med. 2024 May 9:jnumed.123.267248. doi: 10.2967/jnumed.123.267248.
    >> Share

  591. MILLER RJH, Shanbhag A, Michalowska AM, Kavanagh P, et al
    Deep Learning-Enabled Quantification of (99m)Tc-Pyrophosphate SPECT/CT for Cardiac Amyloidosis.
    J Nucl Med. 2024 May 9:jnumed.124.267542. doi: 10.2967/jnumed.124.267542.
    >> Share

  592. ZANG J, Yang Y, Chen S, Wang C, et al
    Diagnostic Performance of [(18)F]AlF-Thretide PET/CT in Patients with Newly Diagnosed Prostate Cancer Using Histopathology as Reference Standard.
    J Nucl Med. 2024 May 9:jnumed.123.266940. doi: 10.2967/jnumed.123.266940.
    >> Share

  593. HOEK R, van Diemen PA, Raijmakers PG, Driessen RS, et al
    Determining Hemodynamically Significant Coronary Artery Disease: Patient-Specific Cutoffs in Quantitative Myocardial Blood Flow Using [(15)O]H(2)O PET Imaging.
    J Nucl Med. 2024 May 9:jnumed.123.267195. doi: 10.2967/jnumed.123.267195.
    >> Share

  594. DIETZ M, Kamani CH, Bousige C, Dunet V, et al
    Natural History of Myocardial alpha(v)beta(3) Integrin Expression After Acute Myocardial Infarction: Correlation with Changes in Myocardial Blood Flow.
    J Nucl Med. 2024 May 9:jnumed.124.267514. doi: 10.2967/jnumed.124.267514.
    >> Share

  595. WU Y, Sun T, Ng YL, Liu J, et al
    Clinical Implementation of Total-Body PET in China.
    J Nucl Med. 2024;65.
    >> Share

  596. ZHANG J, Duan X, Chen X, Zhang Z, et al
    Translational PET Imaging of Nectin-4 Expression in Multiple Different Cancers with (68)Ga-N188.
    J Nucl Med. 2024;65.
    >> Share

  597. MENG X, Kong X, Xia L, Wu R, et al
    The Role of Total-Body PET in Drug Development and Evaluation: Status and Outlook.
    J Nucl Med. 2024;65.
    >> Share

  598. YANG W, Kang F, Chen Y, Zhu Z, et al
    Landscape of Nuclear Medicine in China and Its Progress on Theranostics.
    J Nucl Med. 2024;65.
    >> Share

  599. AN S, Wang L, Xie F, Jiang D, et al
    Pathway to Approval of Innovative Radiopharmaceuticals in China.
    J Nucl Med. 2024;65.
    >> Share

  600. CHEN H, Shi K, Cai W, Li S, et al
    Advancing Global Nuclear Medicine: The Role and Future Contributions of China.
    J Nucl Med. 2024;65.
    >> Share

  601. ZHAO L, Kang F, Pang Y, Fang J, et al
    Fibroblast Activation Protein Inhibitor Tracers and Their Preclinical, Translational, and Clinical Status in China.
    J Nucl Med. 2024;65.
    >> Share

  602. CHEN W, Li Y, Li Z, Jiang Y, et al
    Advantages and Challenges of Total-Body PET/CT at a Tertiary Cancer Center: Insights from Sun Yat-sen University Cancer Center.
    J Nucl Med. 2024;65.
    >> Share

  603. KLINE B, Yadav S, Seo Y, Ippisch RC, et al
    (68)Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with (18)F-FDG.
    J Nucl Med. 2024 May 2:jnumed.123.267281. doi: 10.2967/jnumed.123.267281.
    >> Share

  604. MA Y, Zeng J, Ding F, Xu Y, et al
    Cerebral (18)F-FDG PET/CT Metabolism as Diagnostic Signature for Central Nervous System Toxicity After Immune Checkpoint Blockade Cancer Treatment.
    J Nucl Med. 2024 May 2:jnumed.123.267025. doi: 10.2967/jnumed.123.267025.
    >> Share

  605. FEHER A, Bednarski B, Miller RJ, Shanbhag A, et al
    Artificial Intelligence Predicts Hospitalization for Acute Heart Failure Exacerbation in Patients Undergoing Myocardial Perfusion Imaging.
    J Nucl Med. 2024;65:768-774.
    >> Share


  606. Gerald L. DeNardo, MD, 1932-2024.
    J Nucl Med. 2024;65:823.
    >> Share

    April 2024
  607. ROSEN J, Werner JM, Ceccon GS, Rosen EK, et al
    MRI and (18)F-FET PET for Multimodal Treatment Monitoring in Patients with Brain Metastases: A Cost-Effectiveness Analysis.
    J Nucl Med. 2024 Apr 25:jnumed.123.266687. doi: 10.2967/jnumed.123.266687.
    >> Share

  608. NIKITAS J, Lam E, Booker KA, Fendler WP, et al
    Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial).
    J Nucl Med. 2024 Apr 25:jnumed.123.267004. doi: 10.2967/jnumed.123.267004.
    >> Share

  609. MINGELS C, Spencer BA, Nalbant H, Omidvari N, et al
    Dose Reduction in Pediatric Oncology Patients with Delayed Total-Body [(18)F]FDG PET/CT.
    J Nucl Med. 2024 Apr 25:jnumed.124.267521. doi: 10.2967/jnumed.124.267521.
    >> Share

  610. DUAN H, Song H, Davidzon GA, Moradi F, et al
    Prospective Comparison of (68)Ga-NeoB and (68)Ga-PSMA-R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer.
    J Nucl Med. 2024 Apr 25:jnumed.123.267017. doi: 10.2967/jnumed.123.267017.
    >> Share

  611. BURKETT BJ, Johnson DR, Lowe VJ
    Evaluation of Neurodegenerative Disorders with Amyloid-beta, Tau, and Dopaminergic PET Imaging: Interpretation Pitfalls.
    J Nucl Med. 2024 Apr 25:jnumed.123.266463. doi: 10.2967/jnumed.123.266463.
    >> Share

  612. GAFITA A, Djaileb L, Rauscher I, Fendler WP, et al
    RECIP 1.0 Predicts Progression-Free Survival After [(177)Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 Apr 18:jnumed.123.267234. doi: 10.2967/jnumed.123.267234.
    >> Share

  613. LEUBE J, Gustafsson J, Lassmann M, Salas-Ramirez M, et al
    A Deep-Learning-Based Partial-Volume Correction Method for Quantitative (177)Lu SPECT/CT Imaging.
    J Nucl Med. 2024 Apr 18:jnumed.123.266889. doi: 10.2967/jnumed.123.266889.
    >> Share

  614. HAGENS MJ, van Leeuwen PJ, Wondergem M, Boellaard TN, et al
    A Systematic Review on the Diagnostic Value of Fibroblast Activation Protein Inhibitor PET/CT in Genitourinary Cancers.
    J Nucl Med. 2024 Apr 18:jnumed.123.267260. doi: 10.2967/jnumed.123.267260.
    >> Share

  615. MOSER R, Pfeiffer S, Cala L, Klein E, et al
    Detecting Metastatic Patterns of Oligometastatic Breast Cancer: A Comparative Analysis of (18)F-FDG PET/CT and Conventional CT Imaging.
    J Nucl Med. 2024 Apr 18:jnumed.123.266925. doi: 10.2967/jnumed.123.266925.
    >> Share

  616. SWIHA M, Papa N, Sabahi Z, Ayati N, et al
    Development of a Visually Calculated SUV(mean) (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to (177)Lu-PSMA Therapy: Comparison with Quantitative SUV(mean) and Patient Outcomes.
    J Nucl Med. 2024 Apr 18:jnumed.123.267014. doi: 10.2967/jnumed.123.267014.
    >> Share

  617. QI C, Guo R, Chen Y, Li C, et al
    (68)Ga-NC-BCH Whole-Body PET Imaging Rapidly Targets Claudin18.2 in Lesions in Gastrointestinal Cancer Patients.
    J Nucl Med. 2024 Apr 11:jnumed.123.267110. doi: 10.2967/jnumed.123.267110.
    >> Share

  618. ROHRICH M, Daum J, Gutjahr E, Spektor AM, et al
    Diagnostic Potential of Supplemental Static and Dynamic (68)Ga-FAPI-46 PET for Primary (18)F-FDG-Negative Pulmonary Lesions.
    J Nucl Med. 2024 Apr 11:jnumed.123.267103. doi: 10.2967/jnumed.123.267103.
    >> Share

  619. O'DONNELL JL, Soda AK, Jiang H, Norris SA, et al
    PET Quantification of [(18)F]VAT in Human Brain and Its Test-Retest Reproducibility and Age Dependence.
    J Nucl Med. 2024 Apr 11:jnumed.123.266860. doi: 10.2967/jnumed.123.266860.
    >> Share

  620. VISCUSE P, Devitt M, Dreicer R
    Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical Therapy Fit in the Treatment Algorithm?
    J Nucl Med. 2024 Apr 11:jnumed.123.267006. doi: 10.2967/jnumed.123.267006.
    >> Share

  621. WU Q, Gu F, O'Suilleabhain LD, Sari H, et al
    Mapping (18)F-FDG Kinetics Together with Patient-Specific Bootstrap Assessment of Uncertainties: An Illustration with Data from a PET/CT Scanner with a Long Axial Field of View.
    J Nucl Med. 2024 Apr 11:jnumed.123.266686. doi: 10.2967/jnumed.123.266686.
    >> Share

  622. BARATTO L, Singh SB, Williams SE, Spunt SL, et al
    Detecting High-Dose Methotrexate-Induced Brain Changes in Pediatric and Young Adult Cancer Survivors Using [(18)F]FDG PET/MRI: A Pilot Study.
    J Nucl Med. 2024 Apr 4:jnumed.123.266760. doi: 10.2967/jnumed.123.266760.
    >> Share

  623. GEBHART G, Keyaerts M, Guiot T, Flamen P, et al
    Optimal [(18)F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial.
    J Nucl Med. 2024 Apr 4:jnumed.123.266384. doi: 10.2967/jnumed.123.266384.
    >> Share

  624. BISCHOF GN, Brendel M, Barthel H, Theis H, et al
    Improved Tau PET SUVR Quantification in 4-Repeat Tau Phenotypes with [(18)F]PI-2620.
    J Nucl Med. 2024 Apr 4:jnumed.123.265930. doi: 10.2967/jnumed.123.265930.
    >> Share

  625. RUWANPATHIRANA GP, Williams RC, Masters CL, Rowe CC, et al
    Impact of PET Reconstruction on Amyloid-beta Quantitation in Cross-Sectional and Longitudinal Analyses.
    J Nucl Med. 2024 Apr 4:jnumed.123.266188. doi: 10.2967/jnumed.123.266188.
    >> Share

  626. SCHULER M, Hense J, Darwiche K, Michels S, et al
    Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy in EGFR-Mutated Lung Cancer with Unknown Mechanism of Acquired Resistance.
    J Nucl Med. 2024 Apr 4:jnumed.123.266979. doi: 10.2967/jnumed.123.266979.
    >> Share

  627. LI Z, Benabdallah N, Luo J, Wahl RL, et al
    ISIT-QA: In Silico Imaging Trial to Evaluate a Low-Count Quantitative SPECT Method Across Multiple Scanner-Collimator Configurations for (223)Ra-Based Radiopharmaceutical Therapies.
    J Nucl Med. 2024 Apr 4:jnumed.123.266719. doi: 10.2967/jnumed.123.266719.
    >> Share

    March 2024
  628. ALTENA R, Buren SA, Blomgren A, Karlsson E, et al
    Human Epidermal Growth Factor Receptor 2 (HER2) PET Imaging of HER2-Low Breast Cancer with [(68)Ga]Ga-ABY-025: Results from a Pilot Study.
    J Nucl Med. 2024 Mar 28:jnumed.123.266847. doi: 10.2967/jnumed.123.266847.
    >> Share

  629. COLLARINO A, Feudo V, Pasciuto T, Florit A, et al
    Is PET Radiomics Useful to Predict Pathologic Tumor Response and Prognosis in Locally Advanced Cervical Cancer?
    J Nucl Med. 2024 Mar 28:jnumed.123.267044. doi: 10.2967/jnumed.123.267044.
    >> Share

  630. BLAKKISRUD J, Peterson AB, Wildermann SJ, Kingkiner G, et al
    SPECT/CT Image-Derived Absorbed Dose to Red Marrow Correlates with Hematologic Toxicity in Patients Treated with [(177)Lu]Lu-DOTATATE.
    J Nucl Med. 2024 Mar 28:jnumed.123.266843. doi: 10.2967/jnumed.123.266843.
    >> Share

  631. ZHANG X, Heo GS, Li A, Lahad D, et al
    Development of a CD163-Targeted PET Radiotracer That Images Resident Macrophages in Atherosclerosis.
    J Nucl Med. 2024 Mar 28:jnumed.123.266910. doi: 10.2967/jnumed.123.266910.
    >> Share

  632. WANG Y, Abdelhafez YG, Spencer BA, Verma R, et al
    High-Temporal-Resolution Kinetic Modeling of Lung Tumors with Dual-Blood Input Function Using Total-Body Dynamic PET.
    J Nucl Med. 2024 Mar 28:jnumed.123.267036. doi: 10.2967/jnumed.123.267036.
    >> Share

  633. HAIDER SP, Zeevi T, Sharaf K, Gross M, et al
    Impact of (18)F-FDG PET Intensity Normalization on Radiomic Features of Oropharyngeal Squamous Cell Carcinomas and Machine Learning-Generated Biomarkers.
    J Nucl Med. 2024 Mar 21:jnumed.123.266637. doi: 10.2967/jnumed.123.266637.
    >> Share

  634. PRUIS IJ, Verburg FA, Balvers RK, Harteveld AA, et al
    [(18)F]FET PET/MRI: An Accurate Technique for Detection of Small Functional Pituitary Tumors.
    J Nucl Med. 2024 Mar 21:jnumed.123.266853. doi: 10.2967/jnumed.123.266853.
    >> Share

  635. LIU N, Yang X, Gao C, Wang J, et al
    Noninvasively Deciphering the Immunosuppressive Tumor Microenvironment Using Galectin-1 PET to Inform Immunotherapy Responses.
    J Nucl Med. 2024 Mar 21:jnumed.123.266888. doi: 10.2967/jnumed.123.266888.
    >> Share

  636. JAGUST WJ, Mattay VS, Krainak DM, Wang SJ, et al
    Quantitative Brain Amyloid PET.
    J Nucl Med. 2024 Mar 21:jnumed.123.265766. doi: 10.2967/jnumed.123.265766.
    >> Share

  637. CYTRYN SL, Pandit-Taskar N, Lumish MA, Maron SB, et al
    (18)F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer.
    J Nucl Med. 2024 Mar 21:jnumed.123.267186. doi: 10.2967/jnumed.123.267186.
    >> Share

  638. SHI J, Li D, Chen M, Fu Y, et al
    The Value of (68)Ga-PSMA PET/MRI for Classifying Patients with PI-RADS 3 Lesions on Multiparametric MRI: A Prospective Single-Center Study.
    J Nucl Med. 2024 Mar 14:jnumed.123.266742. doi: 10.2967/jnumed.123.266742.
    >> Share

  639. BERRENS AC, Sorbi MA, Donswijk ML, de Barros HA, et al
    Strong Correlation Between SUV(max) on PSMA PET/CT and Numeric Drop-In gamma-Probe Signal for Intraoperative Identification of Prostate Cancer Lesions.
    J Nucl Med. 2024 Mar 14:jnumed.123.267075. doi: 10.2967/jnumed.123.267075.
    >> Share

  640. SAHIN E, Kus T, Aytekin A, Uzun E, et al
    (68)Ga-FAPI PET/CT as an Alternative to (18)F-FDG PET/CT in the Imaging of Invasive Lobular Breast Carcinoma.
    J Nucl Med. 2024 Mar 14:jnumed.123.266798. doi: 10.2967/jnumed.123.266798.
    >> Share

  641. PORTER JC, Ganeshan B, Win T, Fraioli F, et al
    [(18)F]FDG PET/CT Signal Correlates with Neoangiogenesis Markers in Patients with Fibrotic Interstitial Lung Disease Who Underwent Lung Biopsy: Implication for the Use of PET/CT in Diffuse Lung Diseases.
    J Nucl Med. 2024 Mar 14:jnumed.123.266445. doi: 10.2967/jnumed.123.266445.
    >> Share

  642. PROVIDENCIA L, van der Weijden CWJ, Mohr P, van Sluis J, et al
    Can Internal Carotid Arteries Be Used for Noninvasive Quantification of Brain PET Studies?
    J Nucl Med. 2024 Mar 14:jnumed.123.266675. doi: 10.2967/jnumed.123.266675.
    >> Share

  643. THOR M, Lee C, Sun L, Patel P, et al
    An (18)F-FDG PET/CT and Mean Lung Dose Model to Predict Early Radiation Pneumonitis in Stage III Non-Small Cell Lung Cancer Patients Treated with Chemoradiation and Immunotherapy.
    J Nucl Med. 2024 Mar 14:jnumed.123.266965. doi: 10.2967/jnumed.123.266965.
    >> Share

  644. DRESCHER R, Greiser J, Grober S, Weisheit T, et al
    (64)Cu-DOTA Enables Late PET Imaging and Leak Detection in the Cerebrospinal Fluid Space.
    J Nucl Med. 2024 Mar 14:jnumed.123.267329. doi: 10.2967/jnumed.123.267329.
    >> Share

  645. HARTRAMPF PE, Huttmann T, Seitz AK, Kubler H, et al
    Prognostic Performance of RECIP 1.0 Based on [(18)F]PSMA-1007 PET in Prostate Cancer Patients Treated with [(177)Lu]Lu-PSMA I&T.
    J Nucl Med. 2024 Mar 7:jnumed.123.266702. doi: 10.2967/jnumed.123.266702.
    >> Share

  646. LI C, Chen Q, Tian Y, Chen J, et al
    (68)Ga-FAPI-04 PET/CT in Non-Small Cell Lung Cancer: Accurate Evaluation of Lymph Node Metastasis and Correlation with Fibroblast Activation Protein Expression.
    J Nucl Med. 2024 Mar 7:jnumed.123.266806. doi: 10.2967/jnumed.123.266806.
    >> Share

  647. HOVHANNISYAN-BAGHDASARIAN N, Luporsi M, Captier N, Nioche C, et al
    Promising Candidate Prognostic Biomarkers in [(18)F]FDG PET Images: Evaluation in Independent Cohorts of Non-Small Cell Lung Cancer Patients.
    J Nucl Med. 2024 Mar 7:jnumed.123.266331. doi: 10.2967/jnumed.123.266331.
    >> Share

  648. CUZZANI G, Fortunati E, Zanoni L, Nanni C, et al
    Case Report: Pulmonary Actinomyces Infection Mimics Lung Cancer on [(68)Ga]Ga-FAPI PET/CT.
    J Nucl Med. 2024 Mar 7:jnumed.123.267155. doi: 10.2967/jnumed.123.267155.
    >> Share

  649. FAROLFI A, Armstrong WR, Djaileb L, Gafita A, et al
    Differences and Common Ground in (177)Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers.
    J Nucl Med. 2024;65:438-445.
    >> Share

    February 2024
  650. LEUNG KH, Rowe SP, Sadaghiani MS, Leal JP, et al
    Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT.
    J Nucl Med. 2024 Feb 29:jnumed.123.267048. doi: 10.2967/jnumed.123.267048.
    >> Share

  651. JIANG M, Tang S, Jenkins MD, Lee AC, et al
    Robust Quantification of Phosphodiesterase-4D in Monkey Brain with PET and (11)C-Labeled Radioligands That Avoid Radiometabolite Contamination.
    J Nucl Med. 2024 Feb 29:jnumed.123.266750. doi: 10.2967/jnumed.123.266750.
    >> Share

  652. GRIFFITHS MR, Pattison DA, Latter M, Kuan K, et al
    First-in-Human (212)Pb-PSMA-Targeted alpha-Therapy SPECT/CT Imaging in a Patient with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 Feb 29:jnumed.123.267189. doi: 10.2967/jnumed.123.267189.
    >> Share

  653. BOSCH D, van der Velden KJM, Oving IM, Wyndaele DNJ, et al
    The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of (223)Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
    J Nucl Med. 2024 Feb 29:jnumed.123.266654. doi: 10.2967/jnumed.123.266654.
    >> Share

  654. EL FAKIRI M, Ayada N, Muller M, Hvass L, et al
    Development and Preclinical Evaluation of [(211)At]PSAt-3-Ga: An Inhibitor for Targeted alpha-Therapy of Prostate Cancer.
    J Nucl Med. 2024 Feb 29:jnumed.123.267043. doi: 10.2967/jnumed.123.267043.
    >> Share

  655. KOVACS DG, Ladefoged CN, Andersen KF, Brittain JM, et al
    Clinical Evaluation of Deep Learning for Tumor Delineation on (18)F-FDG PET/CT of Head and Neck Cancer.
    J Nucl Med. 2024 Feb 22:jnumed.123.266574. doi: 10.2967/jnumed.123.266574.
    >> Share

  656. LI G, Ma W, Li X, Yang W, et al
    Performance Evaluation of the uMI Panorama PET/CT System in Accordance with the National Electrical Manufacturers Association NU 2-2018 Standard.
    J Nucl Med. 2024 Feb 22:jnumed.123.265929. doi: 10.2967/jnumed.123.265929.
    >> Share

  657. SLART RHJA, Bengel FM, Akincioglu C, Bourque JM, et al
    Total-Body PET/CT Applications in Cardiovascular Diseases: A Perspective Document of the SNMMI Cardiovascular Council.
    J Nucl Med. 2024 Feb 22:jnumed.123.266858. doi: 10.2967/jnumed.123.266858.
    >> Share

  658. BOURBONNE V, Morjani M, Pradier O, Hatt M, et al
    PET/CT-Based Radiogenomics Supports KEAP1/NFE2L2 Pathway Targeting for Non-Small Cell Lung Cancer Treated with Curative Radiotherapy.
    J Nucl Med. 2024 Feb 15:jnumed.123.266749. doi: 10.2967/jnumed.123.266749.
    >> Share

  659. LOHMANN P, Gutsche R, Werner JM, Shah NJ, et al
    Example of Artificial Intelligence-Based Decision Support for Amino Acid PET: Early Prediction of Suspected Brain Tumor Foci for Patient Management.
    J Nucl Med. 2024 Feb 15:jnumed.123.267112. doi: 10.2967/jnumed.123.267112.
    >> Share

  660. DRAKE LR, Wu Y, Naganawa M, Asch R, et al
    First-in-Human Study of (18)F-SynVesT-2: An SV2A PET Imaging Probe with Fast Brain Kinetics and High Specific Binding.
    J Nucl Med. 2024 Feb 15:jnumed.123.266470. doi: 10.2967/jnumed.123.266470.
    >> Share

  661. LIU Z, Mhlanga JC, Xia H, Siegel BA, et al
    Need for Objective Task-Based Evaluation of Image Segmentation Algorithms for Quantitative PET: A Study with ACRIN 6668/RTOG 0235 Multicenter Clinical Trial Data.
    J Nucl Med. 2024 Feb 15:jnumed.123.266018. doi: 10.2967/jnumed.123.266018.
    >> Share

  662. KISHAN AU, Siva S, Hofman MS, Nagarajah J, et al
    The Potential Contribution of Radiopharmaceutical Therapies in Managing Oligometastatic Disease.
    J Nucl Med. 2024 Feb 15:jnumed.123.266772. doi: 10.2967/jnumed.123.266772.
    >> Share

  663. DUBASH S, Barwick TD, Kozlowski K, Rockall AG, et al
    Somatostatin Receptor Imaging with [(18)F]FET-betaAG-TOCA PET/CT and [(68)Ga]Ga-DOTA-Peptide PET/CT in Patients with Neuroendocrine Tumors: A Prospective, Phase 2 Comparative Study.
    J Nucl Med. 2024 Feb 8:jnumed.123.266601. doi: 10.2967/jnumed.123.266601.
    >> Share

  664. HIRMAS N, Hamacher R, Sraieb M, Kessler L, et al
    Diagnostic Accuracy of (68)Ga-FAPI Versus (18)F-FDG PET in Patients with Various Malignancies.
    J Nucl Med. 2024 Feb 8:jnumed.123.266652. doi: 10.2967/jnumed.123.266652.
    >> Share

  665. GONDRY O, Caveliers V, Xavier C, Raes L, et al
    Phase II Trial Assessing the Repeatability and Tumor Uptake of [(68)Ga]Ga-HER2 Single-Domain Antibody PET/CT in Patients with Breast Carcinoma.
    J Nucl Med. 2024;65:178-184.
    >> Share

  666. OH M, Oh SJ, Lee SJ, Oh JS, et al
    One-Year Longitudinal Changes in Tau Accumulation on [(18)F]PI-2620 PET in the Alzheimer Spectrum.
    J Nucl Med. 2024 Feb 1:jnumed.123.265893. doi: 10.2967/jnumed.123.265893.
    >> Share

  667. SOULEN MC, Rilling WS
    Clinical Outcomes After Personalized Dosimetry for (90)Y Radioembolization of Advanced Hepatocellular Carcinoma: Defining the Role of a Device in a Pharma-Centric Landscape.
    J Nucl Med. 2024;65:270-271.
    >> Share

  668. AL MANSOUR L, De Mestier L, Haissaguerre M, Afchain P, et al
    Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by (177)Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Networ
    J Nucl Med. 2024;65:258-263.
    >> Share

  669. HAMACHER R, Pabst KM, Cheung PF, Heilig CE, et al
    Fibroblast Activation Protein alpha-Directed Imaging and Therapy of Solitary Fibrous Tumor.
    J Nucl Med. 2024;65:252-257.
    >> Share

  670. WAGEMANS MEHM, Kunnen B, Stella M, van Rooij R, et al
    Comparison of 3 Different Therapeutic Particles in Radioembolization of Locally Advanced Intrahepatic Cholangiocarcinoma.
    J Nucl Med. 2024;65:272-278.
    >> Share

  671. HE Y, Kramer SD, Grether U, Wittwer MB, et al
    Identification of (R)-[(18)F]YH134 for Monoacylglycerol Lipase Neuroimaging and Exploration of Its Use for Central Nervous System and Peripheral Drug Development.
    J Nucl Med. 2024;65:300-305.
    >> Share

  672. MILEVA M, Marin G, Levillain H, Artigas C, et al
    Prediction of (177)Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study.
    J Nucl Med. 2024;65:236-244.
    >> Share

  673. GIRUM KB, Cottereau AS, Vercellino L, Rebaud L, et al
    Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma Patients: A Demonstration from the REMARC Trial.
    J Nucl Med. 2024;65:313-319.
    >> Share

  674. CHIESA C, Bagnalasta M, Maccauro M
    Good Voxel Dosimetry with a Simplified Study Design Resulted in Improvable Safety Limits.
    J Nucl Med. 2024;65:331-332.
    >> Share

    January 2024
  675. GU B, Yang Z, Du X, Xu X, et al
    Imaging of Tumor Stroma Using (68)Ga-FAPI PET/CT to Improve Diagnostic Accuracy of Primary Tumors in Head and Neck Cancer of Unknown Primary: A Comparative Imaging Trial.
    J Nucl Med. 2024 Jan 25:jnumed.123.266556. doi: 10.2967/jnumed.123.266556.
    >> Share

  676. KIRBY A, Graf D, Suchy M, Calvert ND, et al
    It's a Trap! Aldolase-Prescribed C(4) Deoxyradiofluorination Affords Intracellular Trapping and the Tracing of Fructose Metabolism by PET.
    J Nucl Med. 2024 Jan 25:jnumed.123.266905. doi: 10.2967/jnumed.123.266905.
    >> Share

  677. YEH R, O'Donoghue JA, Jayaprakasam VS, Mauguen A, et al
    First-in-Human Evaluation of Site-Specifically Labeled (89)Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer.
    J Nucl Med. 2024 Jan 25:jnumed.123.266392. doi: 10.2967/jnumed.123.266392.
    >> Share

  678. BUCHERT R, Szabo B, Kovacs A, Buddenkotte T, et al
    Dopamine Transporter SPECT with 12-Minute Scan Duration Using Multiple-Pinhole Collimators.
    J Nucl Med. 2024 Jan 18:jnumed.123.266276. doi: 10.2967/jnumed.123.266276.
    >> Share

  679. LIGHT A, Lazic S, Houghton K, Bayne M, et al
    Diagnostic Performance of (68)Ga-PSMA-11 PET/CT Versus Multiparametric MRI for Detection of Intraprostatic Radiorecurrent Prostate Cancer.
    J Nucl Med. 2024 Jan 11:jnumed.123.266527. doi: 10.2967/jnumed.123.266527.
    >> Share

  680. BARLATEY SL, Mignardot CG, Friedrichs-Maeder C, Schindler K, et al
    Triggered Seizures for Ictal SPECT Imaging: A Case Series and Feasibility Study.
    J Nucl Med. 2024 Jan 11:jnumed.123.266515. doi: 10.2967/jnumed.123.266515.
    >> Share

  681. KOSHKIN VS, Kumar V, Kline B, Escobar D, et al
    Initial Experience with (68)Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer.
    J Nucl Med. 2024 Jan 11:jnumed.123.266390. doi: 10.2967/jnumed.123.266390.
    >> Share

  682. UNTERRAINER LM, Memarzadeh S, Moatamed NA, Benz MR, et al
    [(68)Ga]Ga-FAPI-46 PET in a Borderline Ovarian Tumor.
    J Nucl Med. 2024 Jan 11:jnumed.123.266732. doi: 10.2967/jnumed.123.266732.
    >> Share

  683. HOPE TA, Jadvar H
    PSMA PET AUC Updates: Inclusion of rh-PSMA-7.3.
    J Nucl Med. 2024 Jan 4:jnumed.123.267042. doi: 10.2967/jnumed.123.267042.
    >> Share

  684. UNTERRAINER LM, Ruchalski K, Allen-Auerbach MS, Calais J, et al
    PSMA PET/CT Dual-Time-Point Imaging: Nice to Have or Need to Have?
    J Nucl Med. 2024 Jan 4:jnumed.123.266722. doi: 10.2967/jnumed.123.266722.
    >> Share

  685. DE WINTER RW, van Diemen PA, Schumacher SP, Jukema RA, et al
    Hemodynamic Insights into Combined Fractional Flow Reserve and Instantaneous Wave-Free Ratio Assessment Through Quantitative [(15)O]H(2)O PET Myocardial Perfusion Imaging.
    J Nucl Med. 2024 Jan 4:jnumed.123.265973. doi: 10.2967/jnumed.123.265973.
    >> Share

  686. RAHBAR K, Boegemann M
    The Imperative for Comparative Studies in Nuclear Medicine: Elevating (177)Lu-PSMA-617 in the Treatment Paradigm for mCRPC.
    J Nucl Med. 2024 Jan 4:jnumed.123.266952. doi: 10.2967/jnumed.123.266952.
    >> Share

  687. LI X, Lu N, Lin L, Chen Y, et al
    (18)F-FAPI-04 Outperforms (18)F-FDG PET/CT in Clinical Assessments of Patients with Pancreatic Adenocarcinoma.
    J Nucl Med. 2024 Jan 4:jnumed.123.266283. doi: 10.2967/jnumed.123.266283.
    >> Share

  688. ZHAO L, Pang Y, Fang J, Chen J, et al
    Design, Preclinical Evaluation, and Clinical Translation of (68)Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma.
    J Nucl Med. 2024 Jan 4:jnumed.123.266183. doi: 10.2967/jnumed.123.266183.
    >> Share

  689. STRUNK M, Heo GS, Hess A, Luehmann H, et al
    Toward Quantitative Multisite Preclinical Imaging Studies in Acute Myocardial Infarction: Evaluation of the Immune-Fibrosis Axis.
    J Nucl Med. 2024 Jan 4:jnumed.123.266526. doi: 10.2967/jnumed.123.266526.
    >> Share

  690. SCHILHAM MGM, Somford DM, Kusters-Vandevelde HVN, Hermsen R, et al
    Prostate-Specific Membrane Antigen-Targeted Radioguided Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients with a Suspicion of Locoregional Lymph Node Metastases: The DETECT Trial.
    J Nucl Med. 2024 Jan 4:jnumed.123.266495. doi: 10.2967/jnumed.123.266495.
    >> Share

  691. SPEKTOR AM, Gutjahr E, Lang M, Glatting FM, et al
    Immunohistochemical FAP Expression Reflects (68)Ga-FAPI PET Imaging Properties of Low- and High-Grade Intraductal Papillary Mucinous Neoplasms and Pancreatic Ductal Adenocarcinoma.
    J Nucl Med. 2024;65:52-58.
    >> Share

  692. PAPPAS V, Czernin J
    Expanding the Mission and Influence of SNMMI: A Conversation Between Johannes Czernin and Virginia Pappas About Her Career in SNMMI Leadership.
    J Nucl Med. 2024;65:1-3.
    >> Share

  693. POPLAWSKI SE, Hallett RM, Dornan MH, Novakowski KE, et al
    Preclinical Development of PNT6555, a Boronic Acid-Based, Fibroblast Activation Protein-alpha (FAP)-Targeted Radiotheranostic for Imaging and Treatment of FAP-Positive Tumors.
    J Nucl Med. 2024;65:100-108.
    >> Share

  694. MALIHA PG, Hotta M, Czernin J, Calais J, et al
    Characterizing Normal Variant [(68)Ga]Ga-FAPI-46 Uptake in the Epididymis.
    J Nucl Med. 2024;65:59-62.
    >> Share

  695. LUTHRIA G, Baratto L, Adams L, Morakote W, et al
    Increased Metabolic Activity of the Thymus and Lymph Nodes in Pediatric Oncology Patients After Coronavirus Disease 2019 Vaccination.
    J Nucl Med. 2024;65:22-24.
    >> Share

  696. ENKE JS, Reitsam NG, Grosser B, Kircher M, et al
    C-X-C Motif Chemokine Receptor 4-Directed Scintigraphy of Multiple Myeloma Using [(99m)Tc]Tc-PentixaTec.
    J Nucl Med. 2024;65:163-164.
    >> Share

    December 2023
  697. CHAN DL, Hayes AR, Karfis I, Conner A, et al
    [(18)F]FDG PET/CT-Avid Discordant Volume as a Biomarker in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Study.
    J Nucl Med. 2023 Dec 21:jnumed.123.266346. doi: 10.2967/jnumed.123.266346.
    >> Share

  698. MIAO Y, Feng R, Yu T, Guo R, et al
    Value of (68)Ga-FAPI-04 and (18)F-FDG PET/CT in Early Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer.
    J Nucl Med. 2023 Dec 21:jnumed.123.266403. doi: 10.2967/jnumed.123.266403.
    >> Share

  699. VENTURA D, Dittmann M, Buther F, Schafers M, et al
    Diagnostic Performance of [(18)F]TFB PET/CT Compared with Therapeutic Activity [(131)I]Iodine SPECT/CT and [(18)F]FDG PET/CT in Recurrent Differentiated Thyroid Carcinoma.
    J Nucl Med. 2023 Dec 21:jnumed.123.266513. doi: 10.2967/jnumed.123.266513.
    >> Share

  700. DIERKS A, Gable A, Rinscheid A, Wienand G, et al
    First Safety and Efficacy Data with the Radiohybrid (177)Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer.
    J Nucl Med. 2023 Dec 21:jnumed.123.266741. doi: 10.2967/jnumed.123.266741.
    >> Share

  701. BARTLETT EA, Lesanpezeshki M, Anishchenko S, Shkolnik I, et al
    Dynamic Human Brain Imaging with a Portable PET Camera: Comparison to a Standard Scanner.
    J Nucl Med. 2023 Dec 14:jnumed.122.265309. doi: 10.2967/jnumed.122.265309.
    >> Share

  702. FETTAHOGLU A, Zhao M, Khalighi M, Vossler H, et al
    Early-Frame [(18)F]Florbetaben PET/MRI for Cerebral Blood Flow Quantification in Patients with Cognitive Impairment: Comparison to an [(15)O]Water Gold Standard.
    J Nucl Med. 2023 Dec 7:jnumed.123.266273. doi: 10.2967/jnumed.123.266273.
    >> Share

  703. MANKOFF D, Balogova S, Dunnwald L, Dehdashti F, et al
    Summary: SNMMI Procedure Standard/EANM Practice Guideline for Estrogen Receptor Imaging of Patients with Breast Cancer Using 16alpha-[(18)F]Fluoro-17beta-Estradiol PET.
    J Nucl Med. 2023 Dec 7:jnumed.123.266938. doi: 10.2967/jnumed.123.266938.
    >> Share

  704. NADEL HR
    A Strategic Approach to Advancing Nuclear Medicine and Molecular Imaging.
    J Nucl Med. 2023;64:1843-1844.
    >> Share

  705. BLAZHENETS G, Soleimani-Meigooni DN, Thomas W, Mundada N, et al
    [(18)F]PI-2620 Binding Patterns in Patients with Suspected Alzheimer Disease and Frontotemporal Lobar Degeneration.
    J Nucl Med. 2023;64:1980-1989.
    >> Share

  706. FANI M, Nicolas GP
    (61)Cu-Labeled Radiotracers: Alternative or Choice?
    J Nucl Med. 2023;64:1855-1857.
    >> Share

    November 2023
  707. EMMETT L, Papa N, Counter W, Calais J, et al
    Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database.
    J Nucl Med. 2023 Nov 30:jnumed.123.266164. doi: 10.2967/jnumed.123.266164.
    >> Share

  708. WANG F, Liu C, Vidal I, Mana-Ay M, et al
    Comparison of Multiple Segmentation Methods for Volumetric Delineation of Primary Prostate Cancer with Prostate-Specific Membrane Antigen-Targeted (18)F-DCFPyL PET/CT.
    J Nucl Med. 2023 Nov 30:jnumed.123.266005. doi: 10.2967/jnumed.123.266005.
    >> Share

  709. DING J, Li X, Liu S, Gao Y, et al
    Clinical Value of (68)Ga-Pentixafor PET/CT in Subtype Diagnosis of Primary Aldosteronism Patients with Adrenal Micronodules.
    J Nucl Med. 2023 Nov 30:jnumed.123.266061. doi: 10.2967/jnumed.123.266061.
    >> Share

  710. KLUGE K, Einspieler H, Haberl D, Spielvogel C, et al
    Examining the Relationship and Prognostic Significance of Cell-Free DNA Levels and the PSMA-Positive Tumor Volume in Men with Prostate Cancer: A Retrospective-Prospective [(68)Ga]Ga-PSMA-11 PET/CT Study.
    J Nucl Med. 2023 Nov 30:jnumed.123.266158. doi: 10.2967/jnumed.123.266158.
    >> Share

  711. PUUVUORI E, Shen Y, Hulsart-Billstrom G, Mitran B, et al
    Noninvasive PET Detection of CD69-Positive Immune Cells Before Signs of Clinical Disease in Inflammatory Arthritis.
    J Nucl Med. 2023 Nov 30:jnumed.123.266336. doi: 10.2967/jnumed.123.266336.
    >> Share

  712. NDLOVU H, Lawal I, Mokoala K, Disenyane D, et al
    Imaging PARP Upregulation with [(123)I]I-PARPi SPECT/CT in Small Cell Neuroendocrine Carcinoma.
    J Nucl Med. 2023 Nov 30:jnumed.123.266348. doi: 10.2967/jnumed.123.266348.
    >> Share

  713. DOERING E, Antonopoulos G, Hoenig M, van Eimeren T, et al
    MRI or (18)F-FDG PET for Brain Age Gap Estimation: Links to Cognition, Pathology, and Alzheimer Disease Progression.
    J Nucl Med. 2023 Nov 30:jnumed.123.265931. doi: 10.2967/jnumed.123.265931.
    >> Share

  714. KURONUMA K, Wei CC, Singh A, Lemley M, et al
    Automated Motion Correction for Myocardial Blood Flow Measurements and Diagnostic Performance of (82)Rb PET Myocardial Perfusion Imaging.
    J Nucl Med. 2023 Nov 30:jnumed.123.266208. doi: 10.2967/jnumed.123.266208.
    >> Share

  715. QUAN Z, Han Z, Yang Y, Wang J, et al
    Noninvasive Monitoring of Immunotherapy in Lung Cancer by Lymphocyte Activation Gene 3 PET Imaging of Tumor-Infiltrating Lymphocytes.
    J Nucl Med. 2023 Nov 16:jnumed.123.266002. doi: 10.2967/jnumed.123.266002.
    >> Share

  716. KESSLER L, Hirmas N, Pabst KM, Hamacher R, et al
    (68)Ga-Labeled Fibroblast Activation Protein Inhibitor ((68)Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the (68)Ga-FAPI PET Observational Trial.
    J Nucl Med. 2023 Nov 16:jnumed.122.264827. doi: 10.2967/jnumed.122.264827.
    >> Share

  717. NAMMAS W, Paunonen C, Teuho J, Siekkinen R, et al
    Imaging of Myocardial alpha(v)beta(3) Integrin Expression for Evaluation of Myocardial Injury After Acute Myocardial Infarction.
    J Nucl Med. 2023 Nov 16:jnumed.123.266148. doi: 10.2967/jnumed.123.266148.
    >> Share

  718. BALAJI V, Song TA, Malekzadeh M, Heidari P, et al
    Artificial Intelligence for PET and SPECT Image Enhancement.
    J Nucl Med. 2023 Nov 9:jnumed.122.265000. doi: 10.2967/jnumed.122.265000.
    >> Share

  719. GUNTHER T, Holzleitner N, Viering O, Beck R, et al
    Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [(68)Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer.
    J Nucl Med. 2023 Nov 9:jnumed.123.266537. doi: 10.2967/jnumed.123.266537.
    >> Share

  720. CARLIER T, Frecon G, Mateus D, Rizkallah M, et al
    Prognostic Value of (18)F-FDG PET Radiomics Features at Baseline in PET-Guided Consolidation Strategy in Diffuse Large B-Cell Lymphoma: A Machine-Learning Analysis from the GAINED Study.
    J Nucl Med. 2023 Nov 9:jnumed.123.265872. doi: 10.2967/jnumed.123.265872.
    >> Share

  721. CHEN L, Zheng S, Chen L, Xu S, et al
    (68)Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study.
    J Nucl Med. 2023 Nov 2:jnumed.123.266079. doi: 10.2967/jnumed.123.266079.
    >> Share

  722. REZAZADEH F, Kilcline AP, Viola NT
    Imaging Agents for PET of Inflammatory Bowel Disease: A Review.
    J Nucl Med. 2023 Nov 2:jnumed.123.265935. doi: 10.2967/jnumed.123.265935.
    >> Share

  723. VIERING O, Gunther T, Holzleitner N, Dierks A, et al
    CCK(2) Receptor-Targeted PET/CT in Medullary Thyroid Cancer Using [(68)Ga]Ga-DOTA-CCK-66.
    J Nucl Med. 2023 Nov 2:jnumed.123.266380. doi: 10.2967/jnumed.123.266380.
    >> Share

  724. GEBHART G
    (18)F-FDG PET "Metabolic Response" to Neoadjuvant Systemic Therapy for Breast Cancer: Quo Vadis?
    J Nucl Med. 2023;64:1697-1698.
    >> Share

  725. KNUUTI J, Tuisku J, Karpijoki H, Iida H, et al
    Quantitative Perfusion Imaging with Total-Body PET.
    J Nucl Med. 2023;64.
    >> Share

  726. DI CARLI MF
    Future of Radionuclide Myocardial Perfusion Imaging: Transitioning from SPECT to PET.
    J Nucl Med. 2023;64.
    >> Share

  727. BENGEL FM, Di Carli MF
    The Evolution of Cardiac Nuclear Imaging.
    J Nucl Med. 2023;64.
    >> Share

  728. ROLL W, Faust A, Hermann S, Schafers M, et al
    Infection Imaging: Focus on New Tracers?
    J Nucl Med. 2023;64.
    >> Share

  729. LI EJ, Lopez JE, Spencer BA, Abdelhafez Y, et al
    Total-Body Perfusion Imaging with [(11)C]-Butanol.
    J Nucl Med. 2023;64:1831-1838.
    >> Share

    October 2023
  730. KAYAL G, Barbosa N, Calderon Marin C, Ferrer L, et al
    Quality Assurance Considerations in Radiopharmaceutical Therapy Dosimetry Using PLANETDose: An International Atomic Energy Agency Study.
    J Nucl Med. 2023 Oct 26:jnumed.122.265340. doi: 10.2967/jnumed.122.265340.
    >> Share

  731. MAULER J, Lohmann P, Maudsley AA, Sheriff S, et al
    Diagnostic Accuracy of MR Spectroscopic Imaging and (18)F-FET PET for Identifying Glioma: A Biopsy-Controlled Hybrid PET/MRI Study.
    J Nucl Med. 2023 Oct 26:jnumed.123.265868. doi: 10.2967/jnumed.123.265868.
    >> Share

  732. XU W, Cai J, Peng T, Meng T, et al
    Fibroblast Activation Protein-Targeted PET/CT with (18)F-Fibroblast Activation Protein Inhibitor-74 for Evaluation of Gastrointestinal Cancer: Comparison with (18)F-FDG PET/CT.
    J Nucl Med. 2023 Oct 26:jnumed.123.266329. doi: 10.2967/jnumed.123.266329.
    >> Share

  733. LASCHINSKY C, Theurer S, Herold T, Rawitzer J, et al
    Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in Patients with Papillary Thyroid Carcinoma.
    J Nucl Med. 2023 Oct 26:jnumed.123.266044. doi: 10.2967/jnumed.123.266044.
    >> Share

  734. KAIREMO K, Czernin J
    Advancing Nuclear Medicine at the Multiomics Intersection: Johannes Czernin Discusses Innovation and Translation with Kalevi Kairemo.
    J Nucl Med. 2023 Oct 19:jnumed.123.266793. doi: 10.2967/jnumed.123.266793.
    >> Share

  735. YAMAGISHI S, Miwa K, Kamitaki S, Anraku K, et al
    Performance Characteristics of a New-Generation Digital Bismuth Germanium Oxide PET/CT System, Omni Legend 32, According to NEMA NU 2-2018 Standards.
    J Nucl Med. 2023 Oct 19:jnumed.123.266140. doi: 10.2967/jnumed.123.266140.
    >> Share

  736. LI X, Ye J, Wang J, Quan Z, et al
    First-in-Humans PET Imaging of KRAS(G12C) Mutation Status in Non-Small Cell Lung and Colorectal Cancer Patients Using [(18)F]PFPMD.
    J Nucl Med. 2023 Oct 12:jnumed.123.265715. doi: 10.2967/jnumed.123.265715.
    >> Share

  737. WATABE T, Kabayama K, Naka S, Yamamoto R, et al
    Immuno-PET and Targeted alpha-Therapy Using Anti-Glypican-1 Antibody Labeled with (89)Zr or (211)At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma.
    J Nucl Med. 2023 Oct 12:jnumed.123.266313. doi: 10.2967/jnumed.123.266313.
    >> Share

  738. AL-TOUBAH T, Montilla-Soler J, El-Haddad G, Haider M, et al
    Somatostatin Receptor Expression in Lung Neuroendocrine Tumors: An Analysis of DOTATATE PET Scans.
    J Nucl Med. 2023 Oct 5:jnumed.123.266185. doi: 10.2967/jnumed.123.266185.
    >> Share

  739. DUELL J, Buck AK, Hartrampf PE, Schlotelburg W, et al
    Chemokine Receptor PET/CT Provides Relevant Staging and Management Changes in Marginal Zone Lymphoma.
    J Nucl Med. 2023 Oct 5:jnumed.123.266074. doi: 10.2967/jnumed.123.266074.
    >> Share

  740. SCHEUERMANN JS, Pryma DA
    Choosing the Right Metrics for Evaluation of Radiopharmaceutical Therapy Dosimetry Methodologies.
    J Nucl Med. 2023;64:1617-1618.
    >> Share

  741. CHICHEPORTICHE A, Sason M, Zidan M, Godefroy J, et al
    Impact of Single-Time-Point Estimates of (177)Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles.
    J Nucl Med. 2023;64:1610-1616.
    >> Share

  742. GANZ PA, Czernin J
    Pioneering Research on Cancer Quality of Life and Outcomes: Johannes Czernin Discusses a Half-Century of Whole-Patient Focus with Patricia A. Ganz.
    J Nucl Med. 2023;64:1506-1508.
    >> Share

  743. MELLHAMMAR E, Dahlbom M, Vilhelmsson-Timmermand O, Strand SE, et al
    Tumor Control Probability and Small-Scale Monte Carlo Dosimetry: Effects of Heterogenous Intratumoral Activity Distribution in Radiopharmaceutical Therapy.
    J Nucl Med. 2023;64:1632-1637.
    >> Share

  744. KOLLER L, Joksch M, Schwarzenbock S, Kurth J, et al
    Preclinical Comparison of the (64)Cu- and (68)Ga-Labeled GRPR-Targeted Compounds RM2 and AMTG, as Well as First-in-Humans [(68)Ga]Ga-AMTG PET/CT.
    J Nucl Med. 2023;64:1654-1659.
    >> Share

  745. COOK BE, Nag S, Arakawa R, Lin EY, et al
    Development of a PET Tracer for OGA with Improved Kinetics in the Living Brain.
    J Nucl Med. 2023;64:1588-1593.
    >> Share

  746. HERINGTON J, McCradden MD, Creel K, Boellaard R, et al
    Ethical Considerations for Artificial Intelligence in Medical Imaging: Deployment and Governance.
    J Nucl Med. 2023;64:1509-1515.
    >> Share

    September 2023
  747. SHAGERA QA, Karfis I, Kristanto P, Spyridon S, et al
    PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors.
    J Nucl Med. 2023 Sep 28:jnumed.123.265874. doi: 10.2967/jnumed.123.265874.
    >> Share

  748. HABERBOSCH L, Gillett D, MacFarlane J, Koulouri O, et al
    Dual Role for l-[Methyl-(11)C]-Methionine PET in Acromegaly: Confirming Remission and Detecting Recurrence.
    J Nucl Med. 2023 Sep 28:jnumed.123.266446. doi: 10.2967/jnumed.123.266446.
    >> Share

  749. CONSTANTINESCU CC, Brown T, Wang S, Yin W, et al
    Clinical Characterization of [(18)F]T-008, a Cholesterol 24-Hydroxylase PET Ligand: Dosimetry, Kinetic Modeling, Variability, and Soticlestat Occupancy.
    J Nucl Med. 2023 Sep 28:jnumed.123.265912. doi: 10.2967/jnumed.123.265912.
    >> Share

  750. ALBERTO S, Ordonez AA, Arjun C, Aulakh GK, et al
    The Development and Validation of Radiopharmaceuticals Targeting Bacterial Infection.
    J Nucl Med. 2023 Sep 28:jnumed.123.265906. doi: 10.2967/jnumed.123.265906.
    >> Share

  751. CHAN CY, Chen Z, Guibbal F, Dias G, et al
    [(123)I]CC1: A PARP-Targeting, Auger Electron-Emitting Radiopharmaceutical for Radionuclide Therapy of Cancer.
    J Nucl Med. 2023 Sep 28:jnumed.123.265429. doi: 10.2967/jnumed.123.265429.
    >> Share

  752. SCHMIDKONZ C, Atzinger A, Ramming A, Kuwert T, et al
    FAPI PET/CT Immune-Fibrosis Imaging for New Insights into Rheumatologic Disorders.
    J Nucl Med. 2023 Sep 21:jnumed.123.266182. doi: 10.2967/jnumed.123.266182.
    >> Share

  753. KLUGE K, Haberl D, Einspieler H, Rasul S, et al
    Antihormonal-Treatment Status Affects (68)Ga-PSMA-HBED-CC PET Biodistribution in Patients with Prostate Cancer.
    J Nucl Med. 2023 Sep 21:jnumed.123.265980. doi: 10.2967/jnumed.123.265980.
    >> Share

  754. ITTI E, Blanc-Durand P, Berriolo-Riedinger A, Kanoun S, et al
    Validation of the DeltaSUV(max) for Interim PET Interpretation in Diffuse Large B-Cell Lymphoma on the Basis of the GAINED Clinical Trial.
    J Nucl Med. 2023 Sep 21:jnumed.123.265871. doi: 10.2967/jnumed.123.265871.
    >> Share

  755. DEMMERT TT, Pomykala KL, Lanzafame H, Pabst KM, et al
    Oncologic Staging with (68)Ga-FAPI PET/CT Demonstrates a Lower Rate of Nonspecific Lymph Node Findings Than (18)F-FDG PET/CT.
    J Nucl Med. 2023 Sep 21:jnumed.123.265751. doi: 10.2967/jnumed.123.265751.
    >> Share

  756. ROGASCH JMM, Metzger G, Preisler M, Galler M, et al
    ChatGPT: Can You Prepare My Patients for [(18)F]FDG PET/CT and Explain My Reports?
    J Nucl Med. 2023 Sep 14:jnumed.123.266114. doi: 10.2967/jnumed.123.266114.
    >> Share

  757. ALTENA R, Af Buren S, Tran T, Axelsson R, et al
    HER2-Low Breast Cancer Can Be Visualized by HER2 PET.
    J Nucl Med. 2023 Sep 14:jnumed.123.266101. doi: 10.2967/jnumed.123.266101.
    >> Share

  758. SEBAN RD
    Reply to: HER2-Low Breast Cancer Can Be Visualized by HER2 PET.
    J Nucl Med. 2023 Sep 14:jnumed.123.266490. doi: 10.2967/jnumed.123.266490.
    >> Share

  759. GEORGOULIAS P, Angelidis G, Koukouraki S, Koutsikos J, et al
    Debating the Future of Nuclear Medicine: The Greek Experience.
    J Nucl Med. 2023 Sep 14:jnumed.123.266646. doi: 10.2967/jnumed.123.266646.
    >> Share

  760. GOGOLA A, Lopresti BJ, Tudorascu D, Snitz B, et al
    Biostatistical Estimation of Tau Threshold Hallmarks (BETTH) Algorithm for Human Tau PET Imaging Studies.
    J Nucl Med. 2023 Sep 14:jnumed.123.265941. doi: 10.2967/jnumed.123.265941.
    >> Share

  761. KOERBER SA, Rohrich M, Walkenbach L, Liermann J, et al
    Impact of (68)Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers.
    J Nucl Med. 2023 Sep 7:jnumed.123.266046. doi: 10.2967/jnumed.123.266046.
    >> Share

  762. MURTHY V, Gafita A, Thin P, Nguyen K, et al
    Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with (177)Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis.
    J Nucl Med. 2023 Sep 7:jnumed.122.265155. doi: 10.2967/jnumed.122.265155.
    >> Share

  763. SUNDERLAND JJ, Graves SA, York DM, Mundt CA, et al
    Response to "Critique and Discussion of 'Multicenter Evaluation of Frequency and Impact of Activity Infiltration in PET Imaging, Including Microscale Modeling of Skin-Absorbed Dose'".
    J Nucl Med. 2023 Sep 7:jnumed.123.266596. doi: 10.2967/jnumed.123.266596.
    >> Share

  764. KARIMZADEH A, Soeiro P, Feuerecker B, Hecker CS, et al
    Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of (177)Lu-PSMA I&T.
    J Nucl Med. 2023 Sep 7:jnumed.123.265878. doi: 10.2967/jnumed.123.265878.
    >> Share

  765. MANKOFF D
    The Future of Nuclear Medicine.
    J Nucl Med. 2023;64:1329-1330.
    >> Share

  766. KRAEBER-BODERE F, Jamet B, Bezzi D, Zamagni E, et al
    New Developments in Myeloma Treatment and Response Assessment.
    J Nucl Med. 2023;64:1331-1343.
    >> Share

  767. WANG C, Peterson AB, Wong KK, Roseland ME, et al
    Single-Time-Point Imaging for Dosimetry After [(177)Lu]Lu-DOTATATE: Accuracy of Existing Methods and Novel Data-Driven Models for Reducing Sensitivity to Time-Point Selection.
    J Nucl Med. 2023;64:1463-1470.
    >> Share

  768. HARTLAPP I, Hartrampf PE, Serfling SE, Wild V, et al
    CXCR4-Directed Imaging and Endoradiotherapy in Desmoplastic Small Round Cell Tumors.
    J Nucl Med. 2023;64:1424-1430.
    >> Share

  769. PANG Y, Zhao L, Fang J, Chen J, et al
    Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy.
    J Nucl Med. 2023;64:1449-1455.
    >> Share

  770. AHMAD AA, Ghim M, Toczek J, Neishabouri A, et al
    Multimodality Imaging of Aortic Valve Calcification and Function in a Murine Model of Calcific Aortic Valve Disease and Bicuspid Aortic Valve.
    J Nucl Med. 2023;64:1487-1494.
    >> Share

  771. MA J, Yang Q, Huo L, Dai J, et al
    Performance of (68)Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT in Evaluation of Erdheim-Chester Disease: A Comparison with (18)F-FDG PET/CT.
    J Nucl Med. 2023;64:1385-1391.
    >> Share

    August 2023
  772. ALAN-SELCUK N, Beydagi G, Demirci E, Ocak M, et al
    Clinical Experience with [(225)Ac]Ac-PSMA Treatment in Patients with [(177)Lu]Lu-PSMA-Refractory Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2023 Aug 24:jnumed.123.265546. doi: 10.2967/jnumed.123.265546.
    >> Share

  773. EIFER M, Alipour R, Hofman MS, Ravi Kumar AS, et al
    Out with the Old, in with the New: Can We Bridge the Gap Between Clinical Trial Results Based on Bone Scans and the Era of Modern Prostate Cancer Imaging?
    J Nucl Med. 2023 Aug 17:jnumed.123.266025. doi: 10.2967/jnumed.123.266025.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016